PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :
C12N 15/62, 15/85, 15/32, C07K 13/00, A61K 39/02, 37/02

A2

(11) International Publication Number: WO 94/18332

(43) International Publication Date: 18 August 1994 (18.08.94)

(21) International Application Number: PCT/US94/01624

(22) International Filing Date: 14 February 1994 (14.02.94)

(30) Priority Data:

08/021,601	12 February 1993 (12.02.93)	US
08/082,849	25 June 1993 (25.06.93)	US

(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
Without international search report and to be republished upon receipt of that report.

(71) Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Box OTT, Bethesda, MD 20892 (US).

(72) Inventors: LEPPLA, Stephen, H.; 5612 Alta Vista Road, Bethesda, MD 20817 (US). KLIMPEL, Kurt; 23816 Woodfield Road, Gaithersburg, MD 20882 (US). ARORA, Naveen; G 110 Ashok Vihar, Phase I, Delhi 110052 (IN). SINGH, Yogendra; SCIR Center for Biochemicals, University of Delhi, Mall Road, Delhi 110007 (IN). NICHOLS, Peter, J.; 40 Axminster Crecent, Welling, Kent DA16 1HG (GB).

(74) Agents: WEBER, Kenneth, A. et al.; Townsend and Townsend Khourie and Crew, Steuart Street Tower, 20th floor, One Market Plaza, San Francisco, CA 94105 (US).

(54) Title: ANTHRAX TOXIN FUSION PROTEINS AND USES THEREOF

(57) Abstract

The present invention provides a nucleic acid encoding a fusion protein comprising a nucleotide sequence encoding the anthrax protective antigen (PA) binding domain of the native anthrax lethal factor (LF) protein and a nucleotide sequence encoding an activity inducing domain of a second protein. Also provided is a nucleic acid encoding a fusion protein comprising a nucleotide sequence encoding the translocation domain and LF binding domain of the native anthrax PA protein and a nucleotide sequence encoding a ligand domain which specifically binds a cellular target. Proteins encoded by the nucleic acid of the invention are also provided, as well as a method for delivering an activity to a cell using such fusion proteins. The invention also provides proteins including an anthrax protective antigen which has been mutated to replace the trypsin cleavage site with residues recognized specifically by the HIV-1 protease.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	**GB**	United Kingdom	**MR**	Mauritania
AU	Australia	**GE**	Georgia	**MW**	Malawi
BB	Barbados	**GN**	Guinea	**NE**	Niger
BE	Belgium	**GR**	Greece	**NL**	Netherlands
BF	Burkina Faso	**HU**	Hungary	**NO**	Norway
BG	Bulgaria	**IE**	Ireland	**NZ**	New Zealand
BJ	Benin	**IT**	Italy	**PL**	Poland
BR	Brazil	**JP**	Japan	**PT**	Portugal
BY	Belarus	**KE**	Kenya	**RO**	Romania
CA	Canada	**KG**	Kyrgystan	**RU**	Russian Federation
CF	Central African Republic	**KP**	Democratic People's Republic of Korea	**SD**	Sudan
CG	Congo			**SE**	Sweden
CH	Switzerland	**KR**	Republic of Korea	**SI**	Slovenia
CI	Côte d'Ivoire	**KZ**	Kazakhstan	**SK**	Slovakia
CM	Cameroon	**LI**	Liechtenstein	**SN**	Senegal
CN	China	**LK**	Sri Lanka	**TD**	Chad
CS	Czechoslovakia	**LU**	Luxembourg	**TG**	Togo
CZ	Czech Republic	**LV**	Latvia	**TJ**	Tajikistan
DE	Germany	**MC**	Monaco	**TT**	Trinidad and Tobago
DK	Denmark	**MD**	Republic of Moldova	**UA**	Ukraine
ES	Spain	**MG**	Madagascar	**US**	United States of America
FI	Finland	**ML**	Mali	**UZ**	Uzbekistan
FR	France	**MN**	Mongolia	**VN**	Viet Nam
GA	Gabon				

ANTHRAX TOXIN FUSION PROTEINS AND USES THEREOF

This application is in a continuation in part application of Serial No. 08/021,601 filed February 12, 1993.

BACKGROUND OF THE INVENTION

The targeting of cytotoxic or other moieties to specific cell types has been proposed as a method of treating diseases such as cancer. Various toxins including *Diphtheria* toxin and *Pseudomonas* exotoxin A have been suggested as potential candidate toxins for this type of treatment. A difficulty of such methods has been the inability to selectively target specific cell types for the delivery of toxins or other active moieties.

One method of targeting specific cells has been to make fusion proteins of a toxin and a single chain antibody. A single-chain antibody (sFv) consists of an antibody light chain variable domain (V_L) and heavy chain variable domain (V_H), connected by a short peptide linker which allows the structure to assume a conformation capable of binding to antigen. In a diagnostic or therapeutic setting, the use of an sFv may offer attractive advantages over the use of a monoclonal antibody (MoAb). Such advantages include more rapid tumor penetration with concomitantly low retention in non-targeted organs (Yokota et al. *Cancer Res* 52:3402,1992), extremely rapid plasma and whole body clearance (resulting in high tumor to normal tissue partitioning) in the course of imaging studies (Colcher et al. *Natl.Cancer Inst.* 82: 1191, 1990; Milenic et al. *Cancer Res.* 51:6363, 1991), and relatively low cost of production and ease of manipulation at the genetic level (Huston et al. *Methods Enzymol.* 203:46, 1991; Johnson, S. and Bird, R. E. *Methods Enzymol.* 203:88, 1991). In addition, sFv-toxin fusion proteins have been shown to exhibit enhanced anti-tumor activity in comparison with conventional chemically cross-linked conjugates (Chaudhary et

al. *Nature* 339:394, 1989; Batra et al. *Cell. Biol.* 11:2200-2295, 1991). Among the first sFv to be generated were molecules capable of binding haptens (Bird et al. *Science* 242:423, 1988; Huston et al. *Proc. Natl. Acad. Sci. USA* 85:5879, 1988), cell-surface receptors (Chaudhary et al., 1989), and tumor antigens (Chaudhary et al. *Proc. Natl. Acad. Sci.* USA 87:1066, 1990; Colcher et al., 1990).

The gene encoding an sFv can be assembled in one of two ways: (i) by *de novo* construction from chemically synthesized overlapping oligonucleotides, or (ii) by polymerase chain reaction (PCR)-based cloning of V_L and V_H genes from hybridoma cDNA. The main disadvantages of the first approach are the considerable expense involved in oligonucleotide synthesis, and the fact that the sequence of V_L and V_H must be known before gene assembly is possible. Consequently, the majority of the sFv reported to date were generated by cloning from hybridoma cDNA; nevertheless, this approach also has inherent disadvantages, because it requires availability of the parent hybridoma or myeloma cell line, and problems are often encountered when attempting to retrieve the correct V region genes from heterologous cDNA. For example, hybridomas in which the immortalizing fusion partner is derived from MOPC-21 may express a V_L kappa transcript which is aberrantly rearranged at the VJ recombination site, and which therefore encodes a non-functional light chain (Cabilly & Riggs, 1985; Carroll et al., 1988). Cellular levels of this transcript may exceed that generated from the productive V_L gene, so that a large proportion of the product on PCR amplification of hybridoma cDNA will not encode a functional light chain. A second disadvantage of the PCR-based method, frequently encountered by the inventors, is the variable success of recovering V_H genes using the conditions so far reported in the literature, presumably because the number of mismatches between primers and the target sequence destabilizes the hybrid to an extent which inhibits PCR amplification.

Thus, methods of targeting toxins to specific cells using single-chain antibodies methods have been difficult to

practice because of the difficulties in obtaining single chain antibodies and other targeting moieties. Also, none of the proposed treatment methods has been fully successful, because of the need to fuse the toxin to the targeting moiety, thus disrupting either the toxin function or the targeting function. Thus, a need exists for a means to target molecules having a desired activity to a specific cell population.

Bacterial and plant protein toxins have evolved novel and efficient strategies for penetrating to the cytosol of mammalian cells, and this ability has been exploited to develop anti-tumor and anti-HIV cytotoxic agents. Examples include ricin and *Pseudomonas* exotoxin A (PE) chimeric toxins and immunotoxins.

Pseudomonas exotoxin A (PE) is a toxin for which a detailed analysis of functional domains exists. The sequence is deposited with GenBank. Structural determination by X-ray diffraction, expression of deleted proteins, and extensive mutagenesis studies have defined three functional domains in PE: a receptor-binding domain (residues 1-252 and 365-399) designated Ia and Ib, a central translocation domain (amino acids 253-364, domain II), and a carboxyl-terminal enzymatic domain (amino acids 400-613, domain III). Domain III catalyzes the ADP-ribosylation of elongation factor 2 (EF-2), which results in inhibition of protein synthesis and cell death. Recently it was also found that an extreme carboxyl terminal sequence is essential for toxicity (Chaudhary et al. *Proc. Natl. Acad. Sci. U.S.A.* 87:308-312, 1990; Seetharam et al. *J. Biol. Chem.* 266:17376-17381, 1991). Since this sequence is similar to the sequence that specifies retention of proteins in the endoplasmic reticulum (ER) (Munro, S. and Pelham, H.R.B. *Cell* 48:899-907, 1987), it was suggested that PE must pass through the ER to gain access to the cytosol. Detailed knowledge of the structure of PE has facilitated use of domains II, Ib, and III (together designated PE40) in hybrid toxins and immunotoxins.

Bacillus anthracis produces three proteins which when combined appropriately form two potent toxins, collectively designated anthrax toxin. Protective antigen

(PA, 82,684 Da (Dalton) (SEQ ID NOS: 3 and 4)) and edema factor (EF, 89,840 Da) combine to form edema toxin (ET), while PA and lethal factor (LF, 90,237 Da (SEQ ID NOS: 1 and 2)) combine to form lethal toxin (LT) (Leppla, S.H. Alouf, J.E. and Freer, J. H., eds. *Academic Press, London* 277-302, 1991). ET and LT each conform to the AB toxin model, with PA providing the target cell binding (B) function and EF or LF acting as the effector or catalytic (A) moieties. A unique feature of these toxins is that LF and EF have no toxicity in the absence of PA, apparently because they cannot gain access to the cytosol of eukaryotic cells.

The genes for each of the three anthrax toxin components have been cloned and sequenced (Leppla, 1991). This showed that LF and EF have extensive homology in amino acid residues 1-300. Since LF and EF compete for binding to PA63, it is highly likely that these amino-terminal regions are responsible for binding to PA63. Direct evidence for this was provided in a recent mutagenesis study (Quinn et al. *J. Biol. Chem.* 266:20124-20130, 1991); all mutations made within amino acid residues 1-210 of LF led to decreased binding to PA63. The same study also suggested that the putative catalytic domain of LF included residues 491-776 (Quinn et al., 1991). In contrast, the location of functional domains within the PA63 polypeptide is not obvious from inspection of the deduced amino acid sequence. However, studies with monoclonal antibodies and protease fragments (Leppla, 1991) and subsequent mutagenesis studies (Singh et al. *J. Biol. Chem.* 266:15493-15497, 1991) showed that residues at and near the carboxyl terminus of PA are involved in binding to receptor.

PA is capable of binding to the surface of many types of cells. After PA binds to a specific receptor (Leppla, 1991) on the surface of susceptible cells, it is cleaved at a single site by a cell surface protease, probably furin, to produce an amino-terminal 19-kDa fragment that is released from the receptor/PA complex (Singh et al. *J. Biol. Chem.* 264:19103-19107, 1989). Removal of this fragment from PA exposes a high-affinity binding site for LF and EF on the

receptor-bound 63-kDa carboxyl-terminal fragment (PA63). The complex of PA63 and LF or EF enters cells and probably passes through acidified endosomes to reach the cytosol.

Cleavage of PA occurs after residues 164-167, Arg-Lys-Lys-Arg. This site is also susceptible to cleavage by trypsin and can be referred to as the trypsin cleavage site. Only after cleavage is PA able to bind either EF or LF to form either ET or LT.

Prior work had shown that the carboxyl terminal PA fragment (PA63) can form ion conductive channels in artificial lipid membranes (Blaustein et al. *Proc. Natl. Acad. Sci. U.S.A.* 86:2209-2213, 1989; Koehler, T. M. and Collier, R.J. *Mol. Microbiol.* 5:1501-1506, 1991), and that LF bound to PA63 on cell surface receptors can be artificially translocated across the plasma membrane to the cytosol by acidification of the culture medium (Friedlander, A. M. *J. Biol. Chem.* 261:7123-7126, 1986). Furthermore, drugs that block endosome acidification protect cells from LF (Gordon et al. *J. Biol. Chem.* 264:14792-14796, 1989; Friedlander, 1986; Gordon et al. *Infect. Immun.* 56:1066-1069, 1988). The mechanisms by which EF is internalized have been studied in cultured cells by measuring the increases in cAMP concentrations induced by PA and EF (Leppla, S. H. *Proc. Natl. Acad. Sci. U.S.A.* 79:3162-3166, 1982; Gordon et al., 1989). However, because assays of cAMP are relatively expensive and not highly precise, this is not a convenient method of analysis. Internalization of LF has been analyzed only in mouse and rat macrophages, because these are the only cell types lysed by the lethal toxin.

SUMMARY OF THE INVENTION

The present invention provides a nucleic acid encoding a fusion protein comprising a nucleotide sequence encoding the PA binding domain of the native LF protein and a nucleotide sequence encoding an activity inducing domain of a second protein. Also provided is a nucleic acid encoding a fusion protein comprising a nucleotide sequence encoding the translocation domain and LF binding domain of the native PA protein and a nucleotide sequence encoding a ligand domain

which specifically binds a cellular target. Proteins encoded by the nucleic acid of the invention, vectors comprising the nucleic acids and hosts capable of expressing the protein encoded by the nucleic acids are also provided.

A composition comprising the PA binding domain of the native LF protein chemically attached to an activity inducing moiety is further provided.

A method for delivering an activity to a cell is provided. The steps of the method include administering to the cell (a) a protein comprising the translocation domain and the LF binding domain of the native PA protein and a ligand domain and (b) a product comprising the PA binding domain of the native LF protein and a non-LF activity inducing moiety, whereby the product administered in step (b) is internalized into the cell and performs the activity within the cell.

Characteristics unique to anthrax toxin are exploited to make novel cell-specific cytotoxins. A site in the PA protein of the toxin which must be proteolytically cleaved for the activity-inducing moiety of the toxin to enter the cell is replaced by the consensus sequence recognized by a specific protease. Thus, the toxin will only act on cells infected with intracellular pathogens which make that specific protease.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graph of the percent to which mutant proteins are cleaved by purified HIV-1 protease. The mutant proteins include protective antigen (PA) mutated to include the HIV-1 protease cleavage site in place of the natural trypsin cleavage site.

DESCRIPTION OF THE PREFERRED EMBODIMENT

Nucleic Acids

Lethal Factor (LF)

The present invention provides an isolated nucleic acid encoding a fusion protein comprising a nucleotide sequence encoding the PA binding domain of the native LF protein and a nucleotide sequence encoding an activity

inducing domain of a second protein. The LF gene and native LF protein are shown in SEQ ID NO: 1 and 2, respectively. The PA gene and native PA protein are shown in SEQ ID NO: 3 and 4, respectively.

The second protein can be a toxin, for example *Pseudomonas* exotoxin A (PE), the A chain of *Diphtheria* toxin or shiga toxin. The activity inducing domains of numerous other known toxins can be included in the fusion protein encoded by the presently claimed nucleic acid. The activity inducing domain need not be a toxin, but can have other activities, including but not limited to stimulating or reducing growth, selectively inhibiting DNA replication, providing a desired gene, providing enzymatic activity or providing a source of radiation. In any case, the fusion proteins encoded by the nucleic acids of the present invention must be capable of being internalized and capable of expressing the specified activity in a cell. A given LF fusion protein of the present invention can be tested for its ability to be internalized and to express the desired activity using methods as described herein, particularly in Examples 1 and 2.

An example of a nucleic acid of the invention comprises the nucleotide sequence defined in the Sequence Listing as SEQ ID NO: 5. This nucleic acid encodes a fusion of LF residues 1-254 with the two-residue linker "TR" and PE residues 401-602 (SEQ ID NO: 6). The protein includes a Met-Val-Pro- sequence at the beginning of the LF sequence. Means for obtaining this fusion protein are further described below and in Example 1.

A further example of a nucleic acid of this invention comprises the nucleotide sequence defined in the Sequence Listing as SEQ ID NO: 7. This nucleic acid encodes a fusion of LF residues 1-254 with the two-residue linker "TR" and PE residues 398-613. (SEQ ID NO: 8) The junction point containing the "TR" is the sequence LTRA and the Met-Val-Pro- is also present. This fusion protein and methods for obtaining it are further described below and in Example 2.

Another example of the nucleic acid of the present invention comprises the nucleotide sequence defined in the Sequence Listing as SEQ ID NO: 9. This nucleic acid encodes a fusion of LF residues 1-254 with the two residue linker and PE residues 362-613. (SEQ ID NO: 10) This fusion protein is further described in Example 1.

Alternatively, the nucleic acid can include the entire coding sequence for the LF protein fused to a non-LF activity inducing domain. Other LF fusion proteins of various sizes and methods of making and testing them for the desired activity are also provided herein, particularly in Examples 1 and 2.

Protective Antigen (PA)

Also provided is an isolated nucleic acid encoding a fusion protein comprising a nucleotide sequence encoding the translocation domain and LF binding domain of the native PA protein and a nucleotide sequence encoding a ligand domain which specifically binds a cellular target.

An example of a nucleic acid of this invention comprises the nucleotide sequence defined in the Sequence Listing as SEQ ID NO:11. This nucleic acid encodes a fusion of PA residues 1-725 and human CD4 residues 1-178, the portion which binds to gp120 exposed on HIV-1 infected cells (SEQ ID NO:12). This fusion protein and methods for obtaining and testing fusion proteins are further described below and in Examples 3, 4 and 5.

The PA fusion protein encoding nucleic acid provided can encode any ligand domain that specifically binds a cellular target, e.g. a cell surface receptor, an antigen expressed on the cell surface, etc. For example, the nucleic acid can encode a ligand domain that specifically binds to an HIV protein expressed on the surface of an HIV-infected cell. Such a ligand domain can be a single chain antibody which is expressed as a fusion protein as provided above and in Examples 3, 4 and 5. Alternatively, the nucleic acid can encode, for example, a ligand domain that is a growth factor, as provided in Example 3.

Although the PA encoding sequence of the nucleic acid encoding the PA fusion proteins of this invention need only include the nucleotide sequence encoding the translocation domain and LF binding domain of the native PA protein, the nucleic acid can further comprise the nucleotide sequence encoding the remainder of the native PA protein. Any sequences to be included beyond those required, can be determined based on routine considerations such as ease of manipulation of the nucleic acid, ease of expression of the product in the host, and any effect on translocation/ internalization as taught in the examples.

Proteins

Proteins encoded by the nucleic acids of the present invention are also provided.

LF Fusion Proteins

The present invention provides LF fusion proteins encoded by the nucleic acids of the invention as described above and in the examples. Specifically, fusions of the LF gene with domains II, Ib, and III of PE can be made by recombinant methods to produce in-frame translational fusions. Recombinant genes (e.g., SEQ ID NOs: 5, 7 and 9) were expressed in *Escherichia coli (E. coli)*, and the purified proteins were tested for activity on cultured cells as provided in Examples 1 and 2. Certain fusion proteins are efficiently internalized via the PA receptor to the cytosol. These examples demonstrate that this system can be used to deliver many different polypeptides into targeted cells.

Although specific examples of these proteins are provided, given the present teachings regarding the preparation of LF fusion proteins, other embodiments having other activity inducing domains can be practiced using routine skill.

Using current methods of genetic manipulation, a variety of other activity inducing moieties (e.g., polypeptides) can be translated as fusion proteins with LF which in turn can be internalized by cells when administered with PA or PA fusion proteins. Fusion proteins generated by

this method can be screened for the desired activity using the methods set forth in the Examples and by various routine procedures. Based on the data presented here, the present invention provides a highly effective system for delivery of an activity inducing moiety into cells.

PA fusion proteins

The present invention provides PA fusion proteins encoded by the nucleic acids of the invention. Specifically fusions of PA with single chain antibodies and CD4 are provided.

Using current methods of genetic manipulation, a variety of other ligand domains (e.g., polypeptides) can be translated as fusion proteins with PA which in turn can specifically target cells and facilitate internalization LF or LF fusion proteins. Based on the data presented here, the present invention provides a highly effective system for delivery of an activity inducing moiety into a particular type or class of cells.

Although specific examples of these proteins are provided, given the present teachings regarding the preparation of PA fusion proteins, other embodiments having other ligand domains can be practiced using routine skill. The fusion proteins generated can be screened for the desired specificity and activity utilizing the methods set forth in the example and by various routine procedures. In any case, the PA fusion proteins encoded by the nucleic acids of the present invention must be able to specifically bind the selected target cell, bind LF or LF fusions or conjugates and internalize the LF fusion/conjugate.

Conjugates

A composition comprising the PA binding domain of the native LF protein chemically attached to an activity inducing moiety is provided. Such an activity inducing moiety is an activity not present on native LF. The composition can comprise an activity inducing moiety that is, for example, a polypeptide, a radioisotope, an antisense nucleic acid or a nucleic acid encoding a desired gene product.

Using current methods of chemical manipulation, a variety of other moieties (e.g., polypeptides, nucleic acids, radioisotopes, etc.) can be chemically attached to LF and can be internalized into cells and can express their activity when administered with PA or PA fusion proteins. The compounds can be tested for the desired activity and internalization following the methods set forth in the Examples. For example, the present invention provides an LF protein fragment 1-254 (LF1-254) with a cysteine residue added at the end of LF1-254 (LF1-254Cys). Since there are no other cysteines in LF, this single cysteine provides a convenient attachment point through which to chemically conjugate other proteins or non-protein moieties.

Vectors and Hosts

A vector comprising the nucleic acids of the present invention is also provided. The vectors of the invention can be in a host capable of expressing the protein encoded by the nucleic acid.

To express the proteins and conjugates of the present invention, the nucleic acids can be operably linked to signals that direct gene expression. A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame.

The gene encoding a protein of the invention can be inserted into an "expression vector", "cloning vector", or "vector," terms which usually refer to plasmids or other nucleic acid molecules that are able to replicate in a chosen host cell. Expression vectors can replicate autonomously, or they can replicate by being inserted into the genome of the host cell. Vectors that replicate autonomously will have an origin of replication or autonomous replicating sequence (ARS) that is functional in the chosen host cell(s). Often, it is

desirable for a vector to be usable in more than one host cell, *e.g.*, in *E. coli* for cloning and construction, and in a mammalian cell for expression.

The particular vector used to transport the genetic information into the cell is also not particularly critical. Any of the conventional vectors used for expression of recombinant proteins in prokaryotic or eukaryotic cells can be used.

The expression vectors typically have a transcription unit or expression cassette that contains all the elements required for the expression of the DNA encoding a protein of the invention in the host cells. A typical expression cassette contains a promoter operably linked to the DNA sequence encoding the protein, and signals required for efficient polyadenylation of the transcript. The promoter is preferably positioned about the same distance from the heterologous transcription start site as it is from the transcription start site in its natural setting. As is known in the art, however, some variation in this distance can be accommodated without loss of promoter function.

The DNA sequence encoding the protein of the invention can be linked to a cleavable signal peptide sequence to promote secretion of the encoded protein by the transformed cell. Additional elements of the vector can include, for example, selectable markers and enhancers. Selectable markers, e.g., tetracycline resistance or hygromycin resistance, permit detection and/or selection of those cells transformed with the desired DNA sequences (see, e.g., U.S. Patent 4,704,362).

Enhancer elements can stimulate transcription up to 1,000 fold from linked homologous or heterologous promoters. Many enhancer elements derived from viruses have a broad host range and are active in a variety of tissues. For example, the SV40 early gene enhancer is suitable for many cell types. Other enhancer/promoter combinations that are suitable for the present invention include those derived from polyoma virus, human or murine cytomegalovirus, the long terminal repeat from various retroviruses such as murine leukemia virus, murine or

Rous sarcoma virus, and HIV. *See, Enhancers and Eukaryotic Expression*, Cold Spring Harbor Pres, Cold Spring Harbor, N.Y. 1983, which is incorporated herein by reference.

In addition to a promoter sequence, the expression cassette should also contain a transcription termination region downstream of the structural gene to provide for efficient termination. The termination region can be obtained from the same gene as the promoter sequence or can be obtained from a different gene.

For more efficient translation in mammalian cells of the mRNA encoded by the structural gene, polyadenylation sequences are also commonly added to the vector construct. Two distinct sequence elements are required for accurate and efficient polyadenylation: GU or U rich sequences located downstream from the polyadenylation site and a highly conserved sequence of six nucleotides, AAUAAA, located 11-30 nucleotides upstream. Termination and polyadenylation signals that are suitable for the present invention include those derived from SV40, or a partial genomic copy of a gene already resident on the expression vector.

The vectors containing the gene encoding the protein of the invention are transformed into host cells for expression. "Transformation" refers to the introduction of vectors containing the nucleic acids of interest directly into host cells by well known methods. The particular procedure used to introduce the genetic material into the host cell for expression of the protein is not particularly critical. Any of the well known procedures for introducing foreign nucleotide sequences into host cells can be used. It is only necessary that the particular procedure utilized be capable of successfully introducing at least one gene into the host cell which is capable of expressing the gene.

Transformation methods, which vary depending on the type of host cell, include electroporation; transfection employing calcium chloride, rubidium chloride calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; lipofection; infection (where the vector is an infectious agent); and other methods. *See, generally,*

Sambrook *et al.*, (1989) *supra*, and *Current Protocols in Molecular Biology*, *supra*. Reference to cells into which the nucleic acids described above have been introduced is meant to also include the progeny of such cells.

There are numerous prokaryotic expression systems known to one of ordinary skill in the art useful for the expression of the antigen. *E. coli* is commonly used, and other microbial hosts suitable for use include *bacilli*, such as *Bacillus subtilus*, and other enterobacteriaceae, such as *Salmonella*, *Serratia*, and various *Pseudomonas* species. One can make expression vectors for use in these prokaryotic hosts; the vectors will typically contain expression control sequences compatible with the host cell (e.g., an origin of replication, a promoter). Any number of a variety of well-known promoters can be used, such as the lactose promoter system, a tryptophan (Trp) promoter system, a beta-lactamase promoter system, or a promoter from phage lambda. The promoters will typically control expression, optionally with an operator sequence, and have ribosome binding site sequences, for example, for initiating and completing transcription and translation. If necessary, an amino terminal methionine can be provided by insertion of a Met codon 5' and in-frame with the codons for the protein. Also, the carboxy-terminal end of the protein can be removed using standard oligonucleotide mutagenesis procedures, if desired.

Host bacterial cells can be chosen that are mutated to be reduced in or free of proteases, so that the proteins produced are not degraded. For *Bacillus* expression systems in which the proteins are secreted into the culture medium, strains are available that are deficient in secreted proteases.

Mammalian cell lines can also be used as host cells for the expression of polypeptides of the invention. Propagation of mammalian cells in culture is *per se* well known. *See*, *Tissue Culture*, Academic Press, Kruse and Patterson, ed. (1973). Host cell lines may also include such organisms as bacteria (*e.g.*, *E. coli* or *B. subtilis*), yeast, filamentous fungi, plant cells, or insect cells, among others.

Purification of Protein

After standard transfection or transformation methods are used to produce prokaryotic, mammalian, yeast, or insect cell lines that express large quantities of the protein of the invention, the protein is then purified using standard techniques which are known in the art. *See, e.g.*, Colley *et al.* (1989) *J. Biol. Chem.* 64: 17619-17622; and *Methods in Enzymology*, "Guide to Protein Purification", M. Deutscher, ed. Vol. 182 (1990).

Standard procedures of the art that can be used to purify proteins of the invention include ammonium sulfate precipitation, affinity and fraction column chromatography, gel electrophoresis and the like. See, generally, Scopes, R., *Protein Purification*, Springer-Verlag, New York (1982), and U.S. Pat. No. 4,512,922 disclosing general methods for purifying protein from recombinantly engineered bacteria.

If the expression system causes the protein of the invention to be secreted from the cells, the recombinant cells are grown and the protein is expressed, after which the culture medium is harvested for purification of the secreted protein. The medium is typically clarified by centrifugation or filtration to remove cells and cell debris and the proteins can be concentrated by adsorption to any suitable resin such as, for example, CDP-Sepharose, asialoprothrombin-Sepharose 4B, or Q Sepharose, or by use of ammonium sulfate fractionation, polyethylene glycol precipitation, or by ultrafiltration. Other means known in the art are equally suitable. Further purification of the protein can be accomplished by standard techniques, for example, affinity chromatography, ion exchange chromatography, sizing chromatography, or other protein purification techniques used to obtain homogeneity. The purified proteins are then used to produce pharmaceutical compositions, as described below.

Alternatively, vectors can be employed that express the protein intracellularly, rather than secreting the protein from the cells. In these cases, the cells are harvested, disrupted, and the protein is purified from the cellular extract, *e.g.*, by standard methods. If the cell line has a

cell wall, then initial extraction in a low salt buffer may allow the protein to pellet with the cell wall fraction. The protein can be eluted from the cell wall with high salt concentrations and dialyzed. If the cell line glycosolates the protein, then the purified glycoprotein may be enhanced by using a Con A column. Anion exchange columns (MonoQ, Pharmacia) and gel filtration columns may be used to further purify the protein. A highly purified preparation can be achieved at the expense of activity by denaturing preparative polyacrylamide gel electrophoresis.

Protein analogs can be produced in multiple conformational forms which are detectable under nonreducing chromatographic conditions. Removal of those species having a low specific activity is desirable and is achieved by a variety of chromatographic techniques including anion exchange or size exclusion chromatography.

Recombinant analogs can be concentrated by pressure dialysis and buffer exchanged directly into volatile buffers (e.g., N-ethylmorpholine (NEM), ammonium bicarbonate, ammonium acetate, and pyridine acetate). In addition, samples can be directly freeze-dried from such volatile buffers resulting in a stable protein powder devoid of salt and detergents. In addition, freeze-dried samples of recombinant analogs can be efficiently resolubilized before use in buffers compatible with infusion (e.g., phosphate buffered saline). Other suitable buffers might include hydrochloride, hydrobromide, sulphate acetate, benzoate, malate, citrate, glycine, glutamate, and aspartate.

Specific Embodiments

Toxins Modified to Contain Intracellular Pathogen Protease Recognition sites

One aspect of the invention exploits the fact that PA and other toxins must be proteolytically cleaved in order to acquire activity, in conjunction with the fact that some cells infected with an intracellular pathogen possess an active protease that has a relatively narrow substrate specificity (for example, HIV-infected cells). The protease

site found in the native toxin is replaced with an intracellular pathogen specific protease site. Thus, the protease in cells that are infected by the intracellular pathogen cleaves the modified toxin, which then becomes active and kills the cell.

Intracellular pathogens that can be targeted by the products and methods of the present invention include any pathogen that produces a protease having a specific recognition site. Such pathogens can include prokaryotes (including rickettsia, *Mycobacterium tuberculosis*, etc.), mycoplasma, eukaryotic pathogens (e.g. pathogenic fungi, etc.), and viruses. One example of an intracellular pathogen that produces a specific protease is human immunodeficiency virus (HIV). The HIV-1 protease cleaves viral polyproteins to generate functional structural proteins as well as the reverse transcriptase and the protease itself. HIV-1 replication and viral infectivity are absolutely dependent on the action of the HIV-1 protease.

An intracellular pathogen specific protease site can be introduced into any natural or recombinant toxin for which proteolytic cleavage is required for toxicity. For example, one can replace the anthrax PA trypsin cleavage site (R164-167) of PA with the HIV-1 protease site. Alternatively, the diphtheria toxin disulfide loop sequence (see O'Hare, et al. FEBS 273 (1, 2): 200-204 (Oct. 1990)) can be replaced with the HIV-1 protease cleavage site in order to obtain a toxin specific to HIV-1 infected cells. Similarly, the normally occurring diphtheria toxin sequence at residues 191-194 (Williams, et al. *J. Biol. Chem.* 265(33): 20673-20677 (1990)) can be replaced by an intracellular pathogen specific protease site such as the HIV-1 protease cleavage sequence. The DAB486-IL-2 fusion toxin of Williams and the improved DAB389-IL-2 toxin are effective on HIV-1 infected cells, which express high levels of the IL-2 receptor. Williams, *J. Biol. Chem.* 265:20673. Addition of the HIV-1 protease cleavage site would provide a further degree of specificity. Similarly, the botulinum toxin C2 toxin is like the anthrax toxin in requiring a cleavage within a native protein subunit (see

Ohishi and Yanagimoto, *Infection and Immunity* 60(11): 4648-4655 (Nov. 1992)), so it too can be made specific for cells infected by an intracellular pathogen such as HIV-1.

In one embodiment of the invention, the protease site of PA is replaced by the site recognized by the HIV-1 protease. The cellular protease that cleaves PA absolutely requires the presence of the Arg 164 and Arg 167 residues, because replacement of either residue yields a PA molecule which is not cleaved after binding to the cell surface. However, any PA substitution mutant which retains at least one Arg or Lys residue within residues 164-167 can be activated by treatment with trypsin. Because the PA63 fragments produced by trypsin digestion have a variety of different amino terminal residues, it is clear that there is not a strict constraint on the identity of the terminal residues. Klimpel, et al., *Proc. Natl. Acad. Sci.* 89:10277-10281 (1992).

Replacement of residues 164-167 of PA with residues that match the HIV-1 protease recognition site can render exogenously added PA inactive on cells which do not possess the HIV-1 protease. However, those cells that do express the HIV-1 protease (i.e., cells infected with HIV-1 or cells engineered to produce the protease) would cleave and thereby activate the mutant PA. The activated PA proteins can then bind and internalize cytotoxic fusion proteins, such as LF-PE, added exogenously.

Based on extensive studies of the substrate specificity of the protease, several PA variants were designed and produced which relate to the invention. These are shown below, with the residues underlined between which the cleavage occurred. PA proteins which have been mutated to replace R164-167 with an amino acid sequence recognized by the HIV-1 protease are referred to as "PAHIV."

PAHIV#1	QVSQNYPIVQNI
PAHIV#2	NTATIMMQRGNF
PAHIV#3	TVSFNFPQITLW
PAHIV#4	GGSAFNFPIVMGG

The mutant proteins PAHIV#(1-4) were cleaved correctly by the HIV-1 protease.

Table 1 shows the amino acids and their corresponding abbreviations and symbols.

Table 1

A	Ala	Alanine	M	Met	Methionine
C	Cys	Cysteine	N	Asn	Asparagine
D	Asp	Aspartic acid	P	Pro	Proline
E	Glu	Glutamic acid	Q	Gln	Glutamine
F	Phe	Phenylalanine	R	Arg	Arginine
G	Gly	Glycine	S	Ser	Serine
H	His	Histidine	T	Thr	Threonine
I	Ile	Isoleucine	V	Val	Valine
K	Lys	Lysine	W	Trp	Tryptophan
L	Leu	Leucine	Y	Tyr	Tyrosine

Preferably, the mutations at R164-167 of PA are accomplished by cassette mutagenesis, although other methods are feasible as discussed below. In summary, three pieces of DNA are joined together. The first piece has vector sequences and encodes the "front half" (5' end of the gene) of PA protein, the second is a short piece of DNA (a cassette) and encodes a small middle piece of PA protein and the third encodes the "back half" (3' end of the gene) of PA. The cassette contains codons for the amino acids that are required to complete the cleavage site for the intracellular pathogen protease. This method was used to make mutants in the plasmid pYS5 although other plasmids could be employed.

Alternatively, the mutations can be accomplished by use of the polymerase chain reaction (PCR) and other methods as discussed below. PCR duplicates a segment of DNA many times, resulting in an amplification of that segment. The reaction produces enough of the segment of DNA so that it can be modified with restriction enzymes and cloned. During the reaction a synthetic oligonucleotide primer is used to start the duplication of the target DNA segment. Each synthetic

primer can be designed to introduce novel DNA sequences into the DNA molecule, or to change existing DNA sequences.

Modification of Toxins to Broaden or Alter Target Cell Specificity

Another aspect of the invention involves compounds and methods for broadening or changing the range of cell types against which a toxin is effective. For example, the lethal anthrax toxin, PA+LF, is acutely toxic to mouse macrophage cells, apparently due to the specific expression in these cells of a target for the catalytic activity of LF. Other cell types are not affected by LF. However, in the present invention, LF is used to construct cytotoxins having broad cell specificity.

A detailed analysis of the domains of LF identified the amino-terminal 254 amino acids as the region that binds to PA63. Fusion proteins containing residues 1-254 of LF and the ADP-ribosylation domain of *Pseudomonas* exotoxin A (PE) were designed according to the invention. These fusion proteins are highly toxic to cultured cells, but only when PA is administered simultaneously.

Synthesis of Genes that Encode Proteins of the Invention

Genes that encode toxins having altered protease recognition sites or fusion proteins having a binding domain from one protein and an activity inducing domain of a second protein can be synthesized by methods known to those skilled in the art. As an example of techniques that can be utilized, the synthesis of genes encoding modified anthrax toxin subunits LF and PA are now described.

The DNA sequences for native PA and LF are known. Knowledge of these DNA sequences facilitates the preparation of genes and can be used as a starting point to construct DNA molecules that encode mutants of PA and/or LF. The protein mutants of the invention are soluble and include internal amino acid substitutions. Furthermore, these mutants are purified from, or secreted from, cells that have been transfected or transformed with plasmids containing genes which encode these proteins. Methods for making

modifications, such as amino acid substitutions, deletions, or the addition of signal sequences to cloned genes are known. Specific methods used herein are described below.

The gene for PA or LF can be prepared by several methods. Genomic and cDNA libraries are commercially available. Oligonucleotide probes, specific to the desired gene, can be synthesized using the known gene sequence. Methods for screening genomic and cDNA libraries with oligonucleotide probes are known. A genomic or cDNA clone can provide the necessary starting material to construct an expression plasmid for the desired protein using known methods.

A protein encoding DNA fragment can be cloned by taking advantage of restriction endonuclease sites which have been identified in regions which flank or are internal to the gene. See Sambrook, *et al.*, *Molecular Cloning: A Laboratory Manual* 2d.ed. Cold Spring Harbor Laboratory Press (1989), "Sambrook" hereinafter.

Genes encoding the desired protein can be made from wild-type genes constructed using the gene encoding the full length protein. One method for producing wild-type genes for subsequent mutation combines the use of synthetic oligonucleotide primers with polymerase extension on a mRNA or DNA template. This PCR method amplifies the desired nucleotide sequence. U.S. Patents 4,683,195 and 4,683,202 describe this method. Restriction endonuclease sites can be incorporated into the primers. Genes amplified by PCR can be purified from agarose gels and cloned into an appropriate vector. Alterations in the natural gene sequence can be introduced by techniques such as *in vitro* mutagenesis and PCR using primers that have been designed to incorporate appropriate mutations.

The proteins described herein can be expressed intracellularly and purified, or can be secreted when expressed in cell culture. If desired, secretion can be obtained by the use of the native signal sequence of the gene. Alternatively, genes encoding the proteins of the invention can be ligated in proper reading frame to a signal sequence

other than that corresponding to the native gene. Though the PA recombinant proteins of the invention are typically expressed in *B. anthracis*, they can be expressed in other hosts, such as *E. coli*.

The proteins of this invention are described by their amino acid sequences and by their nucleotide sequence, it being understood that the proteins include their biological equivalents such that this invention includes minor or inadvertent substitutions and deletions of amino acids that have substantially little impact on the biological properties of the analogs. In some circumstances it may be feasible to substitute rare or non-naturally occurring amino acids for one or more of the twenty common amino acids listed in Table 2. Examples include ornithine and acetylated or hydroxylated forms. See generally Stryer, L., *Biochemistry* 3d ed. (1988).

Alternative nucleotide sequences can be used to express analogs in various host cells. Furthermore, due to the degeneracy of the genetic code, equivalent codons can be substituted to encode the same polypeptide sequence. Additionally, sequences (nucleotide and amino acid) with substantial identity to those of the invention are also included. Identity in this sense means the same identity (of base pair or amino acid) and order (of base pairs or amino acids). Substantial identity includes entities that are greater than 80% identical. Preferably, substantial identity refers to greater than 90% identity. More preferably, it refers to greater than 95% identity.

Mutagenesis

Mutagenesis can be performed to yield point mutations, deletions, or insertions to alter the specific regions of the genes described above. Point mutations can be introduced by a variety of methods including chemical mutagenesis, mutagenic copying methods and site specific mutagenesis methods using synthetic oligonucleotides.

Cassette mutagenesis methods are conveniently used to introduce point mutations into the specified regions of the PA or LF genes. A double-stranded oligonucleotide region

containing alterations in the specified sequences of the gene is prepared. This oligonucleotide cassette region can be prepared by synthesizing an oligonucleotide with the sequence alteration in residues of the PA or LF gene, annealing to a primer, elongating with the large fragment of DNA polymerase and trimming with BstBI. This double-stranded oligonucleotide is ligated into the Bamhi/BstBI fragment from pYS5 and the PpuMI-BamHI fragment from pYS6 to produce an intact recombinant DNA. Other methods of producing the double stranded oligonucleotides and other recombinant DNA vectors can be practiced.

Chemical mutagenesis can be performed using the M13 vector system. A single strand M13 recombinant DNA is prepared containing recombinant PA or LF DNA. Another M13 recombinant containing the same recombinant DNA but in double stranded form is used to prepare a deletion in the targeted region of the gene. This double stranded M13 recombinant is cleaved into a linear molecule with an endonuclease, denatured, and annealed with the single strand M13 recombinant, resulting in a single strand gap in the target region of the PA or LF DNA.

This gapped DNA M13 recombinant is then treated with a compound such as sodium bisulfite to deaminate the cytosine residues in the single strand DNA region to uracil. This results in limited and specific mutations in the single strand DNA region. Finally, the gap in the DNA is filled in by incubation with DNA polymerase, resulting in a U-A base pair to replace a G-C base pair in the in unmutated portion of the gene. Upon replication the new recombinant gene contains T-A base pairs, which are point mutations from the original sequence. Other forms of chemical mutagenesis are also available.

Mutagenic copying of the PA or LF recombinant DNA can be carried out using several methods. For example, a single-stranded gapped DNA region is created as described above. This region is incubated with DNA polymerase I and one or more mutagenic analogs of normal ribonucleoside triphosphates. Copying of the single stranded region with the DNA polymerase

substitutes the mutagenic analogs as the single strand gap region is filled in. Transfection and replication of the resulting DNA results in production of some mutated recombinant DNAs for PA, LF, or EF which can then be selected by cloning. Other mutagenic copying methods can be used.

Point mutations can be introduced into the specified regions of the PA or LF genes by methods using synthetic oligonucleotides for site-specific mutagenesis. PCR copying of the PA or LF genes is performed using oligonucleotide primers covering the specified target regions, and which contain modifications from the wild type sequence in these regions. The PA gene in a pYS5 vector can be PCR amplified using this method to result in mutations in the 164-167 position. PCR amplification can also be used to introduce mutations in the target region of the LF gene.

Synthetic oligonucleotide methods of introducing point mutations can be preformed using heteroduplex DNA. A M13 recombinant DNA vector containing the PA or LF gene is prepared and a single-stranded M13 recombinant is produced. A single strand oligonucleotide containing an alteration in the specified target sequence for the PA or LF gene is annealed to the single strand M13 recombinant to produce a mismatched sequence. Incubation with DNA polymerase I results in a double-stranded M13 recombinant containing base pair mismatches in the specified region of the gene. This M13 recombinant is replicated in a host such as *B. anthracis* or *E. coli* to produce both wild type and mutant M13 recombinants. The mutated M13 recombinants are cloned and isolated. Other vector systems for mutagenesis involving synthetic nucleotides and heteroduplex formation can be applicable.

Expression of Proteins in Prokaryotic Cells

In addition to the use of cloning methods in bacteria such as *Bacillus anthracis* for amplification of cloned sequences, it may be desirable to express the proteins in other prokaryotes. It is possible to recover a functional protein from *E. coli* transformed with an expression plasmid encoding a PA or LF protein. Conveniently, the mutated PA

proteins of the invention were expressed in *B. anthracis* and the LF-fusion proteins were expressed in *E. coli*.

Methods for the expression of cloned genes in bacteria are well known. See Sambrook. To optimize expression of a cloned gene in a prokaryotic system, expression vectors can be constructed which include a promoter to direct mRNA transcription termination. The inclusion of selection markers in DNA vectors transformed in bacteria are useful. Examples of such markers include the genes specifying resistance to ampicillin, tetracycline, or chloramphenicol.

See Sambrook, previously cited, for details concerning selection markers and promoters for use in bacteria such as *E. coli*. In an embodiment of this invention, pYS5 is a vector for the subcloning and amplification of desired gene sequences although other vectors could be used.

Strains of *Bacillus anthracis* producing mutated protein(s)

For PA protein production, *B. anthracis* strains cured of both pX01 and pX02 are preferred because they are avirulent. Examples of such strains are UM23C1-1 and UM44-1C9, obtained from Curtis Thorne, University of Massachusetts. Similar strains can be made by curing of plasmids, as described by P. Mikesell, *et al.*, "Evidence for plasmid-mediated toxin production in *Bacillus anthracis*," *Infect. Immun.* 39:371-376 (1983).

See generally commonly assigned U.S. Patent Application Serial No. 08/042,745, filed April 5, 1993, incorporated by reference herein.

Treatment Methods

A method for delivering a desired activity to a cell is provided. The steps of the method include administering to the cell (a) a protein comprising the translocation domain and the LF binding domain of the native PA protein and a ligand domain, and (b) a product comprising the PA binding domain of the native LF protein and a non-LF activity inducing moiety, whereby the product administered in step (b) is internalized into the cell and performs the activity within the cell.

The method of delivering an activity to a cell can use a ligand domain that is the receptor binding domain of the native PA protein. Other ligand domains are selected for their specificity for a particular cell type or class of cells. The specificity of the PA fusion protein for the targeted cell can be determined using standard methods and as described in Examples 2 and 3.

The method of delivering an activity to a cell can use an activity inducing moiety that is a polypeptide, for example a growth factor, a toxin, an antisense nucleic acid, or a nucleic acid encoding a desired gene product. The actual activity inducing moiety used will be selected based on its functional characteristics, e.g. its activity.

A method of killing a tumor cell in a subject is also provided. The steps of the method can include administering to the subject a first fusion protein comprising the translocation domain and LF binding domain of the native PA protein and a tumor cell specific ligand domain in an amount sufficient to bind to a tumor cell. A second fusion protein is also administered wherein the protein comprises the PA binding domain of the native LF protein and a cytotoxic domain of a non-LF protein in an amount sufficient to bind to the first protein, whereby the second protein is internalized into the tumor cell and kills the tumor cell.

The cytotoxic domain can be a toxin or it can be another moiety not strictly defined as a toxin, but which has an activity that results in cell death. These cytotoxic moieties can be selected using standard tests of cytotoxicity, such as the cell lysis and protein synthesis inhibition assays described in the examples.

The invention further provides a method of killing HIV-infected cells in a subject. The method comprises the steps of administering to the subject a first fusion protein comprising the translocation domain and LF binding domain of the native PA protein and a ligand domain that specifically binds to an HIV protein expressed on the surface of an HIV-infected cell, in an amount sufficient to bind to an HIV-infected cell. The next step is administering to the subject

a second fusion protein comprising the PA binding domain of the native LF protein and a cytotoxic domain of a non-LF protein, in an amount sufficient to bind to the first protein, whereby the second protein is internalized into the HIV-infected cell and kills the HIV-infected cell, thereby preventing propagation of HIV.

Although certain of the methods of the invention have been described as using LF fusion proteins, it will be understood that other LF compositions having chemically attached activity inducing moieties can be used in the methods.

The fusion proteins and other compositions of the inventions can be administered by various methods, e.g., parenterally, intramuscularly or intrapertioneally.

The amount necessary can be deduced from other receptor/ligand or antibody/antigen therapies. The amount can be optimized by routine procedures. The exact amount of such LF and PA compositions required will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the severity of the disease that is being treated, the particular fusion protein of composition used, its mode of administration, and the like. Generally, dosage will approximate that which is typical for the administration of cell surface receptor ligands, and will preferably be in the range of about 2 μg/kg/day to 2 mg/kg/day.

Depending on the intended mode of administration, the compounds of the present invention can be in various pharmaceutical compositions. The compositions will include, as noted above, an effective amount of the selected protein in combination with a pharmaceutically acceptable carrier and, in addition, can include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc. By "pharmaceutically acceptable" is meant a material that is not biologically or otherwise undesirable, i.e., the material can be administered to an individual along with the fusion protein or other composition without causing any undesirable biological effects or interacting in a deleterious manner with

any of the other components of the pharmaceutical composition in which it is contained.

Parenteral administration, if used, is generally characterized by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. A more recently revised approach for parenteral administration involves use of a slow release or sustained release system, such that a constant level of dosage is maintained. See, e.g., U.S. Patent No. 3,710,795, which is incorporated by reference herein.

Formulations and Administration

Proteins of the invention such as PAHIV are typically mixed with a physiologically acceptable fluid prior to administration to a mammal such as a human. Examples of physiologically acceptable fluids include saline solutions such as normal saline, Ringer's solution, and generally mixtures of various salts including potassium and phosphate salts with or without sugar additives such as glucose. The proteins are administered parenterally with intravenous administration being the most typical route. Either a bolus of the protein in solution or a slow infusion can be administered intravenously. The choice of a bolus or an infusion depends on the kinetics, including the half-life, of the protein in the patient. An appropriate evaluation of the time for delivery of the protein is well within the skill of the clinician.

Patients selected for treatment with PAHIV are infected with HIV-1 and they may or may not be symptomatic. Optimally, the protein would be administered to an HIV-1 infected person who is not yet symptomatic. The dosage range of a protein of the invention such as PAHIV is typically from about 5 to about 25 micrograms per kilogram of body weight of the patient. Usually, the dose is about 10 micrograms per kilogram of body weight of the patient. The dosage is repeated at regular intervals, such as weekly for about 4 to 6 weeks. At that time the clinician may opt to evaluate the

patient's immune status, including immuno-tolerance to the PAHIV, to decide future treatment.

The foregoing description and the following examples are offered primarily for purposes of illustration. It will be readily apparent to those skilled in the art that the operating conditions, materials, procedural steps and other parameters of the system described herein can be further modified or substituted in various ways without departing from the spirit and scope of the invention. For example, although human use has been discussed, veterinary use of the invention is also feasible. For instance, cats suffer from a so-called feline AIDS or feline immunodeficiency virus (FIV). Protective antigen can be altered to include a protease cleavage site specific for FIV. Thus, the invention is not limited by the description and examples, but rather by the appended claims.

EXAMPLE 1

Fusions of Anthrax Toxin Lethal Factor to the ADP-Ribosylation Domain of *Pseudomonas* Exotoxin

Reagents and General Procedures

Restriction endonucleases and DNA modifying enzymes were purchased from GIBCO/BRL, Boehringer Mannheim, or New England Biolabs. Low melting point agarose (Sea Plaque) was obtained from FMC Corp. (Rockland, ME). Oligonucleotides were synthesized on a PCR Mate (Applied Biosystems) and purified on oligonucleotide purification cartridges (Applied Biosystems). The PCR was performed with a DNA amplification reagent (GeneAmp) from Perkin-Elmer Cetus Instruments and a thermal cycler (Perkin-Elmer Cetus). The amplification involved denaturation at 94°C for 1 min, annealing at 55°C for 2.5 min and extension at 72°C for 3 min, for 30 cycles. A final extension was run at 72°C for 7 min. For amplification of PE fragments, 10% formamide was added in the reaction mixture to decrease the effect of high GC content. DNA sequencing reactions were done using the Sequenase version 1.0 from U. S. Biochemical Corp. and DNA sequencing gels were made from Gel Mix 6 from GIBCO/BRL. [^{35}S]deoxyadenosine 5'-[α-

thio]triphosphate and L-[3,4,5-^{3}H]leucine were purchased from Dupont-New England Nuclear. J774A.1 cells were obtained from American Type Culture Collection. Chinese Hamster Ovary (CHO) cells were obtained from Michael Gottesman (National Cancer Institute, National Institutes of Health) (ATCC CCL 61).

Plasmid Construction

Construction of plasmids containing LF-PE fusions was performed as follows. Varying portions of the PE gene were amplified by PCR, ligated in frame to the 3'end of the LF gene, and inserted into the pVEX115 f+T expression vector (provided by V. K. Chaudhary, National Cancer Institute, National Institutes of Health). To construct fusion proteins, the 3'-end of the native LF gene (including codon 776 of the mature protein, specifying Ser) was ligated with the 5'-ends of sequences specifying varying portions of domains II, Ib, and III of PE. The LF gene was amplified from the plasmid pLF7 (Robertson, D. L. and Leppla, S.H. *Gene* 44:71-78, 1986) by PCR using oligonucleotide primers which added *Kpn*I and *Mlu*I sites at the 5' and the 3' ends of the gene, respectively. Similarly, varying portions of the PE gene (provided by David FitzGerald, National Cancer Institute, National Institutes of Health) were amplified by PCR so as to add *Mlu*I and *EcoR*I sites at the 5' and 3' ends. The PCR product of the LF gene was digested with *Kpn*I and the DNA was precipitated. The LF gene was subsequently treated with *Mlu*I. Similarly, the PCR products of PE amplification were digested with *Mlu*I and *EcoR*I. The expression vector pVEX115 f+T was cleaved with *Kpn*I and *EcoR*I separately and dephosphorylated. This vector has a T7 promoter, OmpA signal sequence, multiple cloning site, and T7 transcription terminator. All the above DNA fragments were purified from low-melting point agarose, a three-fragment ligation was carried out, and the product transformed into *E. coli* DH5α (ATCC 53868). The four constructs described in this report have the entire LF gene fused to varying portions of PE. The identity of each construct was confirmed by sequencing the junction point using a Sequenase kit (U.S. Biochemical Corp.). For expression, recombinant plasmids were transformed into *E. coli* strain

SA2821 (provided by Sankar Adhya, National Cancer Institute, National Institutes of Health, which is a derivative of BL21(λDE3) (Studier, F. W. and Moffatt, B.A. *J. Mol. Biol.* 189:113-150, 1986). This strain has the T7 RNA polymerase gene under control of an inducible *lac* promotor and also contains the *degP* mutation, which eliminates a major periplasmic protease (Strauch et al. *J. Bacteriol.* 171:2689-2696, 1989).

In the resulting plasmids, the LF-PE fusion genes are under control of the T7 promoter and contain an OmpA signal peptide to obtain secretion of the products to the periplasm so as to facilitate purification. The design of the PCR linkers also led to insertion of two non-native amino acids, Thr-Arg, at the LF-PE junction. The four fusions analyzed in this report contain the entire 776 amino acids of mature LF, the two added residues TR (Thr-Arg), and varying portions of PE. In fusion FP33, the carboxyl-terminal end of PE was changed from the native REDLK (Arg-Glu-Asp-Leu-Lys) to LDER, a sequence that fails to cause retention in the ER (endoplasmic reticulum).

Expression and Purification of Fusion Proteins

Fusion proteins produced from pNA2, pNA4, pNA23 and pNA33 were designated FP2, FP4, FP23 and FP33 respectively. *E. coli* strains carrying the recombinant plasmids were grown in super broth (32 g/L Tryptone, 20 g/L yeast extract, 5 g/L NaCl, pH 7.5) with 100 μg/ml of ampicillin with shaking at 225 rpm at 37°C in 2-L cultures. When A_{600} reached 0.8-1.0, isopropyl-1-thio-β-D-galactopyranoside was added to a final concentration of 1 mM, and cultures were incubated an additional 2 hr. EDTA and 1,10-o-phenanthroline were added to 5 mM and 0.1 mM respectively, and the bacteria were harvested by centrifugation at 4000 x g for 15 min at 4°C. For extraction of the periplasmic contents, cells were suspended in 75 ml of 20% sucrose containing 30 mM Tris and 1 mM EDTA, incubated at 0° for 10 min, and centrifuged at 8000 x g for 15 min at 4°C. Cells were resuspended gently in 50 ml of cold distilled water, kept on ice for 10 min, and the spheroplasts were pelleted. The supernatant was concentrated with

Centriprep-100 units (Amicon) and loaded on a Sephacryl S-200 column (40 x 2 cm) and 1 ml fractions were collected.

Fractions having full length fusion protein as determined by immunoblots were pooled and concentrated as above. Protein was then purified on an anion exchange column (MonoQ HR5/5, Pharmacia-LKB) using a NaCl gradient. The fusion proteins eluted at 280-300 mM NaCl. The proteins were concentrated again on Centriprep-100 (Amicon Division) and the MonoQ chromatography was repeated. Protein concentrations were determined by the bicinchoninic acid method (BCA Protein Assay Reagent, Pierce), using bovine serum albumin as the standard. Proteins were analyzed by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate (SDS). Gels were either stained with Coomassie Brilliant Blue or the proteins were electroblotted to nitrocellulose paper which was probed with polyclonal rabbit antisera to LF or PE (List Biological Laboratories, Campbell, CA). To determine the percent of full length protein, SDS gels stained with Coomassie Brilliant Blue were scanned with a laser densitometer (Pharmacia-LKB Ultrascan XL).

The proteins migrated during gel electrophoresis with molecular masses of more than 106 kDa, consistent with the expected sizes, and immunoblots confirmed that the products had reactivity with antisera to both LF and PE. The fusion proteins differed in their susceptibility to proteolysis as judged by the appearance of smaller fragments on immunoblots, and this led to varying yields of final product. Thus, from 2-L cultures the yields were FP2, 27 μg; FP4, 87 μg; FP23, 18 μg; and FP33, 143 μg.

Cell Culture Techniques and Protein Synthesis Inhibition Assay

CHO cells were maintained as monolayers in Eagle's minimum essential medium (EMEM) supplemented with 10% fetal bovine serum, 10 mM 4-2(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (pH 7.3), 2 mM glutamine, penicillin/streptomycin, and non-essential amino acids (GIBCO/BRL). Cells were plated in 24- or 48-well dishes one day before the experiment. After overnight incubation, the medium was replaced with fresh medium containing 1 μg/ml

of PA unless otherwise indicated. Fusion proteins were added to 0.1-1000 ng/ml. All data points were done in duplicate. Cells were further incubated for 20 hr at 37°C in 5% CO_2 atmosphere. The medium was then aspirated and cells were incubated for 2 hr at 37°C with leucine-free medium containing 1 μCi/ml [^{3}H]leucine. Cells were washed twice with medium, cold 10% trichloroacetic acid was added for 30 min, the cells were washed twice with 5% trichloroacetic acid and dissolved in 0.150 ml 0.1 M NaOH. Samples were counted in Pharmacia-LKB 1410 liquid scintillation counter. In experiments to determine if the toxin is internalized through acidified endosomes, 1 μM monensin (Sigma) was added 90 min prior to toxin and was present during all subsequent steps. To verify that the fusion proteins were internalized through the PA receptor, competition with native LF was carried out. PA (0.1 μg/ml) and LF (0.1-10,000 ng/ml) were added to the CHO cells to block the PA receptor and the fusion proteins were added thereafter at concentrations of 100 ng/ml for FP4 and FP23 and 5 ng/ml for FP33. Protein synthesis inhibition was measured after 20 hr as described above.

Cytotoxic Activity of the Fusion Proteins

All four fusion proteins made and purified were toxic to CHO cells. The concentration causing 50% lysis of cultured cells (EC_{50}) values of the proteins were 350, 8, 10, and 0.2 ng/ml for FP2, FP4, FP23 and FP33 respectively (Table 1). These assays were done with PA present at 1 ug/ml, exceeding the K_m of 0.1 ug/ml (100 pM). The fusion proteins had no toxicity even at 1 μg/ml when PA was omitted, proving that internalization of the fusion proteins was occurring through the action of PA and the PA receptor. Native LF has previously been shown to have no short-term toxic effects on CHO cells when added with PA, and therefore was not included in these assays. The fusion protein having only domain III and an altered carboxyl-terminus (FP33) was most active, whereas the one having the intact domains II and III and the native REDLK terminus (FP2) was least active. The other two fusion proteins (FP4 and FP23) had intermediate potencies.

Among proteins having ADP-ribosylation activity, potencies equalling or exceeding 1 pM have previously been found only for native diphtheria and *Pseudomonas* toxins acting on selected cells (Middlebrook, J. L. and Dorlan, R.B. *Can. J. Microbiol.* 23:183-189, 1977) and for fusion proteins of PE and diphtheria toxin when tested on cells containing > 100,000 receptors for the ligand-recognition domain of the fusion (EGF, transferrin, etc.) (Pastan, I. and FitzGerald, D. *Science* 254:1173-1177, 1991; Middlebrook, et al. 1977). For CHO cells, the potency of FP33 (EC_{50} = 2 pM) is higher than that of PE itself (EC_{50} = 420 pM), even though CHO cells probably have similar numbers of receptors for both PA and PE (approx. 5,000-20,000). If the intracellular trafficking of native PE delivers less than 5% of the molecules to the cytosol, then the 200-fold greater potency of FP33 suggests that the PA/LF system has an inherently high efficiency of delivery to the cytosol.

A comparison of the potencies of the four fusion proteins shows that inclusion of domain II decreases potency. Thus, the fusion with the lowest potency, FP2, was the one containing intact domains II, Ib, and III. In designing the fusion proteins, all or part of PE domain II and Ib was included in several of the constructs because it could not be assumed that the translocation functions possessed by PA and LF would be able to correctly traffic PE domain III to the cytosol. The combination of domains II, Ib, and III, termed PE40, has been used in a large number of toxic hybrid proteins, by fusion to growth factors, monoclonal antibodies, and other proteins (Pastan et al. 1991; Oeltmann, T. N. and Frankel, A. E. *Faseb J.* 5:2334-2337, 1991), and some of these fusions have shown substantial potency. Domain II was found to be essential in these hybrid proteins to provide a translocation function not present in the receptor-binding domain to which it was fused. The potency of many of these PE40 fusion proteins appears to require that they be trafficked through the Golgi and ER and proteolytically activated in the same manner as native PE, so as to achieve delivery of domain III to the cytosol. The fact that

inclusion of the entire domain II in the LF fusion protein FP2 instead decreased activity suggests that internalization of the LF fusions occurs through a different route, one that does not easily accommodate all the sequences in domain II.

Evidence that structures within PE residues 251-278 inhibit translocation of the LF fusions comes from the 35-fold lower potency of FP2 compared to FP23. One structure that might inhibit translocation of the fusions is the disulfide loop formed by Cys265 and Cys287. In native PE, this disulfide loop appears to be required for maximum activity. Thus, native PE and TGF-α-PE40 fusions become 10- to 100-fold less toxic if one or both these cysteines are changed to serine. The disulfide loop probably acts to constrain the polypeptide so that Arg276 and Arg279 are susceptible to the intracellular protease involved in the cleavage that precedes translocation. In contrast, the disulfide loop decreases the potency of the LF fusions, perhaps by preventing the unfolding needed for passage through a protein channel, thereby acting in this situation as a "stop transfer" sequence. FP23, which lacks Cys265, would not contain the domain II disulfide, and therefore would not be subject to this effect. LF, like PA and EF, contains no cysteines, and would not be prevented by disulfide loops from the complete unfolding needed to pass through a protein channel. The suggestion that disulfide loops act as stop-transfer signals would predict that the disulfide Cys372-Cys379 in PE domain Ib, which is retained in all four LF fusions would also decrease potency. It should be noted that neither the fusions made here nor the PE40 fusions have been analyzed chemically to determine if the disulfides in domains II and III are actually formed. If the disulfides do form correctly, it would be predicted that the potencies of all of the fusion proteins, and especially that of FP2, would be increased by treatment with reducing agents. These analyses have not yet been performed. This analysis also suggests that future LF fusions might be made more potent by omission of domain Ib.

The other structural feature of PE known to affect intracellular trafficking is the carboxyl terminal sequence,

REDLK, that specifies retention in the ER (Chaudhary et al. 1990; Muro et al. 1987). To determine if the trafficking of the LF fusion proteins was similar to that of PE, two of the fusion proteins were designed so as to differ only in the terminal sequence. Replacement of the native sequence by LDER, one that does not function as an ER retention signal, produced the most toxic of the four fusion proteins, FP33. FP4, identical except that it retained a functional REDLK sequence, was 30-fold less potent. These data suggest that sequestration of the REDLK-ended fusions decreased their access to cytosolic EF-2. The implication is that PE may require the REDLK terminus to be delivered to the ER for an obligatory processing step, but then be limited in its final toxic potential by sequestration from its cytosolic target. Finally, this comparison strongly argues that internalization of the LF fusions does not follow the same path as PE.

In designing the fusion proteins described here it was hoped that they would have cytotoxic activity against cells that are unaffected by anthrax lethal toxin, and this was successfully realized as shown by the data obtained with CHO cells. However, prior knowledge about LF did not provide a basis for predicting whether the constructs would retain toxicity toward mouse macrophages, the only cells known to be rapidly killed by anthrax lethal toxin. Macrophages are lysed by lethal toxin in 90-120 minutes, long before any inhibition of protein synthesis resulting from ADP-ribosylation of EF-2 leads to decreases in membrane integrity or viability. This kinetic difference made it possible to test directly for LF action. As discussed above, the fusion proteins purified to remove the ≈ 89-kDa LF species formed by proteolysis were not toxic to J774A.1 macrophages. This shows that attachment of a bulky group to the carboxyl terminus of LF eliminates its normal toxic activity. In the absence of any assay for the putative catalytic activity of LF, it is not possible to determine the cause of the loss of LF activity. The inability of the fusions to lyse J774A.1 cells also argues against proteolytic degradation of the fusions either in the medium during incubation with cells or after internalization.

An important result of the invention described here is the demonstration that the anthrax toxin proteins constitute an efficient mechanism for protein internalization into animal cells. The high potency of the present fusion proteins argues that this system is inherently efficient, as well as being amenable to improvement. The high efficiency results in part from the apparent direct translocation from the endosome, without a requirement for trafficking through other intracellular compartments. In addition to its efficiency, the system appears able to tolerate heterologous polypeptides.

Macrophage Lysis Assay of Fusion Proteins

Fusion proteins were assayed for LF functional activity on J774A.1 macrophage cell line in the presence of 1 μg/ml PA. One day prior to use, cells were scraped from flasks and plated in 48-well tissue culture dishes. For cytotoxicity tests, the medium was aspirated and replaced with fresh medium containing 1 μg/ml PA and the LF fusion proteins, and the cells were incubated for 3 hr. All data points were performed in duplicate. To measure the viability of the treated cells, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) was added to the cells to a final concentration of 0.5 mg/ml, and incubation was continued for an additional 45 min to allow the uptake and oxidation of MTT by viable cells. Medium was aspirated and replaced by 200 μl of 0.5% SDS, 40 mM HCl, 90% isopropanol and the plates were vortexed to dissolve the blue pigment. The MTT absorption was read at 570 nm using a UVmax Kinetic Microplate Reader (Molecular Devices Corp.).

The crude periplasmic extracts from which the fusion proteins were purified caused lysis of J774A.1 macrophages when added with PA, indicating the presence of active LF species, probably formed by proteolysis of the fusion proteins. Purification removed this activity, so that none of the final fusion proteins had this activity. This result showed both that the purified proteins were devoid of full size LF or active LF fragments, and that the lytic activity of LF for macrophages is blocked when residues from PE are fused at its carboxyl terminus.

ADP-Ribosylation Assays

For assaying ADP-ribosylation activity, the method of Collier and Kandel (Collier, R. J. and Kandel, J. *J. Biol. Chem.* 246:1496-1503, 1971) was used with some modification. A wheat germ extract enriched for EF-2 was used in the reaction. Briefly, in a 200-μL reaction assay, 20 μL of buffer (500 mM Tris, 10 mM EDTA, 50 mM dithiothreitol and 10 mg/ml bovine serum albumin) was mixed with 30 μL of EF-2, 130 μL of H_2O or sample, and 20 μL of [adenylate-^{32}P]NAD (0.4 μCi per assay, ICN Biochemicals) containing 5 μM of non-radioactive NAD. Samples were incubated for 20 min at 23°C, the reactions were stopped by adding 1 ml 10% trichloroacetic acid, and the precipitates were collected and washed on GA-6 filters (Gelman Sciences). The filters were washed twice with 70% ethanol, air dried, and the radioactivity measured.

Table 1 shows that all the fusion proteins were equally capable of ADP-ribosylation of EF-2. FP2, which had little cytotoxic activity on CHO cells, still retained full ADP-ribosylation activity. It was also found that treatment with urea and dithiothreitol under conditions that activate the enzymatic activity of native PE, caused no increase in the ADP-ribosylation activity of the fusion proteins, suggesting that the proteins were not folded so as to sterically block the catalytic site.

Effect of Mutant PA on LF-PE Activity

To verify that uptake of the fusion proteins requires PA, the activity of the fusion proteins was measured in the presence of a mutant PA which is apparently defective in internalization. This mutant, PA-S395C, has a serine to cysteine substitution at residue 395 of the mature protein, and retains the ability to bind to receptor, become proteolytically nicked, and bind LF, but is unable to lyse macrophages. When PA-S395C was substituted for native PA in combination with FP33, no inhibition of protein synthesis inhibition was observed. Similar results were obtained when the other three fusion proteins were tested in combination with PA-S395C.

Effect of Monensin on Activity of the Fusion Proteins

To verify that internalization of the fusion proteins was occurring by passage through acidified endosomes in the same manner as native LF, the ability of monensin to protect cells was examined. Addition of monensin to 1 μM decreased the potency of FP33 by >100-fold. Protection against the other three fusion proteins exceeded 20-fold.

LF Block of LF-PE Fusion Activity

To further verify that the fusion proteins were internalized through the PA receptor, CHO cells were incubated with PA and different amounts of LF to block the receptor and the fusion proteins were added thereafter. Protein synthesis inhibition assays showed that native LF could competitively block LF-PE fusion proteins in a concentration-dependent manner.

The present data suggest that the receptor-bound 63-kDa proteolytic fragment of PA forms a membrane channel and that regions at or near the amino-termini of LF and EF enter this channel first and thereby cross the endosomal membrane, followed by unfolding and transit of the entire polypeptide to the cytosol. This model differs from that for diphtheria toxin in that the orientation of polypeptide transfer is reversed. Since both EF and LF have large catalytic domains, extending to near their carboxyl termini, it appears probable that the entire polypeptide crosses the membrane. In the LF fusion proteins, the attached PE sequences would be carried along with the LF polypeptide in transiting the channel to the cytosol. Thus, the PA63 protein channel must tolerate diverse amino acid residues and sequences. The data presented is consistent with the mechanism of direct translocation of the LF proteins to the cytosol as suggested herein.

TABLE 1 Cytotoxic and catalytic activity of LF-PE fusion proteins

Prot-ein	Amino acid content			Toxicity (EC_{50})[b]		ADP-Ribosylation activity (relative)
	LF	Linker	PE	(pM)	ng/ml	
PE	none	none	1-613	420	23	100[c]
FP2	776	TR	251-613	2700	350	82
FP4	776	TR	362-613	65	8	105
FP23	776	TR	279-613	70	10	108
FP33	776	TR	362-612[a]	2	0.2	118

[a]REDLK at carboxyl terminus is changed to LDER.

[b]Data is from this example, except for native PE, which is from data not shown, and is equal to a value previously reported (Moehring, T. J. and Moehring, J. M. *Cell* 11:447-454, 1977).

[c]ADP-ribosylation was measured using 30 ng of fusion protein in a final volume of 0.200 ml with 5 μM NAD. Results were corrected for the molecular weights of the proteins and normalized to PE.

EXAMPLE 2: Residues 1-254 of Anthrax Toxin Lethal Factor are Sufficient to Cause Cellular Uptake of Fused Polypeptides

Reagents and General Procedures

Restriction endonucleases and DNA modifying enzymes were purchased from GIBCO/BRL, Boehringer Mannheim or New England Biolabs. Low melting point agarose (Sea Plaque) was obtained from FMC Corporation. Oligonucleotides were synthesized on a PCR Mate (Applied Biosystems) and purified with Oligonucleotide Purification Cartridges (Applied Biosystems). Polymerase chain reactions (PCR) were performed on a thermal cycler (Perkin-Elmer-Cetus) using reagents from U. S. Biochemical Corp. or Perkin-Elmer-Cetus. DNA was amplified as described in Example 1. The DNA was sequenced to confirmed the accuracy of all of the constructs described in the report. SEQUENASE version 2.0 from U. S. Biochemical Corp. was utilized for the sequencing reactions, and DNA sequencing gels were made with Gel Mix 8 from GIBCO/BRL. [^{35}S]dATPαS and L-[3,4,5-^{3}H]leucine were purchased from Dupont-New England Nuclear. Chinese hamster ovary cells (CHO) were obtained from Michael Gottesman (NCI, NIH). J774A.1 macrophage cells were obtained from American Type Culture Collection.

Plasmid Construction

Three types of LF protein constructs were made and analyzed in this report. All the constructs were made by PCR amplification of the desired sequences, using the native LF gene as template. LF proteins deleted at the amino- or carboxyl-terminus were constructed by a single PCR amplification reaction that added restriction sites at the ends for incorporation of the construct into the expression vector. LF proteins deleted for one or more of the 19-amino acid repeats that comprise residues 308-383 were constructed by ligating the products of two separate PCR reactions that amplified the regions bracketing the deletion. The third group of constructs were fusions of varying portions of the amino terminus of LF with PE domains Ib and III. Like the internally-deleted LF proteins, these LF-PE fusions were also made by ligation of two separate PCR products. In the latter

two types of constructs, the ligation of the PCR products resulted in addition of a linker, ACGCGT, at the junction points. This introduced two non-native residues, Thr-Arg, between the fused domains. The PCR manipulations also added three non-native amino acids, Met-Val-Pro, as an extension to the native amino terminus on all the constructs described in this report. Addition of this sequence is not likely to alter the activity of the constructs (discussed below). It should be noted that the LF-PE fusions described herein contain this three-residue extension.

For PCR reactions to make deletions of 40 and 78 amino acids from the amino-terminus of LF, two different mutagenic oligonucleotide primers were made which were substantially identical to the LF gene template at the intended new termini, and which added *KpnI* sites at their 5'-ends. Another (non-mutagenic) oligonucleotide primer for introduction of a *BamHI* site at the 3'end of LF was prepared. Similarly, to make deletions at the carboxyl-terminus of LF, two different mutagenic primers were used which truncated LF at residues 729 and 693 and introduced a *BamHI* site next to the new 3' ends of the LF gene. A second (non-mutagenic) oligonucleotide primer specific for the amino terminus of LF was made which introduced a *KpnI* site at the 5' end of the gene. All of the primers noted above were used in PCR reactions on a pLF7 template (Robertson and Leppla, 1986) to synthesize DNA fragments having *KpnI* and *BamHI* sites at their 5' and 3' ends, respectively. The amplified LF DNAs containing the amino- and carboxyl-terminal deletions were digested with the appropriate restriction enzymes. The expression vector pVEX115f+T (provided by V. K. Chaudhary, NCI, NIH) was cleaved sequentially with *KpnI* and *BamHI* and dephosphorylated. This expression vector contains a T7 promoter, an OmpA signal sequence for protein transport to the periplasm, a multiple cloning site that includes *KpnI* and *BamHI* sites, and a T7 transcription terminator. The LF and pVEX115f+T DNA fragments were purified from low melting point agarose, ligated overnight, and transformed into *E. coli* DH5α. Transformants were screened by restriction digestion to identify the desired

recombinant plasmids. Proteins produced by these constructs are designated according to the amino acid residues retained; for example the LF truncated at residue 693 is designated LF^{1-693}. All of the mutant LF proteins described above contain three non-native amino acids, Met-Val-Pro, added to the amino-terminus as a result of the PCR manipulations.

To analyze the role of the repeat region of LF, four different constructs were made: 1., removal of the entire repeat region ($LF^{1-307}.TR.LF^{384-776}$), 2., removal of the first repeat ($LF^{1-307}.TR.LF^{327-776}$), 3., removal of the last repeat ($LF^{1-364}.TR.LF^{384-776}$), and 4., removal of repeats 2-4 ($LF^{1-326}.TR.LF^{384-776}$). To construct $LF^{1-307}.TR.LF^{384-776}$, four different primers were used in two separate PCR reactions. To amplify LF^{1-307}, one oligonucleotide primer was made at the 5'-end of the LF gene which added a *Kpn*I site, and a second primer was constructed at the end of residue 307, introducing an *Mlu*I site. For amplifying $LF^{384-776}$, a third primer was made at residue 384 with an added *Mlu*I site, and the fourth primer was made at the residue 776 which introduced a *BamH*I site at the end. Two PCR amplifications were done using primers one/two and three/four with pLF7 as template (Robertson and Leppla, 1986). The first amplification reaction was digested with *Kpn*I and *Mlu*I separately, and the second amplification reaction was digested with *Mlu*I and *BamH*I. The expression vector pVEX115f+T was digested separately with *Kpn*I and *BamH*I and dephosphorylated. All three fragments were gel purified, ligated overnight at 16°C and transformed into *E. coli* DH5α. The other three constructs were made by similar strategies. Oligonucleotide primers one and four were the same for all four constructs, whereas primers two and three were changed accordingly. All four constructs contain Met-Val-Pro at the amino terminus of LF and Thr-Arg at the site of the repeat region deletion.

To construct LF-PE fusion proteins, fragments of the LF gene extending from the amino terminus to various lengths were amplified from plasmid pLF7 (Robertson and Leppla, 1986) by PCR using a common oligonucleotide primer that added a *Kpn*I site at the 5' end and mutagenic primers which added *Mlu*I

sites at the intended new 3' ends. The PCR products of the LF gene were digested with *Kpn*I, the DNAs were precipitated, and subsequently digested with *Mlu*I. Domains Ib and III of the PE gene (provided by David FitzGerald, NCI, NIH) were amplified by PCR using primers which added *Mlu*I and *EcoR*I sites at the 5' and 3' ends, respectively. The PCR product of PE was digested with *Mlu*I and *EcoR*I. Similarly, the expression vector pVEX115f+T was digested with *Kpn*I and *EcoR*I. All DNA fragments were purified from low-melting agarose gels, three-fragment ligations were carried out, and the products were transformed into *E. coli* DH5α. The three constructs described in this example have 254, 198 and 79 amino acids of LF joined with PE domains Ib and III. These fusion proteins are designated $LF^{1-254}.TR.PE^{362-613}$ (SEQ ID NO:10), $LF^{1-198}.TR.PE^{362-613}$, and $LF^{1-79}.TR.PE^{362-613}$, respectively. The proteins retain the native carboxyl-terminal sequence of PE, REDLK. It should be noted that these abbreviations do not specify the entire amino acid content of the proteins, because all the constructs also contain Met-Val-Pro, which was added to the amino-terminus of the LF domain by the PCR manipulations.

Expression and Purification of Deleted LF and Fusion Proteins

Recombinant plasmids were transformed into *E. coli* SA2821 (provided by Sankar Adhya, NCI, NIH), a derivative of BL21(λDE3) (Studier and Moffatt, 1986) that lacks the proteases encoded by the *lon*, *OmpT*, and *degP* genes, and has the T7 RNA polymerase gene under control of the *lac* promoter (Strauch et al., 1989). Transformants were grown in super broth with 100 μg/ml ampicillin, with shaking at 225 rpm, 37°C, in 2-L cultures. When A_{600} reached 0.8-1.0, isopropyl-1-thio-β-D-galactopyranoside was added to a final concentration of 1 mM, and cultures were incubated for an additional 2 h. EDTA and 1,10-*o*-phenanthroline were added to 5 and 0.1 mM, respectively, and periplasmic protein was extracted as described in Example 1. The supernatant fluids were concentrated by Centriprep-30 units (Amicon) and proteins were purified to near homogeneity by gel filtration (Sephacryl S-200, Pharmacia-LKB) and anion exchange

chromatography (MonoQ, Pharmacia-LKB) as described in Example 1. To determine the percentage of full length protein, SDS gels stained with Coomassie Brilliant Blue were scanned with a laser densitometer (Pharmacia-LKB Ultrascan XL). Western blots were performed as described previously (Singh et al., 1991).

The LF proteins having terminal deletions and the LF-PE fusion proteins were obtained from periplasmic extracts and purified to near homogeneity by gel filtration and anion exchange chromatography. The migration of the proteins was consistent with their expected molecular weights. Immunoblots confirmed that the LF proteins had reactivity with LF antisera, and the LF-PE fusion proteins had reactivity with both LF and PE antisera. Fusion proteins and terminally-deleted LF proteins differed in their susceptibility to proteolysis as judged by the appearance of peptide fragments on the immunoblots, and this was also reflected in the different amounts of purified proteins obtained. Thus, from 2-L cultures the yields of purified proteins were LF^{41-776}, 39 μg; LF^{79-776}, 32 μg; LF^{1-729}, 50 μg; LF^{1-693}, 46 μg; $LF^{1-254}.TR.PE^{362-613}$, 184 μg; $LF^{1-198}.TR.PE^{362-613}$, 80 μg; $LF^{1-79}.TR.PE^{362-613}$, 127 μg.

LF proteins deleted in the repeat region were found to be unstable and full size product could not be purified. Therefore, the activities of these proteins were determined by assay of crude periplasmic extracts, and immunoblots were used to estimate the amount of the full size proteins present.

Cytotoxicity on Macrophages of LF Proteins Having Terminal and Internal Deletions

Deleted LF proteins were assayed for LF functional activity on the J774A.1 macrophage cell line in the presence of native PA as described in Example 1. Briefly, cells were plated in 24- or 48-well dishes in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal bovine serum, and allowed to grow for 18 h. PA (1 μg/ml) and the mutant LF proteins were added and cells were incubated for 3 h. To measure the viability of the treated cells, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) was added to the cells

to a final concentration of 0.5 mg/ml. After incubating for 45 min, the medium was aspirated and cells were dissolved in 90% isopropanol, 0.5% SDS, 40 mM HCl, and read at 540 nm using a UVmax Kinetic Microplate Reader (Molecular Devices Corp.).

To determine the extent of essential sequences at the amino terminus of LF, the toxicities of the two LF proteins deleted at the amino-terminus were measured in combination with PA in the macrophage lysis assay. Purified LF^{41-776} and LF^{79-776} were unable to lyse J774A.1 macrophage cells. This indicates that some portion of the sequence preceding residue 41 is needed to maintain an active LF protein.

To examine the role of the carboxyl terminus of LF, two proteins truncated in this region were prepared and analyzed. The proteins LF^{1-693} and LF^{1-729} were assayed on J774A.1 cells and found to be inactive. This is presumed to be due to inactivation of the putative catalytic domain.

To begin study of the role of the repeat region of LF, four constructs were made having deletions in this region. The proteins expressed from these mutants were unstable. Of the four deleted proteins, only $LF^{1-307}.TR.LF^{327-776}$ had immunoreactive material at the position expected of intact fusion protein. The amount of intact $LF^{1-307}.TR.LF^{327-776}$ was similar to that of native LF expressed in the same vector. When these unpurified periplasmic extracts were tested in J774A.1 macrophages, only the native LF control was toxic. $LF^{1-307}.TR.LF^{327-776}$ did not lyse macrophages even when present at 50-fold higher concentration than that of crude periplasmic protein of LF. Conclusions cannot be drawn about the toxicities of the other three constructs because full size fusion proteins were not present in the periplasmic extracts.

Cell Culture Techniques and Protein Synthesis Inhibition Assay of Fusion Proteins

CHO cells were maintained as monolayers in α-modified minimum essential medium (α-MEM) supplemented with 5% fetal bovine serum, 10 mM HEPES (pH 7.3), and penicillin/streptomycin. Protein synthesis assays were carried out in 24- or 48-well dishes as described in Example 1. CHO cells were incubated with PA (0.1 ug/ml) and varying

concentrations of LF, which is expected to block the receptor. Fusion proteins were added at fixed concentrations, as follows: FP4, 100 ng/ml, FP23, 100 ng/ml, and FP33, 5 ng/ml. Cells were incubated for 20 hr and protein synthesis inhibition was evaluated by [^{3}H]leucine incorporation.

Cytotoxicity of the LF-PE Fusion Proteins on CHO Cells

The use of fusion proteins provides a more defined method for measuring the translocation of LF, as demonstrated in Example 1 showing that fusions of LF with domains Ib and III of PE are highly toxicy. Translocation of these fusions is conveniently measured because domain III blocks protein synthesis by ADP-ribosylation of elongation factor 2. The new fusions containing varying portions of LF fused to PE domains Ib and III were designed to identify the minimum LF sequence able to promote translocation. The EC_{50} of $LF^{1-254}.TR.PE^{362-613}$ (SEQ ID NO: 10) was 1.7 ng/ml, whereas $LF^{1-198}.TR.PE^{362-613}$ and $LF^{1-79}.TR.PE^{362-613}$ did not kill 50% of the cells even at a 1200-fold higher concentration. Other constructs were also made and analyzed, containing larger portions of LF fused to PE domains Ib and III, and found those to be equal in potency to $LF^{1-254}.TR.PE^{362-613}$. These results show that residues 1-254 contain all the sequences essential for binding to PA63. The fusion proteins had no toxicity in the absence of PA, proving that their internalization absolutely requires interaction with PA.

Binding of Fusion Proteins and Deleted LF Proteins to PA

Binding of LF proteins to cell bound PA was determined by competition with radiolabeled ^{125}I-LF. Native LF was radiolabeled (3.1×10^6 cpm/μg protein) using the Bolton-Hunter reagent. Binding studies employed the L6 rat myoblast cell line, which has approximately twice as many receptors as the J774A.1 macrophage line (Singh et al., 1989). For convenience, cells were chemically fixed by a gentle procedure that preserves the binding activity of the receptor as well as the ability of the cell-surface protease to cleave PA to produce receptor-bound PA63. Assays were carried out

were washed twice with Hanks' balanced salt solution (HBSS) containing 25 mM HEPES and were chemically fixed for 30 min at 23° in 10 mM N-hydroxysuccinimide and 30 mM 1-ethyl-3-[3-dimethyl[aminopropyl] carbodiimide, in buffer containing 10 mM HEPES, 140 mM NaCl, 1 mM $CaCl_2$, and 1 mM $MgCl_2$. Monolayers were washed with HBSS containing 25 mM HEPES and the fixative was inactivated by incubating 30 min at 23° in DMEM (without serum) containing 25 mM HEPES. Native PA was added at 1 μg/ml in minimum essential medium containing Hanks' salts, 25 mM HEPES, 1% bovine serum albumin, and a total of 4.5 mM $NaHCO_3$. Cells were incubated overnight at room temperature to allow binding and cleavage of PA. Cells were washed twice in HBSS and mutant LF proteins (0-5000 ng/ml) along with 50 ng/ml ^{125}I-LF was added to each well. Cells were further incubated for 5 h, washed three times in HBSS, dissolved in 0.5 ml 1 N NaOH, and counted in a gamma counter (Beckman Gamma 9000).

Using this assay, the LF mutant proteins having amino-terminal deletions were found incapable of binding to PA, thereby explaining their lack of toxicity. Carboxyl-terminal deleted LF proteins did bind to PA in a dose dependent manner, although they had slightly lower affinity than LF. The proteins deleted in the repeat region could not be tested for competitive binding because their instability prevented purification of intact protein.

The EC_{50} for LF^{1-254}.TR.$PE^{362-613}$ binding was found to be 220 ng/ml, which is similar to that of LF, 300 ng/ml. Therefore the binding data correlate well with the toxicity of this construct. In contrast, neither LF^{1-198}.TR.$PE^{362-613}$ nor LF^{1-79}.TR.$PE^{362-613}$ bound to PA63 on cells, thereby explaining their lack of toxicity.

EXAMPLE 3: Construction of Genes Encoding PA Fusion Proteins

The genes encoding PA (or PA truncated at the carboxyl terminus to abrogate binding to the PA receptor) and an alternative targeting moiety (a single-chain antibody, growth factor, or other cell type-specific domain) are spliced using conventional molecular biological techniques. The PA gene is

readily available, and the genes encoding alternative targeting domains are derived as described below.

Single-chain antibodies (sFv)

See Example 4, below.

Growth factors and other targeting proteins

The nucleotide sequences of genes encoding a number of growth factors and other proteins that are targeted to specific cell types or classes are reported in freely accessible databases (e.g., GenBank), and in many cases the genes are available. In circumstances where this is not the case, genes can be cloned from genomic or cDNA libraries, using probes based on the known nucleotide sequence of the gene that codes for the growth factor, or derived from a partial amino acid sequence of the protein (see, e.g. Sambrook, supra.). Alternatively, genes encoding the growth factor or other targeting moiety can be produced *de novo* from chemically synthesized overlapping oligonucleotides, using the preferred codon usage of the expression host. For example, the gene for human epidermal growth factor urogastrone was synthesized from the known amino acid sequence of human urogastrone using yeast preferred codons. The cloned DNA, under control of the yeast GAPDH promoter and yeast ADH-1 terminator, expresses a product having the same properties as natural human urogastrone. The product of this synthesized gene is nearly identical to that of the natural urogastrone, the only difference being that the product of the synthetic gene has a trptophan at amino acid 13, while the other has a tyrosine (Urdea et al. *Proc. Natl. Acad. Sci. USA* 80:7461-7465, 1983).

Expression of PA Fusion proteins

Once constructed, genes encoding PA-fusion proteins are expressed in *Bacillus anthracis*, and recombinant proteins are purified by one of the following methods: (i) size-based chromatographic separation; (ii) affinity chromatography. In the case of PA-sFv fusions, immobilized metal chelate affinity chromatography may be the purification method of choice, because addition of a string of six histidine resi[illegible]

on binding to antigen. Additional methods of expression of PA-fusion proteins utilize an *in vitro* rabbit reticulocyte lysate-based coupled transcription/translation system, which has been demonstrated to accurately refold chimeric proteins consisting of an sFv fused to diphtheria toxin, or *Pseudomonas* exotoxin A as demonstrated in Example 4.

Functional testing of PA Fusion proteins

After expression and purification, functionality of PA-fusion proteins are tested by determining their ability to act in concert with an LF-PE fusion protein to inhibit protein synthesis in an appropriate cell line. Using a PA-anti human transferrin receptor sFv fusion as a model, the following properties are examined: (i) Cell type-specificity (protein synthesis should be inhibited in cell lines which express the human transferrin receptor, but not in those which do not); (ii) Independence of toxicity from PA receptor binding (excess free PA should have no effect on toxicity of the PA-sFv/LF-PE complex); (iii) Competitive inhibition by excess free antibody (toxicity should be abrogated in the presence of excess sFv, or the monoclonal antibody from which it was derived). For example such tests are described in Examples 4 and 5. These studies and other studies are used to confirm that PA has been successfully re-routed to an alternative receptor to permit the use of the present anthrax toxin-based cell type-specific cytotoxic agents for the treatment of disease.

EXAMPLE 4: Generating Fusion Proteins with Single-chain Antibodies Reagents

Methionine-free rabbit reticulocyte lysate-based coupled transcription/translation reagents, recombinant ribonuclease inhibitor (rRNasin), and cartridges for the purification of plasmid DNA were purchased from Promega (Madison, WI). Tissue culture supplies were from GIBCO (Grand Island, NY) and Biofluids (Rockville, MD). OKT9 monoclonal antibody was purchased from Ortho Diagnostic Systems (Raritan, NJ). PCR reagents were obtained from by Perkin-Elmer Cetus Instruments (Norwalk, CT), and restriction and nucleic acid modifying enzymes (including M-MLV reverse transcriptase) were

from GIBCO-BRL (Gaithersburg, MD). A Geneclean kit for the recovery of DNA from agarose gels was supplied by BIO 101 (La Jolla, CA). Hybridoma mRNA was isolated using a Fast Trak mRNA isolation kit (Invitrogen, San Diego, CA). All isotopes were purchased from Du Pont-New England Nuclear (Boston, MA), except [Adenylate-^{32}P]NAD, which was supplied by ICN Biomedicals (Costa Mesa, CA). *Pseudomonas* exotoxin A was obtained from List Biologicals (Campbell, CA). Oligonucleotides were synthesized on a dual column Milligen-Biosearch Cyclone Plus DNA synthesizer (Burlington, MA), and purified using OPC cartridges (Applied Biosystems, Foster City, CA). DNA templates were sequenced using a Sequenase II kit (United States Biochemical Corp., Cleveland, OH), and SDS-polyacrylamide gel electrophoresis (PAGE) was performed using 10-20% gradient gels (Daiichi, Tokyo, Japan). After electrophoresis, gels were fixed in 10% methanol/7% acetic acid, and soaked in autoradiography enhancer (Amplify, Amersham Arlington Heights, IL). After drying, autoradiography was performed overnight using X-OMAT AR2 film (Eastman Kodak, Rochester, NY).

Plasmids

The vector pET-11d is available from Novagen, Inc., Madison, WI. Plasmids were maintained and propagated in *E. coli* strain XL1-Blue (Stratagene, La Jolla, CA).

Cell Lines

K562, a human erythroleukemia-derived cell line [ATCC CCL 243] known to express high levels of the human transferrin receptor at the cell surface, was cultured in RPMI 1640 medium containing 24 mM $NaHCO_3$, 10% fetal calf serum, 2 mM glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, and 10 μg/ml gentamycin. An African green monkey kidney line, Vero (ATCC CCL 81), was grown in Dulbecco's modified Eagle's medium (DMEM) supplemented as indicated above. The OKT9 hybridoma (ATCC CRL 8021), which produces a MoAb (IgG_1) reactive to the human transferrin receptor, was maintained in Iscove's modified Dulbecco's medium containing 20% fetal calf serum, in addition to the supplements described above. All cell lines were cultured at 37°C in a 5% CO_2 humidified atmosphere.

Construction of sFv from Hybridomas

Antibody V_L and V_H genes were cloned using a modification of a previously described technique (Larrick et al. *Biotechniques* 7:360, 1989; Orlandi et al. *Proc. Natl. Acad. Sci. USA* 86:3833, 1989; Chaudhary et al., 1990). Briefly, mRNA was isolated from 1 x 10^8 antibody producing hybridoma cells, and approximately 3 μg was reverse transcribed with M-MLV reverse transcriptase, using random hexanucleotides as primers. The resulting cDNA was screened with two sets of PCR primer pairs designed to ascertain from which Kabat gene family the heavy and light chains were derived (Kabat et al. *Sequences of proteins of immunological interest*. Fifth Edition. (Bethesda, Maryland: U.S. Public Health Service, 1991). Having identified the most effective primer pairs, cDNA's encoding V_L and V_H were spliced, separated by a region encoding a 15 amino acid peptide linker, using a previously described PCR technique known as gene splicing by overlap extension (SOE) (Johnson & Bird *Methods Enzymol.* 203:88, 1991). The sFv gene was then cloned into pET-11d, in frame and on the 5'-side of the PE40 gene, such that expression of the construct should generate an sFv-PE40 fusion protein approximately 70 kDa in size.

Design of primers for PCR amplification of V region genes

The first and third complementarity determining regions (CDRs) of terminally rearranged immunoglobulin variable region genes are flanked by conserved sequences (the first framework region, FR1 on the 5' side of CDR1, and the fourth framework region, FR4, on the 3' side of CDR3).

Although murine variable region genes have been successfully cloned, regardless of family, with just two pairs of highly degenerate primers (one pair for V_L and another for V_H) (Gussow et al. *Cold Spring Harbor Symp. Quant. Biol.* 54:265, 1989; Orlandi et al., 1989; Chaudhary et al., 1990; Batra et al., 1991), the method may not be effective in cases where the number of mismatches between primers and the target sequence is extensive. With this in mind, using the Kabat database of murine V gene sequences the present invention provides a set of ten FR1-derived primers (six for V_L and four

for V_H), such that any of the database sequences selected at random would have a maximum of three mismatches with the most homologous primer. This set of primers can be used effectively to clone V region genes from a number of MoAb secreting cell lines.

Assembly of the OKT9 sFv gene

mRNA isolated from the hybridoma secreting the OKT9 MoAb was converted to cDNA as described previously (Larrick et al., 1989; Orlandi et al., 1989; Chaudhary et al., 1990). Despite the fact that CL-UNI is the partnering oligonucleotide in each case, a product the required size (approximately 400 bp) is not produced by V_L primers IV/VI, IIa or IIb. This suggests that mismatches between these primers and the target sequence were too extensive to allow efficient amplification. A similar argument can be used to explain the failure of V_H primers I and III to produce the required product. It is clear that primers V_L-I/III and V_H-V are most effective at amplifying the OKT9 V_L and V_H genes respectively. PCR amplified OKT9 V_L and V_H genes were spliced together using the SOE technique as previously described (Johnson & Bird, 1991)

were produced in similar conditions, except that the isotope was replaced with 20 μM unlabeled L-methionine in the latter case. Control lysate was produced by adding all reagents except plasmid DNA. After translation, unlabeled samples were dialysed overnight at 4°C against phosphate-buffered saline (PBS), pH 7.4 in Spectra/Por 6 MWCO (molecular weight cutoff) 50,000 tubing (Spectrum, Houston, TX).

Constructs incorporating the aberrant kappa transcript will contain a translation termination codon in the V_L chain as previously described, and would therefore be expected to generate a translation product approximately 12 kDa in size. On the other hand, constructs which have incorporated the productive V_L gene contain no such termination codon, and a full-length fusion protein (approximately 70 kDa in size) should be produced.

In vitro expression studies were used to determine the size of the protein encoded by the OKT9 sFv-PE40 gene. The constructs tested in this experiment clearly produce a protein of approximately 70 kDa, indicating that the clones do not contain the aberrant V_L gene, and are devoid of frameshift mutations. Of several OKT9 sFv constructs tested, none apparently incorporated the incorrect VL gene. However, in the case of another sFv generated by this method (1B7 sFv, derived from a MoAb which binds to pertussis toxin), the majority of the clones tested produced a 12 kDa protein, and were found to contain the aberrant transcript on DNA sequencing. It should be noted that the 12kDa fragment is frequently obscured in 10-20% gradient gels by unincorporated ^{35}S-methionine which co-migrates with the dye front.

Determination of Protein Concentration

The enzymatic activities of fusion proteins were compared with those of known concentrations of PE in an ADP-ribosyl transferase assay, allowing molarities to be determined (Johnson et al. *J. Biol. Chem.* 263:1295-1399, 1988). Samples were adjusted to contain equivalent concentrations of lysate, thus maintaining an identical amount of substrate (elongation factor 2) in all cases.

Protein Synthesis Inhibition Assay for Functional sFv-PE40 Binding

Binding of the OKT9 sFv to the human transferrin receptor was qualitatively determined by assessing the ability of the OKT9 sFv-PE40 fusion protein to inhibit protein synthesis in the K562 cell line. *Pseudomonas* exotoxin A is a bacterial protein which is capable of inhibiting *de novo* protein synthesis in a variety of eukaryotic cell types. The toxin binds to the cell surface, and ultimately translocates to the cytosol where it enzymatically inactivates elongation factor 2. PE40 is a mutant form of exotoxin A which lacks a binding domain, but is enzymatically active, and capable of translocation. Fusion proteins containing PE40 and an alternative binding domain (for example, an sFv to a cell surface receptor) will inhibit protein synthesis in an appropriate cell line only if the sFv binds to a cell-surface antigen which subsequently internalizes into an acidified endosome (Chaudhary et al., 1989). The TfnR is such an antigen, so a qualitative assessment of binding may be determined by measuring the ability of the OKT9 sFv-PE40 fusion protein to inhibit protein synthesis in a cell line like K562, which expresses the TfnR. Protein synthesis inhibition assays were performed as described previously (Johnson et al., 1988). Briefly, samples were serially diluted in ice cold PBS, 0.2% BSA, and 11μl volumes were added to the appropriate well of a 96-well microtiter plate (containing 10^4 cells/100μl/well in leucine-free RPMI 1640). After carefully mixing the contents of each well, the plate was incubated for the indicated time at 37°C in a 5% CO_2 humidified atmosphere. Each well was then pulsed with 20μl of L-[^{14}C(U)]leucine (0.1 μCi/20μl), incubated for 1 hour, and harvested onto glass fiber filters using a PHD cell harvester (Cambridge Technology, Cambridge, MA). Results are expressed as a percentage of the isotope incorporation in cells treated with appropriate concentrations of control dialyzed lysate.

The results of this assay, clearly indicate that OKT9 sFv-PE40 is capable of inhibiting protein synthesis with an IC_{50} (the concentration of a reagent which inhibits protein

synthesis by 50%) of approximately 2 x 10^{-9} M. The toxicity of the fusion protein, but not of PE, was abrogated in the presence of excess OKT9 MoAb (12 μg/ml), indicating that binding is specific for the TfnR. No toxicity was observed when K562 was substituted with Vero (an African Green monkey cell line which expresses the simian version of the transferrin receptor), indicating that the OKT9 sFv retains the human receptor-specific antigen binding properties of the parent antibody.

Having demonstrated binding of the OKT9 sFv to TfnR, its nucleotide sequence was determined using dideoxynucleotide chain-terminating methods, confirming extensive homology with the respective regions of immunoglobulins of known sequence.

EXAMPLE 5: Characterization of single-chain antibody (sFv)-toxin fusion proteins produced *in vitro* in rabbit reticulocyte lysate

The present invention provides *in vitro* production of proteins containing a toxin domain (derived from Diphtheria toxin (DT) or PE) fused to a domain encoding a single-chain antibody directed against the human transferrin receptor (TfnR). The expression of this antigen on the cell surface is coordinately regulated with cell growth; TfnR exhibits a limited pattern of expression in normal tissue, but is widely distributed on carcinomas and sarcomas (Gatter, et al. *J. Clin. Pathol.* 36:539-545, 1983), and may therefore be a suitable target for immunotoxin-based therapeutic strategies (Johnson, V. G. and Youle, R. J. "Intracellular Trafficking of Proteins" *Cambridge Univ. Press, Cambridge England*, Steer and Hover eds., pp. 183-225; Batra et al., 1991; Johnson et al., 1988).

Proteins consisting of a fusion between an sFv directed against the TfnR and either the carboxyl-terminus 40 kDa of PE, or the DT mutant CRM 107 [S(525)F] were expressed in rabbit reticulocyte lysates, and found to be specifically cytotoxic to K562, a cell line known to express TfnR. In comparison, a chimeric protein consisting of a fusion between a second DT mutant, DTM1 [S(508)F, S(525)F] and the E6 sFv

exhibited significantly lower cytotoxicity. Legal restrictions imposed on manipulating toxin genes *in vivo* previously prevented expression of potentially interesting toxin-containing fusion proteins (*Federal Register* 51(88)(III):16961 and Appendix F:16971); the present invention provides a novel procedure for *in vitro* gene construction and expression which satisfies the regulatory requirements, facilitating the first study of the potential of non-truncated DT mutants in fusion protein ITs. The present data also demonstrates that functional recombinant antibodies can be generated *in vitro*.

Reagents

DT and PE were purchased from List Biologicals (Campbell, CA). Nuclease treated, methionine-free rabbit reticulocyte lysate and recombinant ribonuclease inhibitor (rRNasin) were obtained from Promega (Madison, WI). Tissue culture supplies were from GIBCO (Grand Island, NY) and Biofluids (Rockville, MD). Reagents for PCR were provided by Perkin-Elmer Cetus (Norwalk, CT). Restriction and nucleic acid modifying enzymes were from Stratagene (La Jolla, CA), as was the mCAP kit used to produce capped mRNA *in vitro*. Geneclean and RNaid kits (for the purification of DNA and RNA respectively) were supplied by BIO 101 (La Jolla, CA). L-[^{35}S]-methionine, L-[^{14}C(U)]-amino acids and 5'-(alpha-thio)-

MD). All plasmids were maintained and propagated in *E. coli* strain XL1-Blue (Stratagene, La Jolla, CA).

Cell Lines

Corynebacterium diphtheriae strain $C7_s(\beta)^{tox+}$ (ATCC 27012) was obtained from the ATCC (Rockville, MD), and the strain producing the binding-deficient DT mutant CRM 103 was the generous gift of Dr. Neil Groman, University of Washington (Seattle, WA). Both strains were propagated in LB broth. K562 (a human erythroleukemia-derived cell line, ATCC CCL 243) was cultured in RPMI 1640 medium containing 24 mM $NaHCO_3$, 10% fetal calf serum, 2 mM glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, and 10 μg/ml gentamycin. Vero (an African green monkey kidney line, ATCC CCL 81) was grown in Dulbecco's modified Eagle's medium supplemented as described above. All eukaryotic cells were cultured at 37°C in a 5% CO_2 humidified atmosphere.

Splicing Genes using PCR

Genes encoding antibody V_L and V_H were spliced, separated by a region encoding a 15 amino acid peptide linker, using a previously described PCR technique known as gene splicing by overlap extension (SOE) (Horton et al. *Gene* 77:61-68, 1989; Horton et al. *Biotechniques 8:528-535, 1990*). For studies requiring *in vitro* expression of PCR products, *tox* gene-derived fragments were linked to those encoding sFv using a similar method, without the use of restriction enzymes.

Construction of Plasmids Encoding Toxin-sFv Fusion Proteins

The gene encoding PE40 was obtained as an insert in pET-11d, and the sFv gene was cloned on the 5' side of this insert as indicated. To clone the gene encoding the DT binding-site mutant DTM1 [S(508)F, S(525)F], genomic DNA was isolated from the *C. diphtheriae* strain which produces CRM 103. DNA was extracted by a modification of the cetyltrimethylammonium bromide extraction procedure (Wilson, K. "Current Protocols in Molecular Biology" *Asubel et al. eds. John Wiley & Sons* New York, 2.4.1 - 2.4.5, 1988) and subjected to 20 cycles of PCR amplification. Primers were designed to: (i) amplify the 1605 bp region encoding CRM 103, concomitantly mutating the codon at position 525 from TCT to TTT, and (ii)

incorporate restriction sites appropriate for cloning. The mutations present in CRM 107 and CRM 103 were thus combined on a single gene.

In Vitro Transcription of DNA Templates

For transcription, DNA templates required a T7 RNA polymerase promoter immediately upstream of the gene of interest (Oakley, J. L. and Coleman, J. E. *Proc. Acad. Sci. U.S.A.* 74:4266-4270, 1977). Such a promoter was conveniently present in pET-11d (Studier et al. *Enzymol* 185:60-89, 1990). In the case of PCR products, the upstream primer (a 57-mer, T7-DT) was used to introduce all of the elements necessary for *in vitro* transcription/translation. T7-DT includes a consensus T7 RNA polymerase promoter, together with the first seven codons of mature DT (Greenfield et al. *Proc. Natl. Acad. Sci. U.S.A.* 80:6853-6857, 1983) immediately preceded by an ATG translation initiation codon in the optimum Kozak context (Kozak, M. *J. Biol. Chem.* 266:19867-19870, 1991). $m^7G(5')ppp(5')G$-capped RNA was produced by transcription from linearized plasmids or PCR products using an mCAP kit, according to the manufacturer's protocol. Prior to translation, RNA was purified using an RNaid kit, recovered in nuclease free water, and analyzed by formaldehyde gel electrophoresis.

In Vitro Expression of Fusion Proteins

L-[^{35}S]methionine-labelled proteins (for analysis by SDS-PAGE) were produced from capped RNA in methionine-free, nuclease treated rabbit reticulocyte lysate, according to the supplier's instructions. Unlabeled proteins (for bioassay), were produced in similar conditions, except that the isotope was replaced with 20 μM unlabeled L-methionine. Control lysate was produced by adding all reagents except exogenous RNA. After translation, samples were dialysed overnight at 4°C against PBS, pH 7.4 in Spectra/Por 6 MWCO 50,000 tubing (Spectrum, Houston, TX).

Prior to transcription, plasmids were linearized at the *BglII* site and treated with proteinase K to destroy ribonucleases that may contaminate the sample. After phenol/chloroform extraction and ethanol precipitation, DNA

was dissolved in nuclease free water to a concentration of approximately 0.2 μg/μl. $m^7G(5')ppp(5')G$-capped RNA was synthesized by T7 RNA polymerase using the conditions recommended by the manufacturer, and its integrity was confirmed by formaldehyde gel electrophoresis. Capped RNA was translated in a commercially available rabbit reticulocyte lysate, according to the instructions of the manufacturer. It is clear from the gel that the major band in each case has a molecular weight corresponding to that of the protein of interest, and that relatively large molecules (approximately 120 kDa in the case of DTM1-E6 sFv-PE40) can be synthesized in the lysate using the conditions described.

Immediately following translation, samples were extensively dialyzed overnight at 4°C against PBS, pH 7.4. The dialysis step was found to be essential, because non-dialyzed rabbit reticulocyte lysate resulted in the incorporation of significantly lower amounts of ^{14}C-leucine upon assay by protein synthesis inhibition in all cell lines tested. After determining the concentration of the newly synthesized protein using a standard assay for measuring ADP-ribosyltransferase activity (Johnson et al., 1988), the cytotoxic activity of samples was immediately determined.

ADP-ribosyl Transferase Assay

The enzymatic activity (and therefore molarity) of fusion proteins was determined by comparison with DT or PE standard curves, as described previously (Johnson et al., 1988). Appropriate volumes of control lysate were added to each standard curve sample, in order to control for the presence of significant levels of EF-2 in reticulocyte lysate.

Other Methods

SDS-PAGE was performed as previously described (Laemmli, U. K. *Nature* 227:680-685, 1970), using 10-20% gradient gels (Daiichi, Tokyo, Japan). Once electrophoresis was complete, gels were fixed for 15 minutes in 10% methanol, 7% acetic acid, and then soaked for 30 minutes in autoradiography enhancer (Amplify, Amersham Arlington Heights, IL). After drying, autoradiography was performed overnight using X-OMAT AR2 film (Eastman Kodak, Rochester, NY), in the

absence of intensifying screens. Dideoxynucleotide chain-termination sequencing of double-stranded DNA templates was performed using a Sequenase II kit (United States Biochemical Corp., Cleveland, OH), according to the manufacturer's protocol.

Cytotoxicity of Toxin-sFv Fusion Proteins Expressed in Reticulocyte Lysates

The cytotoxic activity of fusion proteins was determined by their ability to inhibit protein synthesis in relevant cell lines (e.g., K562). Assays were performed as described previously (Johnson et al., 1988). Briefly, samples were serially diluted in ice cold PBS, 0.2% BSA, and 11μl volumes were added to the appropriate well of a 96-well microtiter plate (containing 10^4 cells/well in leucine-free RPMI 1640). After carefully mixing the contents of each well, the plate was incubated for the indicated time at 37°C in a 5% CO_2 humidified atmosphere. Each well was then pulsed with 20μl of L-[^{14}C(U)]leucine (0.1 μCi/20μl), incubated for 1 hour, and harvested onto glass fiber filters using a PHD cell harvester (Cambridge Technology, Cambridge, MA). Results were expressed as a percentage of the isotope incorporation in cells treated with appropriate concentrations of control dialyzed lysate.

The results of the protein synthesis inhibition assay clearly indicate that PE40-containing fusion proteins synthesized in cell-free reticulocyte lysates are highly cytotoxic to this cell line (IC_{50} 1 x 10^{-10} M). In contrast, DTM1-E6 sFv was at least ten-fold less toxic to K562 than the PE40-containing fusion protein, despite the fact that it exhibited ADP-ribosyl transferase activity indistinguishable from that of wt DT synthesized from an equivalent amount of RNA in an identical reticulocyte lysate mix. Since the decreased toxicity of DTM1-E6 sFv is clearly not due to a deficit in enzymatic activity, the binding and/or translocation process is implicated. Possible mechanisms by which the sFv-antigen interaction could be inhibited include: (i) misfolding of the sFv domain or (ii) steric interactions with other regions of the fusion protein preventing close

association of sFv with the TfnR. It is of interest that a tripartite protein, DTM1-E6 sFv-PE40 was significantly cytotoxic to K562 (IC_{50} around 1 x 10^{-10} M, similar to that of PE40-E6 sFv), and the toxic effect was clearly mediated via the TfnR, since this activity was blocked by addition of excess E6 Mab. Although it is possible that the inclusion of the PE40 moiety at the carboxyl end of the tripartite molecule results in a significant conformational change in domains more proximal to the amino terminus, it seems unlikely that the sFv binding domain of DTM1-E6 is misfolded, or unavailable to interact with the TfnR. Interactions of DTM1-E6 sFv with the cell surface could be measured in a direct binding assay (Greenfield et al. *Science* 238:536-539, 1987), but these studies were not performed in the course of this investigation. Nevertheless, it appears likely that the lack of toxicity of the DTM1-E6 sFv fusion protein is due to a deficit in its translocation function.

The expression system developed is rapid and easy, and facilitates the manipulation of a number of samples at once. No complicated protein purification or refolding procedures are required, and the method can be used to express proteins which, due to restrictions imposed on the manipulation of toxin-encoding genes, could not be produced by more conventional methods. The technique is ideal for ascertaining the suitability of new sFv for IT development; it is theoretically possible to assemble the sFv-encoding gene (and that encoding the IT itself) by splicing of PCR products derived directly from the hybridoma, without the necessity for cloning. This would facilitate the selection of the most promising candidate molecule, prior to investing considerable effort and expense in large scale protein production and purification. Toxins and toxin-containing fusion proteins are proving to be powerful aids in our understanding of receptor mediated endocytosis and intracellular routing, and are providing valuable insight into normal cell function (reviewed in ref. 2). The method described simplifies the generation of such molecules, and facilitates their production and use in

laboratories in which the application of more conventional expression methods would be impractical.

Example 6: Cassette Mutagenesis to Produce PAHIV Mutants.

Three pieces of DNA are joined together. Piece A has vector sequences and encodes the "front half" (5' end of the gene) of PA protein, B is short piece of DNA (referred to as a cassette) and encodes a small middle piece of PA protein and piece C which encodes the "back half" (3' end of the gene) of PA.

PA with alternate HIV-1 cleavage sites were created by a cassette mutagenesis procedure. Eight deoxyoligonucleotides were synthesized for construction of cassettes coding for specifically designed amino acid sequences. All four cassettes were generated by annealing two synthetic oligonucleotides (primers).

Primer 1A CG CAA GTA TCA CAA AAT TAT CCG ATC GTG CAA AAC ATA CTG CAG G

Q V S O N Y P I V O N I L Q

Primer 1B G TTC CTG CAG TAT GTT TTG CAC GAT CGG ATA ATT TTG TGA TAC TTG

Primer 2A CG AAC ACT GCC ACT ATC ATG ATG CAA CGT GGT AAT TTT CTG CAG G

N T A T I M M O R G N F L Q

Primer 2B G TCC CTG CAG AAA ATT ACC ACG TTG CAT CAT GAT AGT GGC AGT GTT

Primer 3A CG ACT GTC TCT TTT AAC TTC CCG CAA ATC ACG CTT TGG CTG CAG G

T V S F N F P O I T L W L Q

Primer 3B G TCC CTG CAG CCA AAG CGT GAT TTG CGG GAA GTT AAA AGA GAC AGT

Primer 4A CG GGC GGT TCT GCC TTT AAC TTC CCG ATC GTC ATG GGA GGT CTG CAG G

G G S A F N F P I V M G G L Q

Primer 4B G TCC CTG CAG ACC TCC CAT GAC GAT CGG GAA GTT AAA GGC AGA ACC GCC

The underlined portion of each protein se

Primer pair 2 encodes a protein sequence which duplicates part of the cleavage site between the capsid and the nucleocapsid protein.

Primer pair 3 encodes a protein sequence which duplicates part of the cleavage site between the protease and the p6 protein. Like the protease, p6 is a portion of the large protein produced by HIV.

Primer pair 4 encodes a protein sequence which should be cleaved by the protease. It was created by examining several protein sequences which are recognized by the HIV protease and using the common residues from each sequence. Glycine residues were added to each end to make the molecule more flexible.

The mutagenic cassettes were ligated with the *Bam*HI/*Bst*BI fragment from plasmid pYS5 and the *Ppu*MI-*Bam*I-II fragment from plasmid pYS6. Plasmids shown to have correct restriction maps were transformed into the *E. coli dam*$^-$ *dcm*$^-$ strain GM2163 (available from New England Bio-Labs, Beverly, MA). Unmethylated plasmid DNA was purified from each mutant and used to transform *B. anthracis*. For methods, see Klimpel, et al. *Proc. Natl. Acad. Sci.* 89:10277-10281 (1992). pYS5 and pYS6 construction are described in Singh, et al. *J. Bio. Chem.* 264:19103-19107 (1989).

The nucleotide and amino acid sequence of the mature PA protein after alteration with primer set 2 are shown below. Nucleotides residues 482 to 523 were replaced with cassette 2 resulting in replacement of amino acid residues 162-171 of PA with residues NTATIMMQRGNFLQ, PAHIV#2. The altered DNA sequence and the new amino acid residues are underlined.

Sequence Range: 1 to 2220

```
                                                                      60
                                                                      *
GAA GTT AAA CAG GAG AAC CGG TTA TTA AAA TGA ATC AGA ATC AAG TTC CCA GGG TTA CTA
CTT CAA TTT GTC CTC TTG GCC AAT AAT TTA CTT AGT CTT AGT TCA AGG GTC CCC AAT GAT
Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser Gln Gly Leu Leu>

                                                                     120
                                                                      *
GGA TAC TAT TTT AGT GAT TTG AAT TTT CAA GCA CCC ATG GTG GTT ACC TCT TCT ACT ACA
CCT ATG ATA AAA TCA CTA AAC TTA AAA AGT TCG TGG GTA CAC CAA TGG AGA AGA TGA TGT
Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro Met Val Val Thr Ser Ser Thr Thr>

                                                                     180
                                                                      *
GGG GAT TTA TCT ATT CCT AGT TCT GAG TTA GAA AAT ATT CCA TCG GAA AAC CAA TAT TTT
CCC CTA AAT AGA TAA GGA TCA AGA CTC AAT CTT TTA TAA GGT AGC CTT TTG GTT ATA AAA
Gly Asp Leu Ser Ile Pro Ser Ser Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe>

                                                                     240
                                                                      *
CAA TCT GCT ATT TGG TCA GGA TTT ATC AAA GTT AAG AAG AGT GAT GAA TAT ACA TTT GCT
GTT AGA CGA TAA ACC AGT CCT AAA TAG TTT CAA TTC TTC TCA CTA CTT ATA TGT AAA CGA
Gln Ser Ala Ile Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala>

                                                                     300
                                                                      *
ACT TCC GCT GAT AAT CAT GTA ACA ATG TGG GTA GAT GAC CAA GAA GTG ATT AAT AAA GCT
TGA AGG CGA CTA TTA GTA CAT TGT TAC ACC CAT CTA CTG GTT CTT CAC TAA TTA TTT CGA
Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val Ile Asn Lys Ala>

                                                                     360
                                                                      *
TCT AAT TCT AAC AAA ATC AGA TTA GAA AAA GGA AGA TTA TAT CAA ATA AAA ATT CAA TAT
AGA TTA AGA TTG TTT TAG TCT AAT CTT TTT CCT TCT AAT ATA GTT TAT TTT TAA GTT ATA
Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg Leu Tyr Gln Ile Lys Ile Gln Tyr>

                                                                     420
                                                                      *
CAA CGA GAA AAT CCT ACT GAA AAA GGA TTG GAT TTC AAG TTG TAC TGG ACC GAT TCT CAA
GTT GCT CTT TTA GGA TGA CTT TTT CCT AAC CTA AAG TTC AAC ATG ACC TGG CTA AGA GTT
Gln Arg Glu Asn Pro Thr Glu Lys Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln>

                                                                     480
                                                                      *
AAT AAA AAA GAA GTG ATT TCT AGT GAT AAC TTA CAA TTG CCA GAA TTA AAA CAA AAA TCT
TTA TTT TTT CTT CAC TAA AGA TCA CTA TTG AAT GTT AAC GGT CTT AAT TTT GTT TTT AGA
Asn Lys Lys Glu Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser>

                                                                     540
                                                                      *
TCG AAC ACT GCC ACT ATC ATG ATG CAA CGT GGT AAT TTT CTG CAG GGA CCT ACG GTT CCA
AGC TTG TGA CGG TGA TAG TAC TAC GTT GCA CCA TTA AAA GAC GTC CCT GGA TGC CAA GGT
Ser Asn Thr Ala Thr Ile Met Met Gln Arg Gly Asn Phe Leu Gln Gly Pro Thr Val Pro>

                                                                     600
                                                                      *
GAC CGT GAC AAT GAT GGA ATC CCT GAT TCA TTA GAG GTA GAA GGA TAT ACG GTT GAT GTC
CTG GCA CTG TTA CTA CCT TAG GGA CTA AGT AAT CTC CAT CTT CCT ATA TGC CAA CTA CAG
Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr Thr Val Asp Val>

                                                                     660
                                                                      *
AAA AAT AAA AGA ACT TTT CTT TCA CCA TGG ATT TCT AAT ATT CAT GAA AAG AAA GGA TTA
TTT TTA TTT TCT TGA AAA GAA AGT GGT ACC TAA AGA TTA TAA GTA CTT TTC TTT CCT AAT
Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser Asn Ile His Glu Lys Lys Gly Leu>
```

720
*
ACC AAATAT AAA TCA TCT CCT GAAAAATGG AGC ACGGCT TCT GAT CCG TAC AGT GATTTC
TGG TTTATA TTT AGT AGA GGA CTTTTTACC TCG TGC CGA AGA CTA GGC ATG TCA CTAAAG
Thr LysTyr Lys Ser Ser Pro GluLysTrp Ser ThrAla SerAsp ProTyr Ser AspPhe>

780
*
GAA AAGGTT ACA GGA CGG ATT GATAAGAAT GTA TCA CCA GAG GCA AGA CAC CCC CTTGTG
CTT TTCCAA TGT CCT GCC TAA CTATTCTTA CAT AGT GGT CTC CGT TCT GTG GGG GAACAC
Glu LysVal Thr Gly Arg Ile AspLysAsn Val SerPro GluAla ArgHis Pro LeuVal>

840
*
GCA GCTTAT CCG ATT GTA CAT GTAGATATG GAG AATATT ATT CTC TCAAAA AAT GAGGAT
CGT CGAATA GGC TAA CAT GTA CATCTATAC CTC TTATAA TAAGAG AGTTTT TTA CTCCTA
Ala AlaTyr Pro Ile Val His ValAspMet Glu AsnIle IleLeu SerLys Asn GluAsp>

900
*
CAA TCCACA CAG AAT ACT GAT AGTGAAACG AGA ACAATA AGT AAAAATACT TCT ACAAGT
GTT AGGTGT GTC TTA TGA CTA TCACTTTGC TCT TGTTAT TCATTT TTATGA AGA TGTTCA
Gln SerThr Gln Asn Thr Asp SerGluThr Arg Thr Ile Ser Lys AsnThr Ser ThrSer>

960
*
AGG ACACAT ACT AGT GAA GTA CATGGAAAT GCA GAAGTG CAT GCG TCG TTC TTT GATATT
TCC TGTGTA TGA TCA GTT CAT GTACCTTTA CGT CTT CAC GTA CGC AGC AAG AAA CTATAA
Arg ThrHis Thr Ser Glu Val HisGlyAsnAla GluVal HisAla Ser Phe Phe AspIle>

1020
*
GGT GGGAGT GTA TCT GCA GGA TTTAGTAAT TCG AATTCA AGT ACG GTC GCA ATT GATCAT
CCA CCCTCA CAT AGA CGT CCT AAATCATTA AGC TTAAGT TCA TGC CAG CGT TAA CTAGTA
Gly GlySer Val Ser Ala Gly PheSerAsn Ser AsnSer SerThr ValAla Ile AspHis>

1080
*
TCA CTATCT CTA GCA GGG GAA AGAACTTGG GCT GAAACA ATG GGT TTAAAT ACC GCTGAT
AGT GATAGA GAT CGT CCC CTT TCTTGAACC CGA CTTTGT TAC CCA AATTTA TGG CGACTA
Ser LeuSer Leu Ala Gly Glu ArgThrTrp Ala GluThr Met Gly LeuAsn Thr AlaAsp>

1140
*
ACA GCAAGA TTA AAT GCC AAT ATTAGATAT GTA AATACT GGG ACG GCT CCA ATC TACAAC
TGT CGTTCT AAT TTA CGG TTA TAATCTATA CAT TTATGA CCC TGC CGA GGT TAG ATGTTG
Thr AlaArg Leu Asn Ala Asn IleArgTyr Val AsnThr GlyThr Ala Pro Ile TyrAsn>

1200
*
GTG TTACCA ACG ACT TCG TTA GTGTTAGGA AAA AAT CAA ACA CTC GCG ACA ATT AAAGCT
CAC AATGGT TGC TGA AGC AAT CACAATCCT TTT TTAGTT TGT GAG CGC TGT TAA TTTCGA
Val LeuPro Thr Thr Ser Leu Val LeuGly Lys AsnGln Thr LeuAla Thr Ile LysAla>

1260
*
AAG GAAAAC CAA TTA AGT CAA ATACTTGCA CCT AATAAT TAT TAT CCT TCT AAA AACTTG
TTC CTTTTG GTT AAT TCA GTT TATGAACGT GGA TTATTA ATAATA GGAAGA TTT TTGAAC
Lys GluAsn Gln Leu Ser Gln IleLeuAla Pro AsnAsn Tyr Tyr ProSer Lys AsnLeu>

1320
*
GCG CCAATC GCA TTA AAT GCA CAAGACGAT TTC AGT TCT ACT CCA ATT ACA ATG AATTAC
CGC GGTTAG CGT AAT TTA CGT GTT CTGCTAAAG TCAAGA TGAGGT TAATGT TAC TTAATG
Ala ProIle Ala Leu Asn Ala GlnAspAsp Phe SerSer Thr Pro IleThr Met AsnTyr>

1440
*
GGG AATATA GCA ACA TAC AAT TTT GAAAAT GGA AGAGTG AGG GTG GAT ACA GGC TCG AAC
CCC TTATAT GCT TGT ATG TTA AAACTTTTA CCT TCT CAC TCC CAC CTATGT CCG AGC TTG
Gly AsnIle Ala Thr Tyr Asn PheGluAsn Gly ArgVal ArgVal AspThr Gly SerAsn

1500
*
TGG AGTGAA GTG TTA CCG CAA ATT CAAGAA ACA ACTGCA CGT ATC ATT TTT AAT GGAAAA
ACC TCACTT CAC AAT GGC GTT TAAGTT CTT TGT TGACGT GCA TAG TAAAAA TTA CCTTTT
Trp SerGlu Val Leu Pro Gln IleGlnGlu Thr ThrAla ArgIle Ile Phe Asn GlyLys

1560
*
GAT TTAAAT CTG GTA GAA AGG CGGATAGCG GCG GTTAAT CCTAGT GAT CCA TTA GAAACG
CTA AATTTA GAC CAT CTT TCC GCCTATCGC CGC CAATTA GGATCA CTAGGT AAT CTTTGC
Asp LeuAsn Leu Val Glu Arg ArgIleAla Ala ValAsn Pro Ser Asp Pro Leu GluThr

1620
*
ACT AAACCG GAT ATG ACA TTA AAAGAAGCC CTT AAAATA GCA TTT GGA TTT AAC GAACCG
TGA TTTGGC CTA TAC TGT AAT TTT CTTCGG GAA TTTTAT CGT AAA CCT AAA TTG CTTGGC
Thr Lys Pro Asp Met Thr Leu LysGluAla Leu Lys Ile Ala Phe Gly Phe Asn GluPro

1680
*
AAT GGAAAC TTA CAA TAT CAA GGGAAAGAC ATA ACC GAA TTT GAT TTT AAT TTC GAT CAA
TTA CCTTTG AAT GTT ATA GTT CCCTTTCTG TAT TGG CTT AAA CTA AAA TTA AAG CTAGTT
Asn GlyAsn Leu Gln Tyr Gln GlyLysAsp Ile ThrGlu Phe Asp PheAsn Phe AspGln

1740
*
CAA ACATCT CAA AAT ATC AAG AAT CAGTTA GCG GAATTA AAC GCA ACT AAC ATA TATACT
GTT TGTAGA GTT TTA TAG TTC TTAGTCAAT CGC CTTAAT TTG CGT TGA TTG TAT ATATGA
Gln ThrSer Gln Asn Ile Lys AsnGlnLeuAla GluLeu AsnAla ThrAsn Ile TyrThr

1800
*
GTA TTAGAT AAA ATC AAA TTA AATGCAAAAATG AATATT TTAATAAGAGAT AAA CGTTTT
CAT AATCTA TTT TAG TTT AAT TTACGTTTT TAC TTATAA AATTAT TCT CTA TTT GCAAAA
Val LeuAsp Lys Ile Lys Leu AsnAlaLys Met AsnIle Leu Ile ArgAsp Lys Arg Phe

1860
*
CAT TATGAT AGA AAT AAC ATA GCAGTTGGG GCG GATGAG TCA GTA GTT AAG GAG GCT CAT
GTA ATACTA TCT TTA TTG TAT CGTCAACCC CGC CTACTC AGT CAT CAA TTC CTC CGAGTA
His TyrAsp Arg Asn Asn Ile AlaValGly Ala AspGlu Ser Val Val Lys Glu AlaHis

1920
*
AGA GAAGTA ATT AAT TCG TCA ACAGAGGGA TTA TTGTTA AAT ATT GAT AAG GAT ATAAGA
TCT CTTCAT TAA TTA AGC AGT TGTCTCCCT AAT AACAAT TTA TAA CTATTC CTA TATTCT
Arg GluVal Ile Asn Ser Ser ThrGluGly Leu LeuLeu Asn Ile AspLys Asp IleArg

1980
*
AAA ATATTA TCA GGT TAT ATT GTAGAAATT GAA GATACT GAA GGG CTT AAA GAA GTTATA
TTT TATAAT AGT CCA ATA TAA CATCTTTAA CTT CTATGA CTT CCC GAATTT CTT CAATAT
Lys IleLeu Ser Gly Tyr Ile ValGluIle Glu AspThr GluGly LeuLys Glu Val Ile

2040
*
AAT GACAGA TAT GAT ATG TTG AATATTTCT AGT TTA CGG CAA GAT GGA AAA ACA TTTATA
TTA CTGTCT ATA CTA TAC AAC TTATAAAGA TCA AAT GCC GTT CTA CCTTTT TGT AAATAT
Asn AspArg Tyr Asp Met Leu AsnIle Ser Ser LeuArg GlnAsp GlyLys Thr PheIle

```
                                                                    2100
                                                                     *
GAT TTT AAA AAA TAT AAT GAT AAA TTA CCG TTA TAT ATA AGT AAT CCC AAT TAT AAG GTA
CTA AAA TTT TTT ATA TTA CTA TTT AAT GGC AAT ATA TAT TCA TTA GGG TTA ATA TTC CAT
Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr Ile Ser Asn Pro Asn Tyr Lys Val

                                                                    2160
                                                                     *
AAT GTA TAT GCT GTT ACT AAA GAA AAC ACT ATT ATT AAT CCT AGT GAG AAT GGG GAT ACT
TTA CAT ATA CGA CAA TGA TTT CTT TTG TGA TAA TAA TTA GGA TCA CTC TTA CCC CTA TGA
Asn Val Tyr Ala Val Thr Lys Glu Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr

                                                                    2220
                                                                     *
AGT ACC AAC GGG ATC AAG AAA ATT TTA ATC TTT TCT AAA AAA GGC TAT GAG ATA GGA TAA
TCA TGG TTG CCC TAG TTC TTT TAA AAT TAG AAA AGA TTT TTT CCG ATA CTC TAT CCT ATT
Ser Thr Asn Gly Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly***
```

The above procedure was followed for PAHIV#1, 3 and 4.

Example 7: Cleavage of Mutant PAHIV Proteins *in vitro*.

The mutated proteins were treated with purified HIV-1 protease and evaluated for their degree of cleavage with respect to time. The purified protease was obtained from the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, Bethesda, MD. Alternatively, the protease can be purified following the method of Louis, et al., *Euro. J. Biochem.*, 199:361 (1991).

Extended incubation (12 hours) of PA or the mutated PA proteins with the purified HIV-1 protease resulted in the appearance of two additional protein fragments that were not anticipated. These two fragments are approximately 53 kilodaltons and 30 kilodaltons in size. This may represent cleavage of PA and mutant PA proteins at a site recognized by the HIV-1 protease between PA residues Y^{259} and P^{260}. The residues around this cleavage site, ^{256}VAAYPIVHV^{264}, have not previously been identified as a potential HIV-1 protease cleavage site.

Incubation of RAW 264.7 cells (ATCC No. TIB 71) with lethal factor (LF) and HIV-1 protease-cleaved PAHIV#1 or PAHIV#4 caused cell death, demonstrating that the mutated PA proteins are capable of binding to LF and thus the toxic LF/PE fusion proteins. PAHIV, PAHIV#2 and PAHIV#3 have not yet been tested.

Example 8: Evaluation of cytotoxic agents in cell cultures.

The ability of the PA constructs containing the HIV-1-protease cleavage site to promote killing of HIV-1 infected cells is being evaluated in COS-1 cells (ATCC No. CRL 1650) transfected with the vector HIV-gpt. When COS cells are transfected with this plasmid vector they express all the genes for the production of HIV-1 virus particles except the envelope protein, gp160 (Page, K.A., et al., 1990. *J. Virol.* 64:5270-5276). Without the envelope protein the particles are not infectious. These cells express the HIV-1 proteases and properly cleave the viral protein gp55 to gp24 (Page, K.A., et al., 1990. *J. Virol.* 64:5270-5276). These properties make the transfected cells an excellent model system in which to evaluate the ability of protein constructs of the invention to eliminate HIV-1 infected cells from culture.

The COS-1 cells were transfected with the plasmid vector and the resulting cultures are being selected for stable transfectents. The mutated PA proteins (PAHIV#1, PAHIV#2, PAHIV#3 and PAHIV#4) are added to the culture media of growing HIV-gpt transfected COS-1 cells in the presence of the lethal factor fusion protein FP53 (Arora, N. et al. *J. Biol. Chem.* 267:15542 (1992)). Only cells which properly cleave the mutated PA proteins are able to bind the toxin LF fusion protein. The cultures are evaluated for protein expression (an indirect measure of viability) after 36 hours (Arora, N. and S. H. Leppla. 1992. *J. Biol. Chem.* 268:3334).

Example 9: Treatment of an HIV-1 infected patient.

A human patient who is infected with HIV-1 is selected for treatment. Although infected, this particular patient is asymptomatic. The patient weighs 70 kilograms. A dose of 10 micrograms per kilogram or 700 micrograms of a PAHIV in normal saline is prepared. This dosage is injected into the patient intravenously as a bolus. The dose is repeated weekly for a total of 4 to 6 dosages. The patient is evaluated regularly, such as weekly, in terms of his symptoms, physical exam and laboratory analysis according to the clinician's judgment. Tests of particular interest include the patient's complete

blood count and examination for the presence of HIV infection. The treatment regimen can be repeated with or without alterations at the discretion of the clinician.

Incorporated by reference/paragraph before claims

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications and patent documents referenced in this application are incorporated herein by reference.

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Leppla, Stephen H.
Klimpel, Kurt R.
Arora, Naveen
Singh, Yogendra
Nichols, Peter J.

(ii) TITLE OF INVENTION: ANTHRAX TOXIN FUSION PROTEINS AND RELATED METHODS

(iii) NUMBER OF SEQUENCES: 31

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: TOWNSEND and TOWNSEND KHOURIE and CREW
(B) STREET: Steuart Street Tower, 20th Floor, One Market Plaza
(C) CITY: San Francisco
(D) STATE: CA
(E) COUNTRY: USA
(F) ZIP: 94105

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US
(B) FILING DATE: June 25, 1993
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Weber, Kenneth A.
(B) REGISTRATION NUMBER: 31,677
(C) REFERENCE/DOCKET NUMBER: 15280-115

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (415) 543-9600
(B) TELEFAX: (415) 543-5043

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3291 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus anthracis

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 580..2907
(D) OTHER INFORMATION: /product= "Lethal F[illegible]

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
AAATTAGGAT TTCGGTTATG TTTAGTATTT TTTTAAAATA ATAGTATTAA ATAGTGGAAT      60

GCAAATGATA AATGGGCTTT AAACAAAACT AATGAAATAA TCTACAAATG GAATTTCTCC     120

AGTTTTAGAT TAAACCATAC CAAAAAAATC ACACTGTCAA GAAAAATGAT AGAATCCCTA     180

CACTAATTAA CATAACCAAA TTGGTAGTTA TAGGTAGAAA CTTATTTATT TCTATAATAC     240

CATGCAAAAA AGTAAATATT CTGTTCCATA CTATTTTAGT AAATTATTTA GCAAGTAAAT     300

TTTGGTGTAT AAACAAAGTT TATCTTAATA TAAAAAATTA CTTTACTTTT ATACAGATTA     360

AAATGAAAAA TTTTTTATGA CAAGAAATAT TGCCTTTAAT TTATGAGGAA ATAAGTAAAA     420

TTTTCTACAT ACTTTATTTT ATTGTTGAAA TGTTCACTTA TAAAAAAGGA GAGATTAAAT     480

ATGAATATAA AAAAAGAATT TATAAAAGTA ATTAGTATGT CATGTTTAGT AACAGCAATT     540

ACTTTGAGTG GTCCCGTCTT TATCCCCCTT GTACAGGGG GCG GGC GGT CAT GGT         594
                                              Ala Gly Gly His Gly
                                               1               5

GAT GTA GGT ATG CAC GTA AAA GAG AAA GAG AAA AAT AAA GAT GAG AAT         642
Asp Val Gly Met His Val Lys Glu Lys Glu Lys Asn Lys Asp Glu Asn
                   10                  15                  20

AAG AGA AAA GAT GAA GAA CGA AAT AAA ACA CAG GAA GAG CAT TTA AAG         690
Lys Arg Lys Asp Glu Glu Arg Asn Lys Thr Gln Glu Glu His Leu Lys
               25                  30                  35

GAA ATC ATG AAA CAC ATT GTA AAA ATA GAA GTA AAA GGG GAG GAA GCT         738
Glu Ile Met Lys His Ile Val Lys Ile Glu Val Lys Gly Glu Glu Ala
           40                  45                  50

GTT AAA AAA GAG GCA GCA GAA AAG CTA CTT GAG AAA GTA CCA TCT GAT         786
Val Lys Lys Glu Ala Ala Glu Lys Leu Leu Glu Lys Val Pro Ser Asp
       55                  60                  65

GTT TTA GAG ATG TAT AAA GCA ATT GGA GGA AAG ATA TAT ATT GTG GAT         834
Val Leu Glu Met Tyr Lys Ala Ile Gly Gly Lys Ile Tyr Ile Val Asp
   70                  75                  80                  85

GGT GAT ATT ACA AAA CAT ATA TCT TTA GAA GCA TTA TCT GAA GAT AAG         882
Gly Asp Ile Thr Lys His Ile Ser Leu Glu Ala Leu Ser Glu Asp Lys
                   90                  95                 100

AAA AAA ATA AAA GAC ATT TAT GGG AAA GAT GCT TTA TTA CAT GAA CAT         930
Lys Lys Ile Lys Asp Ile Tyr Gly Lys Asp Ala Leu Leu His Glu His
               105                 110                 115

TAT GTA TAT GCA AAA GAA GGA TAT GAA CCC GTA CTT GTA ATC CAA TCT         978
Tyr Val Tyr Ala Lys Glu Gly Tyr Glu Pro Val Leu Val Ile Gln Ser
           120                 125                 130

TCG GAA GAT TAT GTA GAA AAT ACT GAA AAG GCA CTG AAC GTT TAT TAT        1026
Ser Glu Asp Tyr Val Glu Asn Thr Glu Lys Ala Leu Asn Val Tyr Tyr
       135                 140                 145

GAA ATA GGT AAG ATA TTA TCA AGG GAT ATT TTA AGT AAA ATT AAT CAA        1074
Glu Ile Gly Lys Ile Leu Ser Arg Asp Ile Leu Ser Lys Ile Asn Gln
   150                 155                 160                 165

CCA TAT CAG AAA TTT TTA GAT GTA TTA AAT ACC ATT AAA AAT GCA TCT        1122
Pro Tyr Gln Lys Phe Leu Asp Val Leu Asn Thr Ile Lys Asn Ala Ser
                   170                 175                 180

GAT TCA GAT GGA CAA GAT CTT TTA TTT ACT AAT CAG CTT AAG GAA CAT        1170
```

```
Asp Ser Asp Gly Gln Asp Leu Leu Phe Thr Asn Gln Leu Lys Glu His
            185                 190                 195

CCC ACA GAC TTT TCT GTA GAA TTC TTG GAA CAA AAT AGC AAT GAG GTA      1218
Pro Thr Asp Phe Ser Val Glu Phe Leu Glu Gln Asn Ser Asn Glu Val
        200                 205                 210

CAA GAA GTA TTT GCG AAA GCT TTT GCA TAT TAT ATC GAG CCA CAG CAT      1266
Gln Glu Val Phe Ala Lys Ala Phe Ala Tyr Tyr Ile Glu Pro Gln His
    215                 220                 225

CGT GAT GTT TTA CAG CTT TAT GCA CCG GAA GCT TTT AAT TAC ATG GAT      1314
Arg Asp Val Leu Gln Leu Tyr Ala Pro Glu Ala Phe Asn Tyr Met Asp
230                 235                 240                 245

AAA TTT AAC GAA CAA GAA ATA AAT CTA TCC TTG GAA GAA CTT AAA GAT      1362
Lys Phe Asn Glu Gln Glu Ile Asn Leu Ser Leu Glu Glu Leu Lys Asp
                250                 255                 260

CAA CGG ATG CTG TCA AGA TAT GAA AAA TGG GAA AAG ATA AAA CAG CAC      1410
Gln Arg Met Leu Ser Arg Tyr Glu Lys Trp Glu Lys Ile Lys Gln His
            265                 270                 275

TAT CAA CAC TGG AGC GAT TCT TTA TCT GAA GAA GGA AGA GGA CTT TTA      1458
Tyr Gln His Trp Ser Asp Ser Leu Ser Glu Glu Gly Arg Gly Leu Leu
        280                 285                 290

AAA AAG CTG CAG ATT CCT ATT GAG CCA AAG AAA GAT GAC ATA ATT CAT      1506
Lys Lys Leu Gln Ile Pro Ile Glu Pro Lys Lys Asp Asp Ile Ile His
    295                 300                 305

TCT TTA TCT CAA GAA GAA AAA GAG CTT CTA AAA AGA ATA CAA ATT GAT      1554
Ser Leu Ser Gln Glu Glu Lys Glu Leu Leu Lys Arg Ile Gln Ile Asp
310                 315                 320                 325

AGT AGT GAT TTT TTA TCT ACT GAG GAA AAA GAG TTT TTA AAA AAG CTA      1602
Ser Ser Asp Phe Leu Ser Thr Glu Glu Lys Glu Phe Leu Lys Lys Leu
                330                 335                 340

CAA ATT GAT ATT CGT GAT TCT TTA TCT GAA GAA GAA AAA GAG CTT TTA      1650
Gln Ile Asp Ile Arg Asp Ser Leu Ser Glu Glu Glu Lys Glu Leu Leu
            345                 350                 355

AAT AGA ATA CAG GTG GAT AGT AGT AAT CCT TTA TCT GAA AAA GAA AAA      1698
Asn Arg Ile Gln Val Asp Ser Ser Asn Pro Leu Ser Glu Lys Glu Lys
        360                 365                 370

GAG TTT TTA AAA AAG CTG AAA CTT GAT ATT CAA CCA TAT GAT ATT AAT      1746
Glu Phe Leu Lys Lys Leu Lys Leu Asp Ile Gln Pro Tyr Asp Ile Asn
    375                 380                 385

CAA AGG TTG CAA GAT ACA GGA GGG TTA ATT GAT AGT CCG TCA ATT AAT      1794
Gln Arg Leu Gln Asp Thr Gly Gly Leu Ile Asp Ser Pro Ser Ile Asn
390                 395                 400                 405

CTT GAT GTA AGA AAG CAG TAT AAA AGG GAT ATT CAA AAT ATT GAT GCT      1842
Leu Asp Val Arg Lys Gln Tyr Lys Arg Asp Ile Gln Asn Ile Asp Ala
                410                 415                 420

TTA TTA CAT CAA TCC ATT GGA AGT ACC TTG TAC AAT AAA ATT TAT TTG      1890
Leu Leu His Gln Ser Ile Gly Ser Thr Leu Tyr Asn Lys Ile Tyr Leu
            425                 430                 435

TAT GAA AAT ATG AAT ATC AAT AAC CTT ACA GCA ACC CTA GGT GCG GAT      1938
```

```
     455                 460                 465

     GAA TTC AAA AAA AAT TTC AAA TAT AGT ATT TCT AGT AAC TAT ATG ATT      2034
     Glu Phe Lys Lys Asn Phe Lys Tyr Ser Ile Ser Ser Asn Tyr Met Ile
5    470                 475                 480                 485

     GTT GAT ATA AAT GAA AGG CCT GCA TTA GAT AAT GAG CGT TTG AAA TGG      2082
     Val Asp Ile Asn Glu Arg Pro Ala Leu Asp Asn Glu Arg Leu Lys Trp
                    490                 495                 500
10
     AGA ATC CAA TTA TCA CCA GAT ACT CGA GCA GGA TAT TTA GAA AAT GGA      2130
     Arg Ile Gln Leu Ser Pro Asp Thr Arg Ala Gly Tyr Leu Glu Asn Gly
                505                 510                 515

15   AAG CTT ATA TTA CAA AGA AAC ATC GGT CTG GAA ATA AAG GAT GTA CAA      2178
     Lys Leu Ile Leu Gln Arg Asn Ile Gly Leu Glu Ile Lys Asp Val Gln
            520                 525                 530

     ATA ATT AAG CAA TCC GAA AAA GAA TAT ATA AGG ATT GAT GCG AAA GTA      2226
20   Ile Ile Lys Gln Ser Glu Lys Glu Tyr Ile Arg Ile Asp Ala Lys Val
        535                 540                 545

     GTG CCA AAG AGT AAA ATA GAT ACA AAA ATT CAA GAA GCA CAG TTA AAT      2274
     Val Pro Lys Ser Lys Ile Asp Thr Lys Ile Gln Glu Ala Gln Leu Asn
25   550                 555                 560                 565

     ATA AAT CAG GAA TGG AAT AAA GCA TTA GGG TTA CCA AAA TAT ACA AAG      2322
     Ile Asn Gln Glu Trp Asn Lys Ala Leu Gly Leu Pro Lys Tyr Thr Lys
                    570                 575                 580
30
     CTT ATT ACA TTC AAC GTG CAT AAT AGA TAT GCA TCC AAT ATT GTA GAA      2370
     Leu Ile Thr Phe Asn Val His Asn Arg Tyr Ala Ser Asn Ile Val Glu
                585                 590                 595

35   AGT GCT TAT TTA ATA TTG AAT GAA TGG AAA AAT AAT ATT CAA AGT GAT      2418
     Ser Ala Tyr Leu Ile Leu Asn Glu Trp Lys Asn Asn Ile Gln Ser Asp
            600                 605                 610

     CTT ATA AAA AAG GTA ACA AAT TAC TTA GTT GAT GGT AAT GGA AGA TTT      2466
40   Leu Ile Lys Lys Val Thr Asn Tyr Leu Val Asp Gly Asn Gly Arg Phe
        615                 620                 625

     GTT TTT ACC GAT ATT ACT CTC CCT AAT ATA GCT GAA CAA TAT ACA CAT      2514
     Val Phe Thr Asp Ile Thr Leu Pro Asn Ile Ala Glu Gln Tyr Thr His
45   630                 635                 640                 645

     CAA GAT GAG ATA TAT GAG CAA GTT CAT TCA AAA GGG TTA TAT GTT CCA      2562
     Gln Asp Glu Ile Tyr Glu Gln Val His Ser Lys Gly Leu Tyr Val Pro
                    650                 655                 660
50
     GAA TCC CGT TCT ATA TTA CTC CAT GGA CCT TCA AAA GGT GTA GAA TTA      2610
     Glu Ser Arg Ser Ile Leu Leu His Gly Pro Ser Lys Gly Val Glu Leu
                665                 670                 675

55   AGG AAT GAT AGT GAG GGT TTT ATA CAC GAA TTT GGA CAT GCT GTG GAT      2658
     Arg Asn Asp Ser Glu Gly Phe Ile His Glu Phe Gly His Ala Val Asp
            680                 685                 690

     GAT TAT GCT GGA TAT CTA TTA GAT AAG AAC CAA TCT GAT TTA GTT ACA      2706
60   Asp Tyr Ala Gly Tyr Leu Leu Asp Lys Asn Gln Ser Asp Leu Val Thr
        695                 700                 705

     AAT TCT AAA AAA TTC ATT GAT ATT TTT AAG GAA GAA GGG AGT AAT TTA      2754
     Asn Ser Lys Lys Phe Ile Asp Ile Phe Lys Glu Glu Gly Ser Asn Leu
65   710                 715                 720                 725

     ACT TCG TAT GGG AGA ACA AAT GAA GCG GAA TTT TTT GCA GAA GCC TTT      2802
     Thr Ser Tyr Gly Arg Thr Asn Glu Ala Glu Phe Phe Ala Glu Ala Phe
                    730                 735                 740
```

AGG TTA ATG CAT TCT ACG GAC CAT GCT GAA CGT TTA AAA GTT CAA AAA 2850
Arg Leu Met His Ser Thr Asp His Ala Glu Arg Leu Lys Val Gln Lys
745 750 755

AAT GCT CCG AAA ACT TTC CAA TTT ATT AAC GAT CAG ATT AAG TTC ATT 2898
Asn Ala Pro Lys Thr Phe Gln Phe Ile Asn Asp Gln Ile Lys Phe Ile
760 765 770

ATT AAC TCA TAAGTAATGT ATTAAAAATT TTCAAATGGA TTTAATAATA 2947
Ile Asn Ser
775

ATAATAATAA TAATAATAAC GGGACCAGCC ATTATGAAGC AACTAATTCT AGACTTGATA 3007

GTAATTCTTG GGAAGCACCA GATAGTGTAA AAGGTGGCAT TGCCAGAATG ATATTTTATG 3067

TGTTCGTTAG ATATGAAGGC AAAAACAATG ATCCTGACCT AGAACTTAAT GATAATGTTA 3127

TTAATAATTT AATGCCTTTT ATAGGAATAT TAGTAAAAGT GCCGAAAAGA TCCTGTTGCA 3187

AAGCTTTTAA AGAACATATT ATTCTATCAA GTGGCTGTAT ATTTTGTGTA ATTTTCAATA 3247

AATTTTGTAA TTAAGCATAC GTCAAAAAAC CGAAATCTGA GCTC 3291

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 776 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Ala Gly Gly His Gly Asp Val Gly Met His Val Lys Glu Lys Glu Lys
1 5 10 15

Asn Lys Asp Glu Asn Lys Arg Lys Asp Glu Glu Arg Asn Lys Thr Gln
20 25 30

Glu Glu His Leu Lys Glu Ile Met Lys His Ile Val Lys Ile Glu Val
35 40 45

Lys Gly Glu Glu Ala Val Lys Lys Glu Ala Ala Glu Lys Leu Leu Glu
50 55 60

Lys Val Pro Ser Asp Val Leu Glu Met Tyr Lys Ala Ile Gly Gly Lys
65 70 75 80

Ile Tyr Ile Val Asp Gly Asp Ile Thr Lys His Ile Ser Leu Glu Ala
85 90 95

Leu Ser Glu Asp Lys Lys Lys Ile Lys Asp Ile Tyr Gly Lys Asp Ala
100 105 110

Leu Leu His Glu His Tyr Val Tyr Ala Lys Glu Gly Tyr Glu Pro Val
115 120 125

Leu Val Ile Gln Ser Ser Glu Asp Tyr Val Glu Asn Thr Glu Lys Ala
130 135 140

Leu Asn Val Tyr Tyr Glu Ile Gly Lys Ile Leu Ser Arg Asp Ile Leu
145 150 155 160

Ser Lys Ile Asn Gln Pro Tyr Gln Lys Phe Leu Asp Val Leu Asn Thr
165 170 175

Ile Lys Asn Ala Ser Asp Ser Asp Gly Gln Asp Leu Leu Phe Thr Asn
180 185 190

Gln Leu Lys Glu His Pro Thr Asp Phe Ser Val Glu Phe Leu Glu Gln
195 200 205

Asn Ser Asn Glu Val Gln Glu Val Phe Ala Lys Ala Phe Ala Tyr Tyr
210 215 220

Ile Glu Pro Gln His Arg Asp Val Leu Gln Leu Tyr Ala Pro Glu Ala
225 230 235 240

Phe Asn Tyr Met Asp Lys Phe Asn Glu Gln Glu Ile Asn Leu Ser Leu
245 250 255

Glu Glu Leu Lys Asp Gln Arg Met Leu Ser Arg Tyr Glu Lys Trp Glu
260 265 270

Lys Ile Lys Gln His Tyr Gln His Trp Ser Asp Ser Leu Ser Glu Glu
275 280 285

Gly Arg Gly Leu Leu Lys Lys Leu Gln Ile Pro Ile Glu Pro Lys Lys
290 295 300

Asp Asp Ile Ile His Ser Leu Ser Gln Glu Glu Lys Glu Leu Leu Lys
305 310 315 320

Arg Ile Gln Ile Asp Ser Ser Asp Phe Leu Ser Thr Glu Glu Lys Glu
325 330 335

Phe Leu Lys Lys Leu Gln Ile Asp Ile Arg Asp Ser Leu Ser Glu Glu
340 345 350

Glu Lys Glu Leu Leu Asn Arg Ile Gln Val Asp Ser Ser Asn Pro Leu
355 360 365

Ser Glu Lys Glu Lys Glu Phe Leu Lys Lys Leu Lys Leu Asp Ile Gln
370 375 380

Pro Tyr Asp Ile Asn Gln Arg Leu Gln Asp Thr Gly Gly Leu Ile Asp
385 390 395 400

Ser Pro Ser Ile Asn Leu Asp Val Arg Lys Gln Tyr Lys Arg Asp Ile
405 410 415

Gln Asn Ile Asp Ala Leu Leu His Gln Ser Ile Gly Ser Thr Leu Tyr
420 425 430

Asn Lys Ile Tyr Leu Tyr Glu Asn Met Asn Ile Asn Asn Leu Thr Ala
435 440 445

Thr Leu Gly Ala Asp Leu Val Asp Ser Thr Asp Asn Thr Lys Ile Asn
450 455 460

Arg Gly Ile Phe Asn Glu Phe Lys Lys Asn Phe Lys Tyr Ser Ile Ser
465 470 475 480

Ser Asn Tyr Met Ile Val Asp Ile Asn Glu Arg Pro Ala Leu Asp Asn
485 490 495

Glu Arg Leu Lys Trp Arg Ile Gln Leu Ser Pro Asp Thr Arg Ala Gly
500 505 510

Tyr Leu Glu Asn Gly Lys Leu Ile Leu Gln Arg Asn Ile Gly Leu Glu
515 520 525

Ile Lys Asp Val Gln Ile Ile Lys Gln Ser Glu Lys Glu Tyr Ile Arg
530 535 540

Ile Asp Ala Lys Val Val Pro Lys Ser Lys Ile Asp Thr Lys Ile Gln
545 550 555 560

Glu Ala Gln Leu Asn Ile Asn Gln Glu Trp Asn Lys Ala Leu Gly Leu
565 570 575

Pro Lys Tyr Thr Lys Leu Ile Thr Phe Asn Val His Asn Arg Tyr Ala
580 585 590

Ser Asn Ile Val Glu Ser Ala Tyr Leu Ile Leu Asn Glu Trp Lys Asn
595 600 605

Asn Ile Gln Ser Asp Leu Ile Lys Lys Val Thr Asn Tyr Leu Val Asp
610 615 620

Gly Asn Gly Arg Phe Val Phe Thr Asp Ile Thr Leu Pro Asn Ile Ala
625 630 635 640

Glu Gln Tyr Thr His Gln Asp Glu Ile Tyr Glu Gln Val His Ser Lys
645 650 655

Gly Leu Tyr Val Pro Glu Ser Arg Ser Ile Leu Leu His Gly Pro Ser
660 665 670

Lys Gly Val Glu Leu Arg Asn Asp Ser Glu Gly Phe Ile His Glu Phe
675 680 685

Gly His Ala Val Asp Asp Tyr Ala Gly Tyr Leu Leu Asp Lys Asn Gln
690 695 700

Ser Asp Leu Val Thr Asn Ser Lys Lys Phe Ile Asp Ile Phe Lys Glu
705 710 715 720

Glu Gly Ser Asn Leu Thr Ser Tyr Gly Arg Thr Asn Glu Ala Glu Phe
725 730 735

Phe Ala Glu Ala Phe Arg Leu Met His Ser Thr Asp His Ala Glu Arg
740 745 750

Leu Lys Val Gln Lys Asn Ala Pro Lys Thr Phe Gln Phe Ile Asn Asp
755 760 765

Gln Ile Lys Phe Ile Ile Asn Ser
770 775

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4235 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus anthracis

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1891..4095
(D) OTHER INFORMATION: /product= "Protective Antigen"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AAGCTTCTGT CATTCGTAAA TTTCAAATAG AACGTAAATT TAGACTTCTC ATCATTAAAA 60

ATGAAAAATC TTATCTTTTT GATTCTATTG TATATTTTTA TTAAGGTGTT TAATAGTTAG 120

AAAAGACAGT TGATGCTATT ACTCCAGATA AAATATAGCT AACCATAAAT TTATTAAAGA 180

AACCTTGTTG TTCTAAATAA TGATTTTGTG GATTCCGGAA TAGATACTGG TGAGTTAGCT 240

CTAATTTTAT AGTGATTTAA CTAACAATTT ATAAAGCAGC ATAATTCAAA TTTTTTAATT 300

GATTTTTCCT GAAGCATAGT ATAAAAGAGT CAAGGTCTTC TAGACTTGAC TCTTGGAATC 360

ATTAGGAATT AACAATATAT ATAATGCGCT AGACAGAATC AAATTAAATG CAAAAATGAA 420

TATTTTAGTA AGAGATCCAT ATCATTATGA TAATAACGGT AATATTGTAG GGGTTGATGA 480

TTCATATTTA AAAAACGCAT ATAAGCAAAT ACTTAATTGG TCAAGCGATG GAGTTTCTTT 540

AAATCTAGAT GAAGATGTAA ATCAAGCACT ATCTGGATAT ATGCTTCAAA TAAAAAAACC 600

TTCAAACCAC CTAACAAACA GCCCAGTTAC AATTACATTA GCAGGCAAGG ACAGTGGTGT 660

TGGAGAATTG TATAGAGTAT TATCAGATGG AGCAGGATTC CTGGATTTCA ATAAGTTTGA 720

TGAAAATTGG CGATCATTAG TAGATCCTGG TGATGATGTT TATGTGTATG CTGTTACTAA 780

AGAAGATTTT AATGCAGTTA CTCGAGATGA AAATGGTAAT ATAGCGAATA AATTAAAAAA 840

CACCTTAGTT TTATCGGGTA AAATAAAAGA AATAAACATA AAAACTACAA ATATTAATAT 900

ATTTGTAGTT TTTATGTTTA TTATATACCT CCTATTTTAT ATTATTAGTA GCACAGTTTT 960

TGCAAATCAT GTAATTGTAT ACTTATCTAT GTAGAGGTAT CACAACTTAT GAATAGTGTA 1020

TTTTATTGAA CGTTGGTTAG CTTGGACAGT TGTATGGATA TGCATACTTT ATAACGTATA 1080

AAATTTCACG CACCACAATA AAACTAATTT AACAAAAACA AAAACACACC TAAGATCATT 1140

CAGTTCTTTT AATAAGGAGC TGCCCACCAA GCTAAACCTA AATAATCTTT GTTTCACATA 1200

AGGTTTTTTT CTAAATATAC AGTGTAAGTT ATTGTGAATT TAACCAGTAT ATATTAAAAA 1260

TGTTTTATGT TAACAAATTA AATTGTAAAA CCCCTCTTAA GCATAGTTAA GAGGGGTAGG 1320

TTTTAAATTT TTTGTTGAAA TTAGAAAAAA TAATAAAAAA ACAAACCTAT TTTCTTTCAG 1380

GTTGTTTTTG GGTTACAAAA CAAAAAGAAA ACATGTTTCA AGGTACAATA ATTATGGTTC 1440

TTTAGCTTTC TGTAAAACAG CCTTAATAGT TGGATTTATG ACTATTAAAG TTAGTATACA 1500

GCATACACAA TCTATTGAAG GATATTTATA ATGCAATTCC CTAAAAATAG TTTTGTATAA 1560

CCAGTTCTTT TATCCGAACT GATACACGTA TTTTAGCATA ATTTTTAATG TATCTTCAAA 1620

AACAGCTTCT GTGTCCTTTT CTATTAAACA TATAAATTCT TTTTTATGTT ATATATTTAT 1680

AAAAGTTCTG TTTAAAAAGC CAAAAATAAA TAATTATCTC TTTTTATTTA TATTATATTG 1740

AAACTAAAGT TTATTAATTT CAATATAATA TAAATTTAAT TTTATACAAA AAGGAGAACG 1800

TATATGAAAA AACGAAAAGT GTTAATACCA TTAATGGCAT TGTCTACGAT ATTAGTTTCA 1860

AGCACAGGTA ATTTAGAGGT GATTCAGGCA GAA GTT AAA CAG GAG AAC CGG TTA 1914
Glu Val Lys Gln Glu Asn Arg Leu
1 5

TTA AAT GAA TCA GAA TCA AGT TCC CAG GGG TTA CTA GGA TAC TAT TTT 1962
Leu Asn Glu Ser Glu Ser Ser Ser Gln Gly Leu Leu Gly Tyr Tyr Phe
10 15 20

```
AGT GAT TTG AAT TTT CAA GCA CCC ATG GTG GTT ACC TCT TCT ACT ACA      2010
Ser Asp Leu Asn Phe Gln Ala Pro Met Val Val Thr Ser Ser Thr Thr
 25                  30                  35                  40

GGG GAT TTA TCT ATT CCT AGT TCT GAG TTA GAA AAT ATT CCA TCG GAA      2058
Gly Asp Leu Ser Ile Pro Ser Ser Glu Leu Glu Asn Ile Pro Ser Glu
                 45                  50                  55

AAC CAA TAT TTT CAA TCT GCT ATT TGG TCA GGA TTT ATC AAA GTT AAG      2106
Asn Gln Tyr Phe Gln Ser Ala Ile Trp Ser Gly Phe Ile Lys Val Lys
             60                  65                  70

AAG AGT GAT GAA TAT ACA TTT GCT ACT TCC GCT GAT AAT CAT GTA ACA      2154
Lys Ser Asp Glu Tyr Thr Phe Ala Thr Ser Ala Asp Asn His Val Thr
         75                  80                  85

ATG TGG GTA GAT GAC CAA GAA GTG ATT AAT AAA GCT TCT AAT TCT AAC      2202
Met Trp Val Asp Asp Gln Glu Val Ile Asn Lys Ala Ser Asn Ser Asn
     90                  95                  100

AAA ATC AGA TTA GAA AAA GGA AGA TTA TAT CAA ATA AAA ATT CAA TAT      2250
Lys Ile Arg Leu Glu Lys Gly Arg Leu Tyr Gln Ile Lys Ile Gln Tyr
105                 110                 115                 120

CAA CGA GAA AAT CCT ACT GAA AAA GGA TTG GAT TTC AAG TTG TAC TGG      2298
Gln Arg Glu Asn Pro Thr Glu Lys Gly Leu Asp Phe Lys Leu Tyr Trp
                125                 130                 135

ACC GAT TCT CAA AAT AAA AAA GAA GTG ATT TCT AGT GAT AAC TTA CAA      2346
Thr Asp Ser Gln Asn Lys Lys Glu Val Ile Ser Ser Asp Asn Leu Gln
            140                 145                 150

TTG CCA GAA TTA AAA CAA AAA TCT TCG AAC TCA AGA AAA AAG CGA AGT      2394
Leu Pro Glu Leu Lys Gln Lys Ser Ser Asn Ser Arg Lys Lys Arg Ser
        155                 160                 165

ACA AGT GCT GGA CCT ACG GTT CCA GAC CGT GAC AAT GAT GGA ATC CCT      2442
Thr Ser Ala Gly Pro Thr Val Pro Asp Arg Asp Asn Asp Gly Ile Pro
    170                 175                 180

GAT TCA TTA GAG GTA GAA GGA TAT ACG GTT GAT GTC AAA AAT AAA AGA      2490
Asp Ser Leu Glu Val Glu Gly Tyr Thr Val Asp Val Lys Asn Lys Arg
185                 190                 195                 200

ACT TTT CTT TCA CCA TGG ATT TCT AAT ATT CAT GAA AAG AAA GGA TTA      2538
Thr Phe Leu Ser Pro Trp Ile Ser Asn Ile His Glu Lys Lys Gly Leu
                205                 210                 215

ACC AAA TAT AAA TCA TCT CCT GAA AAA TGG AGC ACG GCT TCT GAT CCG      2586
Thr Lys Tyr Lys Ser Ser Pro Glu Lys Trp Ser Thr Ala Ser Asp Pro
            220                 225                 230

TAC AGT GAT TTC GAA AAG GTT ACA GGA CGG ATT GAT AAG AAT GTA TCA      2634
Tyr Ser Asp Phe Glu Lys Val Thr Gly Arg Ile Asp Lys Asn Val Ser
        235                 240                 245

CCA GAG GCA AGA CAC CCC CTT GTG GCA GCT TAT CCG ATT GTA CAT GTA      2682
Pro Glu Ala Arg His Pro Leu Val Ala Ala Tyr Pro Ile Val His Val
    250                 255                 260

GAT ATG GAG AAT ATT ATT CTC TCA AAA AAT GAG GAT CAA TCC ACA CAG      2730
Asp Met Glu Asn Ile Ile Leu Ser Lys Asn Glu Asp Gln Ser Thr Gln
265                 270                 275                 280

AAT ACT GAT AGT GAA ACG AGA ACA ATA AGT AAA AAT ACT TCT ACA AGT      2778
Asn Thr Asp Ser Glu Thr Arg Thr Ile Ser Lys Asn Thr Ser Thr Ser
                285                 290                 295

AGG ACA CAT ACT AGT GAA GTA CAT GGA AAT GCA GAA GTG CAT GCG TCG      2826
```

```
Arg Thr His Thr Ser Glu Val His Gly Asn Ala Glu Val His Ala Ser
                300                 305                 310

TTC TTT GAT ATT GGT GGG AGT GTA TCT GCA GGA TTT AGT AAT TCG AAT      2874
Phe Phe Asp Ile Gly Gly Ser Val Ser Ala Gly Phe Ser Asn Ser Asn
        315                 320                 325

TCA AGT ACG GTC GCA ATT GAT CAT TCA CTA TCT CTA GCA GGG GAA AGA      2922
Ser Ser Thr Val Ala Ile Asp His Ser Leu Ser Leu Ala Gly Glu Arg
    330                 335                 340

ACT TGG GCT GAA ACA ATG GGT TTA AAT ACC GCT GAT ACA GCA AGA TTA      2970
Thr Trp Ala Glu Thr Met Gly Leu Asn Thr Ala Asp Thr Ala Arg Leu
345                 350                 355                 360

AAT GCC AAT ATT AGA TAT GTA AAT ACT GGG ACG GCT CCA ATC TAC AAC      3018
Asn Ala Asn Ile Arg Tyr Val Asn Thr Gly Thr Ala Pro Ile Tyr Asn
                365                 370                 375

GTG TTA CCA ACG ACT TCG TTA GTG TTA GGA AAA AAT CAA ACA CTC GCG      3066
Val Leu Pro Thr Thr Ser Leu Val Leu Gly Lys Asn Gln Thr Leu Ala
            380                 385                 390

ACA ATT AAA GCT AAG GAA AAC CAA TTA AGT CAA ATA CTT GCA CCT AAT      3114
Thr Ile Lys Ala Lys Glu Asn Gln Leu Ser Gln Ile Leu Ala Pro Asn
        395                 400                 405

AAT TAT TAT CCT TCT AAA AAC TTG GCG CCA ATC GCA TTA AAT GCA CAA      3162
Asn Tyr Tyr Pro Ser Lys Asn Leu Ala Pro Ile Ala Leu Asn Ala Gln
    410                 415                 420

GAC GAT TTC AGT TCT ACT CCA ATT ACA ATG AAT TAC AAT CAA TTT CTT      3210
Asp Asp Phe Ser Ser Thr Pro Ile Thr Met Asn Tyr Asn Gln Phe Leu
425                 430                 435                 440

GAG TTA GAA AAA ACG AAA CAA TTA AGA TTA GAT ACG GAT CAA GTA TAT      3258
Glu Leu Glu Lys Thr Lys Gln Leu Arg Leu Asp Thr Asp Gln Val Tyr
                445                 450                 455

GGG AAT ATA GCA ACA TAC AAT TTT GAA AAT GGA AGA GTG AGG GTG GAT      3306
Gly Asn Ile Ala Thr Tyr Asn Phe Glu Asn Gly Arg Val Arg Val Asp
            460                 465                 470

ACA GGC TCG AAC TGG AGT GAA GTG TTA CCG CAA ATT CAA GAA ACA ACT      3354
Thr Gly Ser Asn Trp Ser Glu Val Leu Pro Gln Ile Gln Glu Thr Thr
        475                 480                 485

GCA CGT ATC ATT TTT AAT GGA AAA GAT TTA AAT CTG GTA GAA AGG CGG      3402
Ala Arg Ile Ile Phe Asn Gly Lys Asp Leu Asn Leu Val Glu Arg Arg
    490                 495                 500

ATA GCG GCG GTT AAT CCT AGT GAT CCA TTA GAA ACG ACT AAA CCG GAT      3450
Ile Ala Ala Val Asn Pro Ser Asp Pro Leu Glu Thr Thr Lys Pro Asp
505                 510                 515                 520

ATG ACA TTA AAA GAA GCC CTT AAA ATA GCA TTT GGA TTT AAC GAA CCG      3498
Met Thr Leu Lys Glu Ala Leu Lys Ile Ala Phe Gly Phe Asn Glu Pro
                525                 530                 535

AAT GGA AAC TTA CAA TAT CAA GGG AAA GAC ATA ACC GAA TTT GAT TTT      3546
Asn Gly Asn Leu Gln Tyr Gln Gly Lys Asp Ile Thr Glu Phe Asp Phe
            540                 545                 550

AAT TTC GAT CAA CAA ACA TCT CAA AAT ATC AAG AAT CAG TTA GCG GAA      3594
Asn Phe Asp Gln Gln Thr Ser Gln Asn Ile Lys Asn Gln Leu Ala Glu
        555                 560                 565

TTA AAC GCA ACT AAC ATA TAT ACT GTA TTA GAT AAA ATC AAA TTA AAT      3642
Leu Asn Ala Thr Asn Ile Tyr Thr Val Leu Asp Lys Ile Lys Leu Asn
```

```
     570                 575                 580

     GCA AAA ATG AAT ATT TTA ATA AGA GAT AAA CGT TTT CAT TAT GAT AGA      3690
     Ala Lys Met Asn Ile Leu Ile Arg Asp Lys Arg Phe His Tyr Asp Arg
5    585                 590                 595                 600

     AAT AAC ATA GCA GTT GGG GCG GAT GAG TCA GTA GTT AAG GAG GCT CAT      3738
     Asn Asn Ile Ala Val Gly Ala Asp Glu Ser Val Val Lys Glu Ala His
                    605                 610                 615
10
     AGA GAA GTA ATT AAT TCG TCA ACA GAG GGA TTA TTG TTA AAT ATT GAT      3786
     Arg Glu Val Ile Asn Ser Ser Thr Glu Gly Leu Leu Leu Asn Ile Asp
                620                 625                 630

15   AAG GAT ATA AGA AAA ATA TTA TCA GGT TAT ATT GTA GAA ATT GAA GAT      3834
     Lys Asp Ile Arg Lys Ile Leu Ser Gly Tyr Ile Val Glu Ile Glu Asp
           635                 640                 645

     ACT GAA GGG CTT AAA GAA GTT ATA AAT GAC AGA TAT GAT ATG TTG AAT      3882
20   Thr Glu Gly Leu Lys Glu Val Ile Asn Asp Arg Tyr Asp Met Leu Asn
     650                 655                 660

     ATT TCT AGT TTA CGG CAA GAT GGA AAA ACA TTT ATA GAT TTT AAA AAA      3930
     Ile Ser Ser Leu Arg Gln Asp Gly Lys Thr Phe Ile Asp Phe Lys Lys
25   665                 670                 675                 680

     TAT AAT GAT AAA TTA CCG TTA TAT ATA AGT AAT CCC AAT TAT AAG GTA      3978
     Tyr Asn Asp Lys Leu Pro Leu Tyr Ile Ser Asn Pro Asn Tyr Lys Val
                    685                 690                 695
30
     AAT GTA TAT GCT GTT ACT AAA GAA AAC ACT ATT ATT AAT CCT AGT GAG      4026
     Asn Val Tyr Ala Val Thr Lys Glu Asn Thr Ile Ile Asn Pro Ser Glu
                700                 705                 710

35   AAT GGG GAT ACT AGT ACC AAC GGG ATC AAG AAA ATT TTA ATC TTT TCT      4074
     Asn Gly Asp Thr Ser Thr Asn Gly Ile Lys Lys Ile Leu Ile Phe Ser
           715                 720                 725

     AAA AAA GGC TAT GAG ATA GGA TAAGGTAATT CTAGGTGATT TTTAAATTAT         4125
40   Lys Lys Gly Tyr Glu Ile Gly
     730                 735

     CTAAAAAACA GTAAAATTAA AACATACTCT TTTTGTAAGA AATACAAGGA GAGTATGTTT    4185

45   TAAACAGTAA TCTAAATCAT CATAATCCTT TGAGATTGTT TGTAGGATCC               4235
```

(2) INFORMATION FOR SEQ ID NO:4:

50 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 735 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

55 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```
Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser
60  1               5                  10                  15

Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
            20                  25                  30

65  Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
        35                  40                  45

Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
    50                  55                  60
```

Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala
65 70 75 80

Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95

Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110

Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125

Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140

Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser
145 150 155 160

Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175

Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190

Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205

Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220

Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr
225 230 235 240

Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255

Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270

Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285

Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300

Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val
305 310 315 320

Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335

Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350

Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365

Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380

Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln
385 390 395 400

Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415

Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430

Thr Met Asn Tyr Asn Gln Phe Leu Glu L u Glu Lys Thr Lys Gln Leu
435 440 445

Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460

Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val
465 470 475 480

Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495

Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510

Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525

Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540

Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln
545 550 555 560

Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575

Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590

Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605

Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620

Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser
625 630 635 640

Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655

Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670

Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685

Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700

Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly
705 710 715 720

Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly
725 730 735

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1368 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus anthracis

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..1368
(D) OTHER INFORMATION: /product=
"LF(1-254)--TR--PE(401-602)"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```
GCG GGC GGT CAT GGT GAT GTA GGT ATG CAC GTA AAA GAG AAA GAG AAA          48
Ala Gly Gly His Gly Asp Val Gly Met His Val Lys Glu Lys Glu Lys
 1               5                  10                  15

AAT AAA GAT GAG AAT AAG AGA AAA GAT GAA GAA CGA AAT AAA ACA CAG          96
Asn Lys Asp Glu Asn Lys Arg Lys Asp Glu Glu Arg Asn Lys Thr Gln
            20                  25                  30

GAA GAG CAT TTA AAG GAA ATC ATG AAA CAC ATT GTA AAA ATA GAA GTA         144
Glu Glu His Leu Lys Glu Ile Met Lys His Ile Val Lys Ile Glu Val
        35                  40                  45

AAA GGG GAG GAA GCT GTT AAA AAA GAG GCA GCA GAA AAG CTA CTT GAG         192
Lys Gly Glu Glu Ala Val Lys Lys Glu Ala Ala Glu Lys Leu Leu Glu
    50                  55                  60

AAA GTA CCA TCT GAT GTT TTA GAG ATG TAT AAA GCA ATT GGA GGA AAG         240
Lys Val Pro Ser Asp Val Leu Glu Met Tyr Lys Ala Ile Gly Gly Lys
65                  70                  75                  80

ATA TAT ATT GTG GAT GGT GAT ATT ACA AAA CAT ATA TCT TTA GAA GCA         288
Ile Tyr Ile Val Asp Gly Asp Ile Thr Lys His Ile Ser Leu Glu Ala
                85                  90                  95

TTA TCT GAA GAT AAG AAA AAA ATA AAA GAC ATT TAT GGG AAA GAT GCT         336
Leu Ser Glu Asp Lys Lys Lys Ile Lys Asp Ile Tyr Gly Lys Asp Ala
            100                 105                 110

TTA TTA CAT GAA CAT TAT GTA TAT GCA AAA GAA GGA TAT GAA CCC GTA         384
Leu Leu His Glu His Tyr Val Tyr Ala Lys Glu Gly Tyr Glu Pro Val
        115                 120                 125

CTT GTA ATC CAA TCT TCG GAA GAT TAT GTA GAA AAT ACT GAA AAG GCA         432
Leu Val Ile Gln Ser Ser Glu Asp Tyr Val Glu Asn Thr Glu Lys Ala
    130                 135                 140

CTG AAC GTT TAT TAT GAA ATA GGT AAG ATA TTA TCA AGG GAT ATT TTA         480
Leu Asn Val Tyr Tyr Glu Ile Gly Lys Ile Leu Ser Arg Asp Ile Leu
145                 150                 155                 160
```

```
AGT AAA ATT AAT CAA CCA TAT CAG AAA TTT TTA GAT GTA TTA AAT ACC          528
Ser Lys Ile Asn Gln Pro Tyr Gln Lys Phe Leu Asp Val Leu Asn Thr
                165                 170                 175

ATT AAA AAT GCA TCT GAT TCA GAT GGA CAA GAT CTT TTA TTT ACT AAT          576
Ile Lys Asn Ala Ser Asp Ser Asp Gly Gln Asp Leu Leu Phe Thr Asn
            180                 185                 190

CAG CTT AAG GAA CAT CCC ACA GAC TTT TCT GTA GAA TTC TTG GAA CAA          624
Gln Leu Lys Glu His Pro Thr Asp Phe Ser Val Glu Phe Leu Glu Gln
        195                 200                 205

AAT AGC AAT GAG GTA CAA GAA GTA TTT GCG AAA GCT TTT GCA TAT TAT          672
Asn Ser Asn Glu Val Gln Glu Val Phe Ala Lys Ala Phe Ala Tyr Tyr
    210                 215                 220

ATC GAG CCA CAG CAT CGT GAT GTT TTA CAG CTT TAT GCA CCG GAA GCT          720
Ile Glu Pro Gln His Arg Asp Val Leu Gln Leu Tyr Ala Pro Glu Ala
225                 230                 235                 240

TTT AAT TAC ATG GAT AAA TTT AAC GAA CAA GAA ATA AAT CTA CTC GGC          768
Phe Asn Tyr Met Asp Lys Phe Asn Glu Gln Glu Ile Asn Leu Leu Gly
                245                 250                 255

GAC GGC GGC GAC GTC AGC TTC AGC ACC CGC GGC ACG CAG AAC TGG ACG          816
Asp Gly Gly Asp Val Ser Phe Ser Thr Arg Gly Thr Gln Asn Trp Thr
            260                 265                 270

GTG GAG CGG CTG CTC CAG GCG CAC CGC CAA CTG GAG GAG CGC GGC TAT          864
Val Glu Arg Leu Leu Gln Ala His Arg Gln Leu Glu Glu Arg Gly Tyr
        275                 280                 285

GTG TTC GTC GGC TAC CAC GGC ACC TTC CTC GAA GCG GCG CAA AGC ATC          912
Val Phe Val Gly Tyr His Gly Thr Phe Leu Glu Ala Ala Gln Ser Ile
    290                 295                 300

GTC TTC GGC GGG GTG CGC GCG CGC AGC CAG GAC CTC GAC GCG ATC TGG          960
Val Phe Gly Gly Val Arg Ala Arg Ser Gln Asp Leu Asp Ala Ile Trp
305                 310                 315                 320

CGC GGT TTC TAT ATC GCC GGC GAT CCG GCG CTG GCC TAC GGC TAC GCC         1008
Arg Gly Phe Tyr Ile Ala Gly Asp Pro Ala Leu Ala Tyr Gly Tyr Ala
                325                 330                 335

CAG GAC CAG GAA CCC GAC GCA CGC GGC CGG ATC CGC AAC GGT GCC CTG         1056
Gln Asp Gln Glu Pro Asp Ala Arg Gly Arg Ile Arg Asn Gly Ala Leu
            340                 345                 350

CTG CGG GTC TAT GTG CCG CGC TCG AGC CTG CCG GGC TTC TAC CGC ACC         1104
Leu Arg Val Tyr Val Pro Arg Ser Ser Leu Pro Gly Phe Tyr Arg Thr
        355                 360                 365

AGC CTG ACC CTG GCC GCG CCG GAG GCG GCG GGC GAG GTC GAA CGG CTG         1152
Ser Leu Thr Leu Ala Ala Pro Glu Ala Ala Gly Glu Val Glu Arg Leu
    370                 375                 380

ATC GGC CAT CCG CTG CCG CTG CGC CTG GAC GCC ATC ACC GGC CCC GAG         1200
Ile Gly His Pro Leu Pro Leu Arg Leu Asp Ala Ile Thr Gly Pro Glu
385                 390                 395                 400

GAG GAA GGC GGG CGC CTG GAG ACC ATT CTC GGC TGG CCG CTG GCC GAG         1248
Glu Glu Gly Gly Arg Leu Glu Thr Ile Leu Gly Trp Pro Leu Ala Glu
                405                 410                 415

CGC ACC GTG GTG ATT CCC TCG GCG ATC CCC ACC GAC CCG CGC AAC GTC         1296
Arg Thr Val Val Ile Pro Ser Ala Ile Pro Thr Asp Pro Arg Asn Val
            420                 425                 430

GGC GGC GAC CTC GAC CCG TCC AGC ATC CCC GAC AAG GAA CAG GCG ATC         1344
```

Gly Gly Asp Leu Asp Pro Ser Ser Ile Pro Asp Lys Glu Gln Ala Ile
435 440 445

AGC GCC CTG CCG GAC TAC GCC AGC 1368
Ser Ala Leu Pro Asp Tyr Ala Ser
450 455

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 456 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Ala Gly Gly His Gly Asp Val Gly Met His Val Lys Glu Lys Glu Lys
1 5 10 15

Asn Lys Asp Glu Asn Lys Arg Lys Asp Glu Glu Arg Asn Lys Thr Gln
20 25 30

Glu Glu His Leu Lys Glu Ile Met Lys His Ile Val Lys Ile Glu Val
35 40 45

Lys Gly Glu Glu Ala Val Lys Lys Glu Ala Ala Glu Lys Leu Leu Glu
50 55 60

Lys Val Pro Ser Asp Val Leu Glu Met Tyr Lys Ala Ile Gly Gly Lys
65 70 75 80

Ile Tyr Ile Val Asp Gly Asp Ile Thr Lys His Ile Ser Leu Glu Ala
85 90 95

Leu Ser Glu Asp Lys Lys Lys Ile Lys Asp Ile Tyr Gly Lys Asp Ala
100 105 110

Leu Leu His Glu His Tyr Val Tyr Ala Lys Glu Gly Tyr Glu Pro Val
115 120 125

Leu Val Ile Gln Ser Ser Glu Asp Tyr Val Glu Asn Thr Glu Lys Ala
130 135 140

Leu Asn Val Tyr Tyr Glu Ile Gly Lys Ile Leu Ser Arg Asp Ile Leu
145 150 155 160

Ser Lys Ile Asn Gln Pro Tyr Gln Lys Phe Leu Asp Val Leu Asn Thr
165 170 175

Ile Lys Asn Ala Ser Asp Ser Asp Gly Gln Asp Leu Leu Phe Thr Asn
180 185 190

Gln Leu Lys Glu His Pro Thr Asp Phe Ser Val Glu Phe Leu Glu Gln
195 200 205

Asn Ser Asn Glu Val Gln Glu Val Phe Ala Lys Ala Phe Ala Tyr Tyr
210 215 220

Ile Glu Pro Gln His Arg Asp Val Leu Gln Leu Tyr Ala Pro Glu Ala
225 230 235 240

Phe Asn Tyr Met Asp Lys Phe Asn Glu Gln Glu Ile Asn Leu Leu Gly
245 250 255

Asp Gly Gly Asp Val Ser Phe Ser Thr Arg Gly Thr Gln Asn Trp Thr
260 265 270

```
Val Glu Arg Leu Leu Gln Ala His Arg Gln Leu Glu Glu Arg Gly Tyr
        275                 280                 285

Val Phe Val Gly Tyr His Gly Thr Phe Leu Glu Ala Ala Gln Ser Ile
    290                 295                 300

Val Phe Gly Gly Val Arg Ala Arg Ser Gln Asp Leu Asp Ala Ile Trp
305                 310                 315                 320

Arg Gly Phe Tyr Ile Ala Gly Asp Pro Ala Leu Ala Tyr Gly Tyr Ala
                325                 330                 335

Gln Asp Gln Glu Pro Asp Ala Arg Gly Arg Ile Arg Asn Gly Ala Leu
            340                 345                 350

Leu Arg Val Tyr Val Pro Arg Ser Ser Leu Pro Gly Phe Tyr Arg Thr
        355                 360                 365

Ser Leu Thr Leu Ala Ala Pro Glu Ala Ala Gly Glu Val Glu Arg Leu
    370                 375                 380

Ile Gly His Pro Leu Pro Leu Arg Leu Asp Ala Ile Thr Gly Pro Glu
385                 390                 395                 400

Glu Glu Gly Gly Arg Leu Glu Thr Ile Leu Gly Trp Pro Leu Ala Glu
                405                 410                 415

Arg Thr Val Val Ile Pro Ser Ala Ile Pro Thr Asp Pro Arg Asn Val
            420                 425                 430

Gly Gly Asp Leu Asp Pro Ser Ser Ile Pro Asp Lys Glu Gln Ala Ile
        435                 440                 445

Ser Ala Leu Pro Asp Tyr Ala Ser
    450                 455
```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1425 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus anthracis

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..1416
(D) OTHER INFORMATION: /product=
"LF(1-254)--TR--PE(398-613)"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```
ATG GTA CCA GCG GGC GGT CAT GGT GAT GTA GGT ATG CAC GTA AAA GAG      48
Met Val Pro Ala Gly Gly His Gly Asp Val Gly Met His Val Lys Glu
 1               5                  10                  15

AAA GAG AAA AAT AAA GAT GAG AAT AAG AGA AAA GAT GAA GAA CGA AAT      96
Lys Glu Lys Asn Lys Asp Glu Asn Lys Arg Lys Asp Glu Glu Arg Asn
            20                  25                  30

AAA ACA CAG GAA GAG CAT TTA AAG GAA ATC ATG AAA CAC ATT GTA AAA     144
```

```
Lys Thr Gln Glu Glu His Leu Lys Glu Ile Met Lys His Ile Val Lys
          35                  40                  45

ATA GAA GTA AAA GGG GAG GAA GCT GTT AAA AAA GAG GCA GCA GAA AAG   192
Ile Glu Val Lys Gly Glu Glu Ala Val Lys Lys Glu Ala Ala Glu Lys
     50                  55                  60

CTA CTT GAG AAA GTA CCA TCT GAT GTT TTA GAG ATG TAT AAA GCA ATT   240
Leu Leu Glu Lys Val Pro Ser Asp Val Leu Glu Met Tyr Lys Ala Ile
 65                  70                  75                  80

GGA GGA AAG ATA TAT ATT GTG GAT GGT GAT ATT ACA AAA CAT ATA TCT   288
Gly Gly Lys Ile Tyr Ile Val Asp Gly Asp Ile Thr Lys His Ile Ser
                 85                  90                  95
```

```
TTA GAA GCA TTA TCT GAA GAT AAG AAA AAA ATA AAA GAC ATT TAT GGG          336
Leu Glu Ala Leu Ser Glu Asp Lys Lys Lys Ile Lys Asp Ile Tyr Gly
               100                 105                 110

AAA GAT GCT TTA TTA CAT GAA CAT TAT GTA TAT GCA AAA GAA GGA TAT          384
Lys Asp Ala Leu Leu His Glu His Tyr Val Tyr Ala Lys Glu Gly Tyr
          115                 120                 125

GAA CCC GTA CTT GTA ATC CAA TCT TCG GAA GAT TAT GTA GAA AAT ACT          432
Glu Pro Val Leu Val Ile Gln Ser Ser Glu Asp Tyr Val Glu Asn Thr
     130                 135                 140

GAA AAG GCA CTG AAC GTT TAT TAT GAA ATA GGT AAG ATA TTA TCA AGG          480
Glu Lys Ala Leu Asn Val Tyr Tyr Glu Ile Gly Lys Ile Leu Ser Arg
145                 150                 155                 160

GAT ATT TTA AGT AAA ATT AAT CAA CCA TAT CAG AAA TTT TTA GAT GTA          528
Asp Ile Leu Ser Lys Ile Asn Gln Pro Tyr Gln Lys Phe Leu Asp Val
                165                 170                 175

TTA AAT ACC ATT AAA AAT GCA TCT GAT TCA GAT GGA CAA GAT CTT TTA          576
Leu Asn Thr Ile Lys Asn Ala Ser Asp Ser Asp Gly Gln Asp Leu Leu
               180                 185                 190

TTT ACT AAT CAG CTT AAG GAA CAT CCC ACA GAC TTT TCT GTA GAA TTC          624
Phe Thr Asn Gln Leu Lys Glu His Pro Thr Asp Phe Ser Val Glu Phe
          195                 200                 205

TTG GAA CAA AAT AGC AAT GAG GTA CAA GAA GTA TTT GCG AAA GCT TTT          672
Leu Glu Gln Asn Ser Asn Glu Val Gln Glu Val Phe Ala Lys Ala Phe
     210                 215                 220

GCA TAT TAT ATC GAG CCA CAG CAT CGT GAT GTT TTA CAG CTT TAT GCA          720
Ala Tyr Tyr Ile Glu Pro Gln His Arg Asp Val Leu Gln Leu Tyr Ala
225                 230                 235                 240

CCG GAA GCT TTT AAT TAC ATG GAT AAA TTT AAC GAA CAA GAA ATA AAT          768
Pro Glu Ala Phe Asn Tyr Met Asp Lys Phe Asn Glu Gln Glu Ile Asn
                245                 250                 255

CTA ACG CGT GCG GAG TTC CTC GGC GAC GGC GGC GAC GTC AGC TTC AGC          816
Leu Thr Arg Ala Glu Phe Leu Gly Asp Gly Gly Asp Val Ser Phe Ser
               260                 265                 270

ACC CGC GGC ACG CAG AAC TGG ACG GTG GAG CGG CTG CTC CAG GCG CAC          864
Thr Arg Gly Thr Gln Asn Trp Thr Val Glu Arg Leu Leu Gln Ala His
          275                 280                 285

CGC CAA CTG GAG GAG CGC GGC TAT GTG TTC GTC GGC TAC CAC GGC ACC          912
Arg Gln Leu Glu Glu Arg Gly Tyr Val Phe Val Gly Tyr His Gly Thr
     290                 295                 300

TTC CTC GAA GCG GCG CAA AGC ATC GTC TTC GGC GGG GTG CGC GCG CGC          960
Phe Leu Glu Ala Ala Gln Ser Ile Val Phe Gly Gly Val Arg Ala Arg
305                 310                 315                 320

AGC CAG GAC CTC GAC GCG ATC TGG CGC GGT TTC TAT ATC GCC GGC GAT         1008
Ser Gln Asp Leu Asp Ala Ile Trp Arg Gly Phe Tyr Ile Ala Gly Asp
                325                 330                 335

CCG GCG CTG GCC TAC GGC TAC GCC CAG GAC CAG GAA CCC GAC GCA CGC         1056
Pro Ala Leu Ala Tyr Gly Tyr Ala Gln Asp Gln Glu Pro Asp Ala Arg
               340                 345                 350

GGC CGG ATC CGC AAC GGT GCC CTG CTG CGG GTC TAT GTG CCG CGC TCG         1104
Gly Arg Ile Arg Asn Gly Ala Leu Leu Arg Val Tyr Val Pro Arg Ser
          355                 360                 365

AGC CTG CCG GGC TTC TAC CGC ACC AGC CTG ACC CTG GCC GCG CCG GAG         1152
```

```
Ser Leu Pro Gly Phe Tyr Arg Thr Ser Leu Thr Leu Ala Ala Pro Glu
    370                 375                 380

GCG GCG GGC GAG GTC GAA CGG CTG ATC GGC CAT CCG CTG CCG CTG CGC      1200
Ala Ala Gly Glu Val Glu Arg Leu Ile Gly His Pro Leu Pro Leu Arg
385                 390                 395                 400

CTG GAC GCC ATC ACC GGC CCC GAG GAG GAA GGC GGG CGC CTG GAG ACC      1248
Leu Asp Ala Ile Thr Gly Pro Glu Glu Glu Gly Gly Arg Leu Glu Thr
                405                 410                 415

ATT CTC GGC TGG CCG CTG GCC GAG CGC ACC GTG GTG ATT CCC TCG GCG      1296
Ile Leu Gly Trp Pro Leu Ala Glu Arg Thr Val Val Ile Pro Ser Ala
            420                 425                 430

ATC CCC ACC GAC CCG CGC AAC GTC GGC GGC GAC CTC GAC CCG TCC AGC      1344
Ile Pro Thr Asp Pro Arg Asn Val Gly Gly Asp Leu Asp Pro Ser Ser
        435                 440                 445

ATC CCC GAC AAG GAA CAG GCG ATC AGC GCC CTG CCG GAC TAC GCC AGC      1392
Ile Pro Asp Lys Glu Gln Ala Ile Ser Ala Leu Pro Asp Tyr Ala Ser
    450                 455                 460

CAG CCC GGC AAA CCG CCG CGC GAG GACCTGAAG                            1425
Gln Pro Gly Lys Pro Pro Arg Glu
465                 470
```

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 472 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```
Met Val Pro Ala Gly Gly His Gly Asp Val Gly Met His Val Lys Glu
 1               5                  10                  15
```

Lys Glu Lys Asn Lys Asp Glu Asn Lys Arg Lys Asp Glu Glu Arg Asn
20 25 30

Lys Thr Gln Glu Glu His Leu Lys Glu Ile Met Lys His Ile Val Lys
35 40 45

Ile Glu Val Lys Gly Glu Glu Ala Val Lys Lys Glu Ala Ala Glu Lys
50 55 60

Leu Leu Glu Lys Val Pro Ser Asp Val Leu Glu Met Tyr Lys Ala Ile
65 70 75 80

Gly Gly Lys Ile Tyr Ile Val Asp Gly Asp Ile Thr Lys His Ile Ser
85 90 95

Leu Glu Ala Leu Ser Glu Asp Lys Lys Lys Ile Lys Asp Ile Tyr Gly
100 105 110

Lys Asp Ala Leu Leu His Glu His Tyr Val Tyr Ala Lys Glu Gly Tyr
115 120 125

Glu Pro Val Leu Val Ile Gln Ser Ser Glu Asp Tyr Val Glu Asn Thr
130 135 140

Glu Lys Ala Leu Asn Val Tyr Tyr Glu Ile Gly Lys Ile Leu Ser Arg
145 150 155 160

Asp Ile Leu Ser Lys Ile Asn Gln Pro Tyr Gln Lys Phe Leu Asp Val
165 170 175

Leu Asn Thr Ile Lys Asn Ala Ser Asp Ser Asp Gly Gln Asp Leu Leu
180 185 190

Phe Thr Asn Gln Leu Lys Glu His Pro Thr Asp Phe Ser Val Glu Phe
195 200 205

Leu Glu Gln Asn Ser Asn Glu Val Gln Glu Val Phe Ala Lys Ala Phe
210 215 220

Ala Tyr Tyr Ile Glu Pro Gln His Arg Asp Val Leu Gln Leu Tyr Ala
225 230 235 240

Pro Glu Ala Phe Asn Tyr Met Asp Lys Phe Asn Glu Gln Glu Ile Asn
245 250 255

Leu Thr Arg Ala Glu Phe Leu Gly Asp Gly Gly Asp Val Ser Phe S

385 390 395 400

Leu Asp Ala Ile Thr Gly Pro Glu Glu Glu Gly Gly Arg Leu Glu Thr
405 410 415

Ile Leu Gly Trp Pro Leu Ala Glu Arg Thr Val Val Ile Pro Ser Ala
420 425 430

Ile Pro Thr Asp Pro Arg Asn Val Gly Gly Asp Leu Asp Pro Ser Ser
435 440 445

Ile Pro Asp Lys Glu Gln Ala Ile Ser Ala Leu Pro Asp Tyr Ala Ser
450 455 460

Gln Pro Gly Lys Pro Pro Arg Glu
465 470

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1524 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus anthracis

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..1524
(D) OTHER INFORMATION: /product=
"LF(1-254)--TR--PE(362-613)"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

```
GCG GGC GGT CAT GGT GAT GTA GGT ATG CAC GTA AAA GAG AAA GAG AAA          48
Ala Gly Gly His Gly Asp Val Gly Met His Val Lys Glu Lys Glu Lys
  1               5                  10                  15

AAT AAA GAT GAG AAT AAG AGA AAA GAT GAA GAA CGA AAT AAA ACA CAG          96
Asn Lys Asp Glu Asn Lys Arg Lys Asp Glu Glu Arg Asn Lys Thr Gln
            20                  25                  30

GAA GAG CAT TTA AAG GAA ATC ATG AAA CAC ATT GTA AAA ATA GAA GTA         144
Glu Glu His Leu Lys Glu Ile Met Lys His Ile Val Lys Ile Glu Val
        35                  40                  45

AAA GGG GAG GAA GCT GTT AAA AAA GAG GCA GCA GAA AAG CTA CTT GAG         192
Lys Gly Glu Glu Ala Val Lys Lys Glu Ala Ala Glu Lys Leu Leu Glu
    50                  55                  60

AAA GTA CCA TCT GAT GTT TTA GAG ATG TAT AAA GCA ATT GGA GGA AAG         240
Lys Val Pro Ser Asp Val Leu Glu Met Tyr Lys Ala Ile Gly Gly Lys
65                  70                  75                  80

ATA TAT ATT GTG GAT GGT GAT ATT ACA AAA CAT ATA TCT TTA GAA GCA         288
Ile Tyr Ile Val Asp Gly Asp Ile Thr Lys His Ile Ser Leu Glu Ala
                85                  90                  95

TTA TCT GAA GAT AAG AAA AAA ATA AAA GAC ATT TAT GGG AAA GAT GCT         336
Leu Ser Glu Asp Lys Lys Lys Ile Lys Asp Ile Tyr Gly Lys Asp Ala
            100                 105                 110

TTA TTA CAT GAA CAT TAT GTA TAT GCA AAA GAA GGA TAT GAA CCC GTA         384
Leu Leu His Glu His Tyr Val Tyr Ala Lys Glu Gly Tyr Glu Pro Val
        115                 120                 125

CTT GTA ATC CAA TCT TCG GAA GAT TAT GTA GAA AAT ACT GAA AAG GCA         432
Leu Val Ile Gln Ser Ser Glu Asp Tyr Val Glu Asn Thr Glu Lys Ala
    130                 135                 140

CTG AAC GTT TAT TAT GAA ATA GGT AAG ATA TTA TCA AGG GAT ATT TTA         480
Leu Asn Val Tyr Tyr Glu Ile Gly Lys Ile Leu Ser Arg Asp Ile Leu
145                 150                 155                 160

AGT AAA ATT AAT CAA CCA TAT CAG AAA TTT TTA GAT GTA TTA AAT ACC         528
Ser Lys Ile Asn Gln Pro Tyr Gln Lys Phe Leu Asp Val Leu Asn Thr
                165                 170                 175

ATT AAA AAT GCA TCT GAT TCA GAT GGA CAA GAT CTT TTA TTT ACT AAT         576
Ile Lys Asn Ala Ser Asp Ser Asp Gly Gln Asp Leu Leu Phe Thr Asn
            180                 185                 190

CAG CTT AAG GAA CAT CCC ACA GAC TTT TCT GTA GAA TTC TTG GAA CAA         624
Gln Leu Lys Glu His Pro Thr Asp Phe Ser Val Glu Phe Leu Glu Gln
        195                 200                 205

AAT AGC AAT GAG GTA CAA GAA GTA TTT GCG AAA GCT TTT GCA TAT TAT         672
Asn Ser Asn Glu Val Gln Glu Val Phe Ala Lys Ala Phe Ala Tyr Tyr
    210                 215                 220

ATC GAG CCA CAG CAT CGT GAT GTT TTA CAG CTT TAT GCA CCG GAA GCT         720
Ile Glu Pro Gln His Arg Asp Val Leu Gln Leu Tyr Ala Pro Glu Ala
225                 230                 235                 240

TTT AAT TAC ATG GAT AAA TTT AAC GAA CAA GAA ATA AAT CTA ACG CGT         768
Phe Asn Tyr Met Asp Lys Phe Asn Glu Gln Glu Ile Asn Leu Thr Arg
                245                 250                 255

GCG GCC AAC GCC GAC GTG GTG AGC CTG ACC TGC CCG GTC GCC GCC GGT         816
Ala Ala Asn Ala Asp Val Val Ser Leu Thr Cys Pro Val Ala Ala Gly
            260                 265                 270

GAA TGC GCG GGC CCG GCG GAC AGC GGC GAC CCC CTC GTC CAC CCC AAC         864
```

```
Glu Cys Ala Gly Pro Ala Asp Ser Gly Asp Ala Leu Leu Glu Arg Asn
        275                 280                 285

TAT CCC ACT GGC GCG GAG TTC CTC GGC GAC GGC GGC GAC GTC AGC TTC      912
Tyr Pro Thr Gly Ala Glu Phe Leu Gly Asp Gly Gly Asp Val Ser Phe
    290                 295                 300

AGC ACC CGC GGC ACG CAG AAC TGG ACG GTG GAG CGG CTG CTC CAG GCG      960
Ser Thr Arg Gly Thr Gln Asn Trp Thr Val Glu Arg Leu Leu Gln Ala
305                 310                 315                 320

CAC CGC CAA CTG GAG GAG CGC GGC TAT GTG TTC GTC GGC TAC CAC GGC     1008
His Arg Gln Leu Glu Glu Arg Gly Tyr Val Phe Val Gly Tyr His Gly
                325                 330                 335

ACC TTC CTC GAA GCG GCG CAA AGC ATC GTC TTC GGC GGG GTG CGC GCG     1056
Thr Phe Leu Glu Ala Ala Gln Ser Ile Val Phe Gly Gly Val Arg Ala
            340                 345                 350

CGC AGC CAG GAC CTC GAC GCG ATC TGG CGC GGT TTC TAT ATC GCC GGC     1104
Arg Ser Gln Asp Leu Asp Ala Ile Trp Arg Gly Phe Tyr Ile Ala Gly
        355                 360                 365

GAT CCG GCG CTG GCC TAC GGC TAC GCC CAG GAC CAG GAA CCC GAC GCA     1152
Asp Pro Ala Leu Ala Tyr Gly Tyr Ala Gln Asp Gln Glu Pro Asp Ala
    370                 375                 380

CGC GGC CGG ATC CGC AAC GGT GCC CTG CTG CGG GTC TAT GTG CCG CGC     1200
Arg Gly Arg Ile Arg Asn Gly Ala Leu Leu Arg Val Tyr Val Pro Arg
385                 390                 395                 400

TCG AGC CTG CCG GGC TTC TAC CGC ACC AGC CTG ACC CTG GCC GCG CCG     1248
Ser Ser Leu Pro Gly Phe Tyr Arg Thr Ser Leu Thr Leu Ala Ala Pro
                405                 410                 415

GAG GCG GCG GGC GAG GTC GAA CGG CTG ATC GGC CAT CCG CTG CCG CTG     1296
Glu Ala Ala Gly Glu Val Glu Arg Leu Ile Gly His Pro Leu Pro Leu
            420                 425                 430

CGC CTG GAC GCC ATC ACC GGC CCC GAG GAG GAA GGC GGG CGC CTG GAG     1344
Arg Leu Asp Ala Ile Thr Gly Pro Glu Glu Glu Gly Gly Arg Leu Glu
        435                 440                 445

ACC ATT CTC GGC TGG CCG CTG GCC GAG CGC ACC GTG GTG ATT CCC TCG     1392
Thr Ile Leu Gly Trp Pro Leu Ala Glu Arg Thr Val Val Ile Pro Ser
    450                 455                 460

GCG ATC CCC ACC GAC CCG CGC AAC GTC GGC GGC GAC CTC GAC CCG TCC     1440
Ala Ile Pro Thr Asp Pro Arg Asn Val Gly Gly Asp Leu Asp Pro Ser
465                 470                 475                 480

AGC ATC CCC GAC AAG GAA CAG GCG ATC AGC GCC CTG CCG GAC TAC GCC     1488
Ser Ile Pro Asp Lys Glu Gln Ala Ile Ser Ala Leu Pro Asp Tyr Ala
                485                 490                 495

AGC CAG CCC GGC AAA CCG CCG CGC GAG GAC CTG AAG                     1524
Ser Gln Pro Gly Lys Pro Pro Arg Glu Asp Leu Lys
            500                 505
```

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 508 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Ala Gly Gly His Gly Asp Val Gly Met His Val Lys Glu Lys Glu Lys
1 5 10 15

Asn Lys Asp Glu Asn Lys Arg Lys Asp Glu Glu Arg Asn Lys Thr Gln
20 25 30

Glu Glu His Leu Lys Glu Ile Met Lys His Ile Val Lys Ile Glu Val
35 40 45

Lys Gly Glu Glu Ala Val Lys Lys Glu Ala Ala Glu Lys Leu Leu Glu
50 55 60

Lys Val Pro Ser Asp Val Leu Glu Met Tyr Lys Ala Ile Gly Gly Lys
65 70 75 80

Ile Tyr Ile Val Asp Gly Asp Ile Thr Lys His Ile Ser Leu Glu Ala
85 90 95

Leu Ser Glu Asp Lys Lys Lys Ile Lys Asp Ile Tyr Gly Lys Asp Ala
100 105 110

Leu Leu His Glu His Tyr Val Tyr Ala Lys Glu Gly Tyr Glu Pro Val
115 120 125

Leu Val Ile Gln Ser Ser Glu Asp Tyr Val Glu Asn Thr Glu Lys Ala
130 135 140

Leu Asn Val Tyr Tyr Glu Ile Gly Lys Ile Leu Ser Arg Asp Ile Leu
145 150 155 160

Ser Lys Ile Asn Gln Pro Tyr Gln Lys Phe Leu Asp Val Leu Asn Thr
165 170 175

Ile Lys Asn Ala Ser Asp Ser Asp Gly Gln Asp Leu Leu Phe Thr Asn
180 185 190

Gln Leu Lys Glu His Pro Thr Asp Phe Ser Val Glu Phe Leu Glu Gln
195 200 205

Asn Ser Asn Glu Val Gln Glu Val Phe Ala Lys Ala Phe Ala Tyr Tyr
210 215 220

Ile Glu Pro Gln His Arg Asp Val Leu Gln Leu Tyr Ala Pro Glu Ala
225 230 235 240

Phe Asn Tyr Met Asp Lys Phe Asn Glu Gln Glu Ile Asn Leu Thr Arg
245 250 255

Ala Ala Asn Ala Asp Val Val Ser Leu Thr Cys Pro Val Ala Ala Gly
260 265 270

Glu Cys Ala Gly Pro Ala Asp Ser Gly Asp Ala Leu Leu Glu Arg Asn
275 280 285

Tyr Pro Thr Gly Ala Glu Phe Leu Gly Asp Gly Gly Asp Val Ser Phe
290 295 300

Ser Thr Arg Gly Thr Gln Asn Trp Thr Val Glu Arg Leu Leu Gln Ala
305 310 315 320

His Arg Gln Leu Glu Glu Arg Gly Tyr Val Phe Val Gly Tyr His Gly
325 330 335

Thr Phe Leu Glu Ala Ala Gln Ser Ile Val Phe Gly Gly Val Arg Ala
340 345 350

Arg Ser Gln Asp Leu Asp Ala Ile Trp Arg Gly Phe Tyr Ile Ala Gly
355 360 365

Asp Pro Ala Leu Ala Tyr Gly Tyr Ala Gln Asp Gln Glu Pro Asp Ala
370 375 380

Arg Gly Arg Ile Arg Asn Gly Ala Leu Leu Arg Val Tyr Val Pro Arg
385 390 395 400

Ser Ser Leu Pro Gly Phe Tyr Arg Thr Ser Leu Thr Leu Ala Ala Pro
405 410 415

Glu Ala Ala Gly Glu Val Glu Arg Leu Ile Gly His Pro Leu Pro Leu
420 425 430

Arg Leu Asp Ala Ile Thr Gly Pro Glu Glu Glu Gly Gly Arg Leu Glu
435 440 445

Thr Ile Leu Gly Trp Pro Leu Ala Glu Arg Thr Val Val Ile Pro Ser
450 455 460

Ala Ile Pro Thr Asp Pro Arg Asn Val Gly Gly Asp Leu Asp Pro Ser
465 470 475 480

Ser Ile Pro Asp Lys Glu Gln Ala Ile Ser Ala Leu Pro Asp Tyr Ala
485 490 495

Ser Gln Pro Gly Lys Pro Pro Arg Glu Asp Leu Lys
500 505

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2709 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus anthracis

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..2709
(D) OTHER INFORMATION: /product= "PA(1-725)-----Human CD4 residues(1-178)"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

```
GAA GTT AAA CAG GAG AAC CGG TTA TTA AAT GAA TCA GAA TCA AGT TCC      48
Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser
 1               5                  10                  15

CAG GGG TTA CTA GGA TAC TAT TTT AGT GAT TTG AAT TTT CAA GCA CCC      96
Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
            20                  25                  30

ATG GTG GTT ACC TCT TCT ACT ACA GGG GAT TTA TCT ATT CCT AGT TCT     144
Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
        35                  40                  45

GAG TTA GAA AAT ATT CCA TCG GAA AAC CAA TAT TTT CAA TCT GCT ATT     192
Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
    50                  55                  60

TGG TCA GGA TTT ATC AAA GTT AAG AAG AGT GAT GAA TAT ACA TTT GCT     240
Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala
65                  70                  75                  80

ACT TCC GCT GAT AAT CAT GTA ACA ATG TGG GTA GAT GAC CAA GAA GTG     288
Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
                85                  90                  95

ATT AAT AAA GCT TCT AAT TCT AAC AAA ATC AGA TTA GAA AAA GGA AGA     336
Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
            100                 105                 110

TTA TAT CAA ATA AAA ATT CAA TAT CAA CGA GAA AAT CCT ACT GAA AAA     384
Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
        115                 120                 125

GGA TTG GAT TTC AAG TTG TAC TGG ACC GAT TCT CAA AAT AAA AAA GAA     432
Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
    130                 135                 140

GTG ATT TCT AGT GAT AAC TTA CAA TTG CCA GAA TTA AAA CAA AAA TCT     480
Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser
145                 150                 155                 160

TCG AAC TCA AGA AAA AAG CGA AGT ACA AGT GCT GGA CCT ACG GTT CCA     528
Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
                165                 170                 175

GAC CGT GAC AAT GAT GGA ATC CCT GAT TCA TTA GAG GTA GAA GGA TAT     576
Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
            180                 185                 190
```

```
ACG GTT GAT GTC AAA AAT AAA AGA ACT TTT CTT TCA CCA TGG ATT TCT          624
Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
        195                 200                 205

AAT ATT CAT GAA AAG AAA GGA TTA ACC AAA TAT AAA TCA TCT CCT GAA          672
Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
    210                 215                 220

AAA TGG AGC ACG GCT TCT GAT CCG TAC AGT GAT TTC GAA AAG GTT ACA          720
Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr
225                 230                 235                 240

GGA CGG ATT GAT AAG AAT GTA TCA CCA GAG GCA AGA CAC CCC CTT GTG          768
Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
                245                 250                 255

GCA GCT TAT CCG ATT GTA CAT GTA GAT ATG GAG AAT ATT ATT CTC TCA          816
Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
            260                 265                 270

AAA AAT GAG GAT CAA TCC ACA CAG AAT ACT GAT AGT GAA ACG AGA ACA          864
Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
        275                 280                 285

ATA AGT AAA AAT ACT TCT ACA AGT AGG ACA CAT ACT AGT GAA GTA CAT          912
Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
    290                 295                 300

GGA AAT GCA GAA GTG CAT GCG TCG TTC TTT GAT ATT GGT GGG AGT GTA          960
Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val
305                 310                 315                 320

TCT GCA GGA TTT AGT AAT TCG AAT TCA AGT ACG GTC GCA ATT GAT CAT         1008
Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
                325                 330                 335

TCA CTA TCT CTA GCA GGG GAA AGA ACT TGG GCT GAA ACA ATG GGT TTA         1056
Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
            340                 345                 350

AAT ACC GCT GAT ACA GCA AGA TTA AAT GCC AAT ATT AGA TAT GTA AAT         1104
Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
        355                 360                 365

ACT GGG ACG GCT CCA ATC TAC AAC GTG TTA CCA ACG ACT TCG TTA GTG         1152
Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
    370                 375                 380

TTA GGA AAA AAT CAA ACA CTC GCG ACA ATT AAA GCT AAG GAA AAC CAA         1200
Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln
385                 390                 395                 400

TTA AGT CAA ATA CTT GCA CCT AAT AAT TAT TAT CCT TCT AAA AAC TTG         1248
Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
                405                 410                 415

GCG CCA ATC GCA TTA AAT GCA CAA GAC GAT TTC AGT TCT ACT CCA ATT         1296
Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
            420                 425                 430

ACA ATG AAT TAC AAT CAA TTT CTT GAG TTA GAA AAA ACG AAA CAA TTA         1344
Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
        435                 440                 445

AGA TTA GAT ACG GAT CAA GTA TAT GGG AAT ATA GCA ACA TAC AAT TTT         1392
Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
    450                 455                 460

GAA AAT GGA AGA GTG AGG GTG GAT ACA GGC TCG AAC TGG AGT GAA GTG         1440
```

```
Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val
465                 470                 475                 480

TTA CCG CAA ATT CAA GAA ACA ACT GCA CGT ATC ATT TTT AAT GGA AAA                1488
Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
                485                 490                 495

GAT TTA AAT CTG GTA GAA AGG CGG ATA GCG GCG GTT AAT CCT AGT GAT                1536
Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
            500                 505                 510

CCA TTA GAA ACG ACT AAA CCG GAT ATG ACA TTA AAA GAA GCC CTT AAA                1584
Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
        515                 520                 525

ATA GCA TTT GGA TTT AAC GAA CCG AAT GGA AAC TTA CAA TAT CAA GGG                1632
Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
    530                 535                 540

AAA GAC ATA ACC GAA TTT GAT TTT AAT TTC GAT CAA CAA ACA TCT CAA                1680
Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln
545                 550                 555                 560

AAT ATC AAG AAT CAG TTA GCG GAA TTA AAC GCA ACT AAC ATA TAT ACT                1728
Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
                565                 570                 575

GTA TTA GAT AAA ATC AAA TTA AAT GCA AAA ATG AAT ATT TTA ATA AGA                1776
Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
            580                 585                 590

GAT AAA CGT TTT CAT TAT GAT AGA AAT AAC ATA GCA GTT GGG GCG GAT                1824
Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
        595                 600                 605

GAG TCA GTA GTT AAG GAG GCT CAT AGA GAA GTA ATT AAT TCG TCA ACA                1872
Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
    610                 615                 620

GAG GGA TTA TTG TTA AAT ATT GAT AAG GAT ATA AGA AAA ATA TTA TCA                1920
Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser
625                 630                 635                 640

GGT TAT ATT GTA GAA ATT GAA GAT ACT GAA GGG CTT AAA GAA GTT ATA                1968
Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
                645                 650                 655

AAT GAC AGA TAT GAT ATG TTG AAT ATT TCT AGT TTA CGG CAA GAT GGA                2016
Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
            660                 665                 670

AAA ACA TTT ATA GAT TTT AAA AAA TAT AAT GAT AAA TTA CCG TTA TAT                2064
Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
        675                 680                 685

ATA AGT AAT CCC AAT TAT AAG GTA AAT GTA TAT GCT GTT ACT AAA GAA                2112
Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
    690                 695                 700

AAC ACT ATT ATT AAT CCT AGT GAG AAT GGG GAT ACT AGT ACC AAC GGG                2160
Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly
705                 710                 715                 720

ATC AAG AAA ATT TTA AAG AAA GTG GTG CTG GGC AAA AAA GGG GAT ACA                2208
Ile Lys Lys Ile Leu Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr
                725                 730                 735

GTG GAA CTG ACC TGT ACA GCT TCC CAG AAG AAG AGC ATA CAA TTC CAC                2256
Val Glu Leu Thr Cys Thr Ala Ser Gln Lys Lys Ser Ile Gln Phe His
```

```
                740                 745                 750

TGG AAA AAC TCC AAC CAG ATA AAG ATT CTG GGA AAT CAG GGC TCC TTC      2304
Trp Lys Asn Ser Asn Gln Il  Lys Ile Leu Gly Asn Gln Gly Ser Phe
     755                 760                 765

TTA ACT AAA GGT CCA TCC AAG CTG AAT GAT CGC GCT GAC TCA AGA AGA      2352
Leu Thr Lys Gly Pro Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg
770                 775                 780

AGC CTT TGG GAC CAA GGA AAC TTC CCC CTG ATC ATC AAG AAT CTT AAG      2400
Ser Leu Trp Asp Gln Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys
785                 790                 795                 800

ATA GAA GAC TCA GAT ACT TAC ATC TGT GAA GTG GAG GAC CAG AAG GAG      2448
Ile Glu Asp Ser Asp Thr Tyr Ile Cys Glu Val Glu Asp Gln Lys Glu
                805                 810                 815

GAG GTG CAA TTG CTA GTG TTC GGA TTG ACT GCC AAC TCT GAC ACC CAC      2496
Glu Val Gln Leu Leu Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His
            820                 825                 830

CTG CTT CAG GGG CAG AGC CTG ACC CTG ACC TTG GAG AGC CCC CCT GGT      2544
Leu Leu Gln Gly Gln Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly
        835                 840                 845

AGT AGC CCC TCA GTG CAA TGT AGG AGT CCA AGG GGT AAA AAC ATA CAG      2592
Ser Ser Pro Ser Val Gln Cys Arg Ser Pro Arg Gly Lys Asn Ile Gln
    850                 855                 860

GGG GGG AAG ACC CTC TCC GTG TCT CAG CTG GAG CTC CAG GAT AGT GGC      2640
Gly Gly Lys Thr Leu Ser Val Ser Gln Leu Glu Leu Gln Asp Ser Gly
865                 870                 875                 880

ACC TGG ACA TGC ACT GTC TTG CAG AAC CAG AAG AAG GTG GAG TTC AAA      2688
Thr Trp Thr Cys Thr Val Leu Gln Asn Gln Lys Lys Val Glu Phe Lys
                885                 890                 895

ATA GAC ATC GTG GTG CTA GCT                                          2709
Ile Asp Ile Val Val Leu Ala
            900
```

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 903 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

```
Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser
 1               5                  10                  15
```

Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30

Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45

Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60

Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala
65 70 75 80

Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95

Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110

Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125

Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140

Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser
145 150 155 160

Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165 170 175

Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180 185 190

Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195 200 205

Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210 215 220

Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr
225 230 235 240

Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245 250 255

Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260 265 270

Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
275 280 285

Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290 295 300

Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val
305 310 315 320

Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
325 330 335

Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
340 345 350

Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
355 360 365

Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
370 375 380

Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln

385 390 395 400

Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
405 410 415

Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
420 425 430

Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
435 440 445

Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450 455 460

Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val
465 470 475 480

Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
485 490 495

Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
500 505 510

Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
515 520 525

Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
530 535 540

Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln
545 550 555 560

Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565 570 575

Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580 585 590

Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595 600 605

Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610 615 620

Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser
625 630 635 640

Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645 650 655

Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660 665 670

Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675 680 685

Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690 695 700

Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly
705 710 715 720

Ile Lys Lys Ile Leu Lys Lys Val Val Leu Gly Lys Lys Gly Asp Thr
725 730 735

Val Glu Leu Thr Cys Thr Ala Ser Gln Lys Lys Ser Ile Gln Phe His
740 745 750

Trp Lys Asn Ser Asn Gln Ile Lys Ile Leu Gly Asn Gln Gly Ser Phe
755 760 765

Leu Thr Lys Gly Pro Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg
770 775 780

Ser Leu Trp Asp Gln Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys
785 790 795 800

Ile Glu Asp Ser Asp Thr Tyr Ile Cys Glu Val Glu Asp Gln Lys Glu
805 810 815

Glu Val Gln Leu Leu Val Phe Gly Leu Thr Ala Asn Ser Asp Thr His
820 825 830

Leu Leu Gln Gly Gln Ser Leu Thr Leu Thr Leu Glu Ser Pro Pro Gly
835 840 845

Ser Ser Pro Ser Val Gln Cys Arg Ser Pro Arg Gly Lys Asn Ile Gln
850 855 860

Gly Gly Lys Thr Leu Ser Val Ser Gln Leu Glu Leu Gln Asp Ser Gly
865 870 875 880

Thr Trp Thr Cys Thr Val Leu Gln Asn Gln Lys Lys Val Glu Phe Lys
885 890 895

Ile Asp Ile Val Val Leu Ala
900

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus anthracis

(ix) FEATURE:
(A) NAME/KEY: Peptide
(B) LOCATION: 1..8
(D) OTHER INFORMATION: /label= PAHIV

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Ser Gln Asn Tyr Pro Val Val Gln
1 5

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus anthracis

(ix) FEATURE:
(A) NAME/KEY: Peptide
(B) LOCATION: 1..12
(D) OTHER INFORMATION: /label= PAHIV-1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Gln Val Ser Gln Asn Tyr Pro Ile Val Gln Asn Ile
1 5 10

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus anthracis

(ix) FEATURE:
(A) NAME/KEY: Peptide
(B) LOCATION: 1..12
(D) OTHER INFORMATION: /label= PAHIV-2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Asn Thr Ala Thr Ile Met Met Gln Arg Gly Asn Phe
1 5 10

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus anthracis

(ix) FEATURE:
(A) NAME/KEY: Peptide
(B) LOCATION: 1..12
(D) OTHER INFORMATION: /label= PAHIV-3

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Thr Val Ser Phe Asn Phe Pro Gln Ile Thr Leu Trp
1 5 10

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus anthracis

(ix) FEATURE:
(A) NAME/KEY: Peptide
(B) LOCATION: 1..13
(D) OTHER INFORMATION: /label= PAHIV-4

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Gly Gly Ser Ala Phe Asn Phe Pro Ile Val Met Gly Gly
1 5 10

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus anthracis

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 3..44
(D) OTHER INFORMATION: /product= "Primer 1A"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CG CAA GTA TCA CAA AAT TAT CCG ATC GTG CAA AAC ATA CTG CAG 44
Gln Val Ser Gln Asn Tyr Pro Ile Val Gln Asn Ile Leu Gln
1 5 10

G 45

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Gln Val Ser Gln Asn Tyr Pro Ile Val Gln Asn Ile Leu Gln
1 5 10

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus anthracis

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1..46
(D) OTHER INFORMATION: /product= "PRIMER 1B"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GTTCCTGCAG TATGTTTTGC ACGATCGGAT AATTTTGTGA TACTTG 46

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus anthracis

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 3..44
(D) OTHER INFORMATION: /product= "Primer 2A"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

```
CG AAC ACT GCC ACT ATC ATG ATG CAA CGT GGT AAT TTT CTG CAG          44
   Asn Thr Ala Thr Ile Met Met Gln Arg Gly Asn Phe Leu Gln
     1               5                  10

G                                                                  45
```

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

```
Asn Thr Ala Thr Ile Met Met Gln Arg Gly Asn Phe Leu Gln
  1               5                  10
```

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus anthracis

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1..46
(D) OTHER INFORMATION: /product= "PRIMER 2B"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GTCCCTGCAG AAAATTACCA CGTTGCATCA TGATAGTGGC AGTGTT 46

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus anthracis

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 3..44
(D) OTHER INFORMATION: /product= "Primer 3A"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

CG ACT GTC TCT TTT AAC TTC CCG CAA ATC ACG CTT TGG CTG CAG 44
Thr Val Ser Phe Asn Phe Pro Gln Ile Thr Leu Trp Leu Gln
1 5 10

G 45

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Thr Val Ser Phe Asn Phe Pro Gln Ile Thr Leu Trp Leu Gln
1 5 10

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus anthracis

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1..46
(D) OTHER INFORMATION: /product= "PRIMER 3B"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GTCCCTGCAG CCAAAGCGTG ATTTGCGGGA AGTTAAAAGA GACAGT 46

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 48 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus anthracis

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 3..47
(D) OTHER INFORMATION: /product= "Primer 4A"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

CG GGC GGT TCT GCC TTT AAC TTC CCG ATC GTC ATG GGA GGT CTG CAG 47
Gly Gly Ser Ala Phe Asn Phe Pro Ile Val Met Gly Gly Leu Gln
1 5 10 15

G 48

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Gly Gly Ser Ala Phe Asn Phe Pro Ile Val Met Gly Gly Leu Gln
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 49 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus anthracis

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1..49
(D) OTHER INFORMATION: /product= "PRIMER 4B"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GTCCCTGCAG ACCTCCCATG ACGATCGGGA AGTTAAAGGC AGAACCGCC 49

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2160 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus anthracis

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..2157
(D) OTHER INFORMATION: /product= "PAHIV#2"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

```
GAA GTT AAA CAG GAG AAC CGG TTA TTA AAT GAA TCA GAA TCA AGT TCC      48
Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser
 1               5                  10                  15

CAG GGG TTA CTA GGA TAC TAT TTT AGT GAT TTG AAT TTT CAA GCA CCC      96
Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
            20                  25                  30

ATG GTG GTT ACC TCT TCT ACT ACA GGG GAT TTA TCT ATT CCT AGT TCT     144
Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
        35                  40                  45

GAG TTA GAA AAT ATT CCA TCG GAA AAC CAA TAT TTT CAA TCT GCT ATT     192
Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
    50                  55                  60

TGG TCA GGA TTT ATC AAA GTT AAG AAG AGT GAT GAA TAT ACA TTT GCT     240
Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala
65                  70                  75                  80

ACT TCC GCT GAT AAT CAT GTA ACA ATG TGG GTA GAT GAC CAA GAA GTG     288
Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
                85                  90                  95

ATT AAT AAA GCT TCT AAT TCT AAC AAA ATC AGA TTA GAA AAA GGA AGA     336
Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
            100                 105                 110

TTA TAT CAA ATA AAA ATT CAA TAT CAA CGA GAA AAT CCT ACT GAA AAA     384
Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
        115                 120                 125

GGA TTG GAT TTC AAG TTG TAC TGG ACC GAT TCT CAA AAT AAA AAA GAA     432
Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
    130                 135                 140

GTG ATT TCT AGT GAT AAC TTA CAA TTG CCA GAA TTA AAA CAA AAA TCT     480
Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser
145                 150                 155                 160

TCG AAC ACT GCC ACT ATC ATG ATG CAA CGT GGT AAT TTT CTG CAG GGA     528
Ser Asn Thr Ala Thr Ile Met Met Gln Arg Gly Asn Phe Leu Gln Gly
                165                 170                 175

CCT ACG GTT CCA GAC CGT GAC AAT GAT GGA ATC CCT GAT TCA TTA GAG     576
Pro Thr Val Pro Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu
            180                 185                 190

GTA GAA GGA TAT ACG GTT GAT GTC AAA AAT AAA AGA ACT TTT CTT TCA     624
Val Glu Gly Tyr Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser
        195                 200                 205
```

```
CCA TGG ATT TCT AAT ATT CAT GAA AAG AAA GGA TTA ACC AAA TAT AAA          672
Pro Trp Ile Ser Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys
    210                 215                 220

TCA TCT CCT GAA AAA TGG AGC ACG GCT TCT GAT CCG TAC AGT GAT TTC          720
Ser Ser Pro Glu Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe
225                 230                 235                 240

GAA AAG GTT ACA GGA CGG ATT GAT AAG AAT GTA TCA CCA GAG GCA AGA          768
Glu Lys Val Thr Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg
                245                 250                 255

CAC CCC CTT GTG GCA GCT TAT CCG ATT GTA CAT GTA GAT ATG GAG AAT          816
His Pro Leu Val Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn
            260                 265                 270

ATT ATT CTC TCA AAA AAT GAG GAT CAA TCC ACA CAG AAT ACT GAT AGT          864
Ile Ile Leu Ser Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser
        275                 280                 285

GAA ACG AGA ACA ATA AGT AAA AAT ACT TCT ACA AGT AGG ACA CAT ACT          912
Glu Thr Arg Thr Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr
    290                 295                 300

AGT GAA GTA CAT GGA AAT GCA GAA GTG CAT GCG TCG TTC TTT GAT ATT          960
Ser Glu Val His Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile
305                 310                 315                 320

GGT GGG AGT GTA TCT GCA GGA TTT AGT AAT TCG AAT TCA AGT ACG GTC         1008
Gly Gly Ser Val Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val
                325                 330                 335

GCA ATT GAT CAT TCA CTA TCT CTA GCA GGG GAA AGA ACT TGG GCT GAA         1056
Ala Ile Asp His Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu
            340                 345                 350

ACA ATG GGT TTA AAT ACC GCT GAT ACA GCA AGA TTA AAT GCC AAT ATT         1104
Thr Met Gly Leu Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile
        355                 360                 365

AGA TAT GTA AAT ACT GGG ACG GCT CCA ATC TAC AAC GTG TTA CCA ACG         1152
Arg Tyr Val Asn Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr
    370                 375                 380

ACT TCG TTA GTG TTA GGA AAA AAT CAA ACA CTC GCG ACA ATT AAA GCT         1200
Thr Ser Leu Val Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala
385                 390                 395                 400

AAG GAA AAC CAA TTA AGT CAA ATA CTT GCA CCT AAT AAT TAT TAT CCT         1248
Lys Glu Asn Gln Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro
                405                 410                 415

TCT AAA AAC TTG GCG CCA ATC GCA TTA AAT GCA CAA GAC GAT TTC AGT         1296
Ser Lys Asn Leu Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser
            420                 425                 430

TCT ACT CCA ATT ACA ATG AAT TAC GGG AAT ATA GCA ACA TAC AAT TTT         1344
Ser Thr Pro Ile Thr Met Asn Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
        435                 440                 445

GAA AAT GGA AGA GTG AGG GTG GAT ACA GGC TCG AAC TGG AGT GAA GTG         1392
Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val
    450                 455                 460

TTA CCG CAA ATT CAA GAA ACA ACT GCA CGT ATC ATT TTT AAT GGA AAA         1440
Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
465                 470                 475                 480

GAT TTA AAT CTG GTA GAA AGG CGG ATA GCG GCG GTT AAT CCT AGT GAT         1488
```

```
Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
                485                 490                 495

CCA TTA GAA ACG ACT AAA CCG GAT ATG ACA TTA AAA GAA GCC CTT AAA      1536
Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
            500                 505                 510

ATA GCA TTT GGA TTT AAC GAA CCG AAT GGA AAC TTA CAA TAT CAA GGG      1584
Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
        515                 520                 525

AAA GAC ATA ACC GAA TTT GAT TTT AAT TTC GAT CAA CAA ACA TCT CAA      1632
Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln
    530                 535                 540

AAT ATC AAG AAT CAG TTA GCG GAA TTA AAC GCA ACT AAC ATA TAT ACT      1680
Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
545                 550                 555                 560

GTA TTA GAT AAA ATC AAA TTA AAT GCA AAA ATG AAT ATT TTA ATA AGA      1728
Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
                565                 570                 575

GAT AAA CGT TTT CAT TAT GAT AGA AAT AAC ATA GCA GTT GGG GCG GAT      1776
Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
            580                 585                 590

GAG TCA GTA GTT AAG GAG GCT CAT AGA GAA GTA ATT AAT TCG TCA ACA      1824
Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
        595                 600                 605

GAG GGA TTA TTG TTA AAT ATT GAT AAG GAT ATA AGA AAA ATA TTA TCA      1872
Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser
    610                 615                 620

GGT TAT ATT GTA GAA ATT GAA GAT ACT GAA GGG CTT AAA GAA GTT ATA      1920
Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
625                 630                 635                 640

AAT GAC AGA TAT GAT ATG TTG AAT ATT TCT AGT TTA CGG CAA GAT GGA      1968
Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
                645                 650                 655

AAA ACA TTT ATA GAT TTT AAA AAA TAT AAT GAT AAA TTA CCG TTA TAT      2016
Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
            660                 665                 670

ATA AGT AAT CCC AAT TAT AAG GTA AAT GTA TAT GCT GTT ACT AAA GAA      2064
Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
        675                 680                 685

AAC ACT ATT ATT AAT CCT AGT GAG AAT GGG GAT ACT AGT ACC AAC GGG      2112
Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly
    690                 695                 700

ATC AAG AAA ATT TTA ATC TTT TCT AAA AAA GGC TAT GAG ATA GGA          2157
Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly
705                 710                 715

TAA                                                                 2160
```

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser
1 5 10 15

Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20 25 30

Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35 40 45

Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50 55 60

Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala
65 70 75 80

Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85 90 95

Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100 105 110

Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115 120 125

Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130 135 140

Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser
145 150 155 160

Ser Asn Thr Ala Thr Ile Met Met Gln Arg Gly Asn Phe Leu Gln Gly
165 170 175

Pro Thr Val Pro Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu
180 185 190

Val Glu Gly Tyr Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser
195 200 205

Pro Trp Ile Ser Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys
210 215 220

Ser Ser Pro Glu Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe
225 230 235 240

Glu Lys Val Thr Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg
245 250 255

His Pro Leu Val Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn
260 265 270

Ile Ile Leu Ser Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser
275 280 285

Glu Thr Arg Thr Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr
290 295 300

Ser Glu Val His Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile
305 310 315 320

Gly Gly Ser Val Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val
325 330 335

Ala Ile Asp His Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu
340 345 350

Thr Met Gly Leu Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile
355 360 365

Arg Tyr Val Asn Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr
370 375 380

Thr Ser Leu Val Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala
385 390 395 400

Lys Glu Asn Gln Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro
405 410 415

Ser Lys Asn Leu Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser
420 425 430

Ser Thr Pro Ile Thr Met Asn Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
435 440 445

Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val
450 455 460

Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
465 470 475 480

Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
485 490 495

Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
500 505 510

Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
515 520 525

Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln
530 535 540

Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
545 550 555 560

Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
565 570 575

Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
580 585 590

Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
595 600 605

Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser
610 615 620

Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
625 630 635 640

Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
645 650 655

Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
660 665 670

Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
675 680 685

Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly
690 695 700

Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly
705 710 715

WHAT IS CLAIMED IS:

1. A nucleic acid encoding a fusion protein, comprising a nucleotide sequence encoding the anthrax protective antigen (PA) binding domain of the native anthrax lethal factor (LF) protein and a nucleotide sequence encoding an activity inducing domain of a second protein.

2. The nucleic acid of claim 1, wherein the second protein is a toxin.

3. The nucleic acid of claim 2, wherein the toxin is *Pseudomonas* exotoxin A.

4. The nucleic acid of claim 2, wherein the toxin is the A chain of *Diphtheria* toxin.

5. The nucleic acid of claim 2, wherein the toxin is shiga toxin.

6. The nucleic acid of claim 1, comprising the nucleotide sequence defined in the Sequence Listing as SEQ ID NO:5.

7. The nucleic acid of claim 1, comprising the nucleotide sequence defined in the Sequence Listing as SEQ ID NO:6.

8. A protein encoded by the nucleic acid of claim 1.

9. A vector comprising the nucleic acid of claim 1.

10. The vector of claim 9 in a host capable of expressing the protein encoded by the nucleic acid.

11. A nucleic acid encoding a fusion protein, the nucleic acid comprising a nucleotide sequence encoding the translocation domain and anthrax lethal factor (LF) binding

domain of native anthrax protective antigen (PA) protein and a nucleotide sequence encoding a ligand domain which specifically binds a cellular target.

12. The nucleic acid of claim 11, wherein the ligand domain specifically binds to an HIV protein expressed on the surface of an HIV-infected cell.

13. The nucleic acid of claim 11, wherein the ligand domain is a growth factor.

14. The nucleic acid of claim 11, wherein the nucleotide sequence encoding the translocation domain and LF binding domain of the native PA protein further comprises the nucleotide sequence encoding the remainder of the native PA protein.

15. A protein encoded by the nucleic acid of claim 11.

16. A vector comprising the nucleic acid of claim 11.

17. The vector of claim 16 in a host capable of expressing the protein encoded by the nucleic acid.

18. A method of killing a tumor cell in a subject, the method comprising the steps of:

a) administering to the subject a first fusion protein comprising the translocation domain and LF binding domain of the native PA protein and a tumor cell specific ligand domain in an amount sufficient to bind to a tumor cell; and

b) administering to the subject a second fusion protein comprising the PA binding domain of the native LF protein and a cytotoxic domain of a non-LF protein in an amount sufficient to bind to the first protein, whereby the second protein is internalized into the tumor cell and kills the tumor cell.

19. A method of killing HIV-infected cells in a subject, the method comprising the steps of:

a) administering to the subject a first fusion protein comprising the translocation domain and LF binding domain of the native PA protein and a ligand domain that specifically binds to an HIV protein expressed on the surface of an HIV-infected cell in an amount sufficient to bind to an HIV-infected cell; and

b) administering to the subject a second fusion protein comprising the PA binding domain of the native LF protein and a cytotoxic domain of a non-LF protein in an amount sufficient to bind to the first protein, whereby the second protein is internalized into the HIV-infected cell and kills the HIV-infected cell, thereby preventing propagation of HIV.

20. A method for delivering an activity to a cell comprising the steps of:

a) administering to the cell a protein comprising the translocation domain and the LF binding domain of the native PA protein and a ligand domain; and

b) administering to the cell a compound comprising the PA binding domain of the native LF protein chemically attached to an activity inducing moiety, whereby the compound administered in step b) is internalized into the cell and effects the activity within the cell.

21. The method of claim 20, wherein the ligand domain is the receptor binding domain of the native PA protein.

22. The method of claim 20, wherein the activity inducing moiety is a polypeptide.

23. The method of claim 22, wherein the polypeptide is a growth factor.

24. The method of claim 20, wherein the activity inducing moiety is an antisense nucleic acid.

25. The method of claim 20, wherein the activity inducing moiety is a nucleic acid encoding a desired gene product.

26. A compound comprising the PA binding domain of the native LF protein chemically attached to a non-LF activity inducing moiety.

27. The composition of claim 26, wherein the activity inducing moiety is a polypeptide.

28. The composition of claim 26, wherein the activity inducing moiety is a radioisotope.

29. The composition of claim 26, wherein the activity inducing moiety is an antisense nucleic acid.

30. The composition of claim 26, wherein the activity inducing moiety is a nucleic acid encoding a desired gene product.

31. The nucleic acid of claim 11, comprising the nucleotide sequence defined in the Sequence Listing as SEQ ID NO:11.

32. A nucleic acid comprising a nucleotide sequence encoding an anthrax protective antigen which is altered to include a cleavage site recognized by a protease produced by an intracellular pathogen.

33. The nucleic acid of claim 32 wherein the intracellular pathogen is a virus.

34. The nucleic acid of claim 33 wherein the

35. The nucleic acid of claim 34 wherein the virus is a retrovirus.

36. The nucleic acid of claim 35 wherein the retrovirus is an HIV.

37. The nucleic acid of claim 36 wherein the amino acids at residues 164-167 are replaced with an amino acid sequence selected from the group comprising NTATIMMQRGNF, QVSQNYPIVQNI, TVSFNFPQITLW, and GGSAFNFPIVMGG.

38. A polypeptide comprising an amino acid sequence encoding an anthrax protective antigen which is altered to include a cleavage site recognized by a protease produced by a retrovirus.

39. The polypeptide of claim 38 wherein the alteration comprises a mutation in at least one of amino acid residues 164-167 (the trypsin cleavage site).

40. The polypeptide of claim 39 wherein the retrovirus is an HIV.

41. The polypeptide of claim 40 wherein the amino acid residues 164-167 are replaced with an amino acid sequence selected from the group comprising NTATIMMQRGNF, QVSQNYPIVQNI, TVSFNFPQITLW, and GGSAFNFPIVMGG.

42. A method of killing a cell which is infected with an intracellular pathogen, the method comprising:

applying to the cell a composition comprising an effective amount an altered anthrax protective antigen (PA) having a cleavage site recognized by a protease produced by the intracellular pathogen.

43. The method of claim 42 wherein the cleavage site is at amino acid residues 164-167.

44. The method of claim 42 wherein the intracellular pathogen is a virus.

45. The method of claim 44 wherein the virus is a retrovirus.

46. A method of claim 45 wherein the retrovirus is an HIV.

47. The method of claim 46 wherein the amino acids at residues 164-167 are replaced with an amino acid sequence selected from the group comprising NTATIMMQRGNF, QVSQNYPIVQNI, TVSFNFPQITLW, and GGSAFNFPIVMGG.

48. The method of claim 42 wherein the cell is harbored in a human.

49. The method of claim 48 wherein the step of applying the composition includes parenterally administering the composition to the human.

50. The method of claim 49 wherein the parenteral administration is intravenous.

51. The method of claim 48 wherein the effective amount of altered protective antigen is from about 5 to about 25 micrograms per kilogram of body weight of a human harboring the infected cell.

52. The method of claim 51 wherein the effective

Figure 1


Cleavage of mutant PAHIV proteins with purified HIV-1 protease
% Cleavage
Time (min)
PAHIV#1
PAHIV#2
PAHIV#4
0
20
40
60
80
100